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ABBREVIATIONS 
 
ACR: Acute cellular rejection 
AIH : auto immune hepatitis 
AFP: alpha phoeto protein 
AJCC: American Joint Committee on Cancer staging system 
ALF: acute liver failure 
ALT : alanine aminotransferase 
AST : aspartate aminotransferase 
APRI : AST to Platelet Ratio Index calculator 
ARFI: acoustic radiation force impulse imaging 
BCLC:  Barcelona Clinic Liver Cancer (staging system) 
cACLD: compensated advanced chronic liver disease’ 
CE: ceruloplasmin 
CMV: cytomegalovirus 
CNI: calcineurin inhibitor 
CSF1R : colony stimulating factor 1 receptor 
DAA: direct acting antiviral 
DBD: Donors after brain-dead 
DCD: donors after circulatory death 
DRI: donor risk index 
DSA: donor-specific antibodies 
DSA FACE: DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis 
EAD : early allograft dysfunction 
ECD: extended criteria donors  
ER: endoplasmic reticulum 
ERAD: ER-associated protein degradation 
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ERCP: endoscopic retrograde cholangiopancreaticography 
ET: Eurotransplant 
FLISA : Fluorophore-linked immunosorbent assay 
Gal: galactose 
GGT: Gamma-glutamyltransferase 
Glc : glucose 
GlcNAc : N-acetyl-D-glucosamine 
GDP : guanosine diphosphate  
HBV: hepatitis B virus infection 
HC: healthy controls 
HCC: hepatocellular carcinoma 
HCV: hepatitis C virus infection 
HGF: Hepatocyte Growth factor 
HLE-EPI: Epirubicin resistant human hepatocellular carcinoma cell lines 
HLE-MIT: Mitoxantrone resistant human hepatocellular carcinoma cell lines 
HRG: histidine-rich glycoprotein 
HRS: hepatorenal syndrome 
IGOT: isotope-coded glycosylation site–specific tagging 
IMS: Ion mobility spectrometry 
INF: interpheron 
INR: International Normalized Ratio 
ITBL: ischemic type bile duct lesions 
LC-ESI-HCD-MS/MS: Liquid chromatography – Electrospray Ionisation - Higher Energy Collision 
Dissociation tandem mass spectometry 
LT: liver transplantation 
MALDI-QIT-TOF : Matrix Assisted Laser Desorption/Ionization, Quadrupole Ion Trap Time of Flight 
Man: mannose 
MELD: Model for End-Stage Liver Disease 
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MS : Mass spectrometry 
m-TOR: mammalian target of rapamycin 
NAFLD : non alcoholic fatty liver disease 
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PBC: primary biliary cholangitis 
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PVT: portal vein thrombosis 
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TAE: Transarterial embolisation 
TE: transient elastography  
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TNF: tumor necrosis factor  
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I. INTRODUCTION
1.1 GENERAL INTRODUCTION  
The most advanced stage of chronic liver disease is called cirrhosis1 (Figure 1). The presence of 
cirrhosis can lead to major complications linked to the development of portal hypertension and 
hepatocellular carcinoma. The WHO reports that liver cirrhosis accounts for 1.8% of all deaths in 
Europe (170,000 deaths per year) with the highest rates observed in south-eastern and north-eastern 
Europe2. The ultimate therapy for these complications is liver transplantation3. 
Figure 1. Evolution of chronic liver disease. (adapted from Pellicoro et al. Nature Reviews 
Immunology 2014;14:181-194). 
Cirrhosis is the result of increasing hepatic fibrosis, caused by chronic liver injury. Etiologies include 
viral infection (eg. chronic hepatitis B and C), alcohol, non-alcoholic steatohepatitis (NASH), 
autoimmune liver disease, excessive iron or copper accumulation amongst others. Hepatic fibrosis is 
the wound-healing response of the liver. The iterative injury causes inflammatory damage; 
subsequent matrix deposition, parenchymal cell death and angiogenesis lead to progressive fibrosis 
deposition. Although scarring accumulates very slowly (eg. in chronic hepatitis C median time to 
cirrhosis is more than 30 years), once cirrhosis is established, the potential for a reversal of this 
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process is decreased and complications occur. Genetic polymorphisms, epigenetic marks and 
cofactors (such as obesity and alcohol) can modulate the risk of fibrosis progression4.  
Hepatocarcinogenesis is a multi-step process in which hepatic precancerous lesions progress into 
early HCC5. These precancerous lesions, macroscopic dysplastic nodules, result from cirrhosis. 
Dysplastic nodules can be divided into low-grade dysplastic nodules and high-grade dysplastic 
nodules, the latter carrying a higher risk of malignant transformation6. 
Various etiological factors, particularly inflammation and viral hepatitis, appear to contribute 
significantly to approximately 90% of HCC cases by creating phenotypically altered hepatocytes. The 
stepwise progression from altered hepatocytes to dysplastic nodules, or precancerous lesion, occurs 
as a consequence of chronic inflammation and genomic alterations, which commonly precede HCC7–
9. The accumulation of genetic and epigenetic changes, such as the loss of tumor suppressor genes
and the gain of an oncogene, causes the development of primary tumor cells10. In the liver, cytokines
and reactive oxygen and nitrogen species produced by inflammatory cells have been shown to
mediate liver damage and induce the liver's regenerative response10. This predisposes the
proliferating cell to a variety of genetic changes at the genomic and transcriptional levels. 
Typical findings in HCC tumors are loss or mutation of tumor suppressor genes such as TP5311, 
retinoblastoma RB112, CDKN2A (p16INK4A)13 and insulin-like growth factor-2 receptor14, which are 
strongly associated with carcinogenetic signaling pathways. Gain of function mutations have also 
been observed in HCC, for example mutations in CTNNBI (?-catenin)15, which results in the 
deregulation of similar signaling pathways in HCC15 . 
Recently, a new model for HCC carcinogenesis has been proposed, based on the hypothesis that HCC 
could be derived from progenitor cells or de-differentiated transformed cells. This could explain the 
heterogeneity of HCC morphology, behavior and molecular profiles10,16. These bi-potential progenitor 
cells can give rise to hepatocytes or cholangiocytes, which could possibly develop into HCC or 
intrahepatic cholangiocarcinoma, respectively17,18. 
In this work we explore the prognostic potential of glycomics-based biomarkers for outcome in 
patients with cirrhosis and for patients who undergo liver transplantation.  
This introduction will cover (1) a general introduction of cirrhosis and its major complications, (2) a 
general introduction on liver transplantation including a review of non invasive biomarkers for the 
diagnosis of acute cellular rejection and (3) an introduction in glycosylation and glycomics with a 
review of glycomics-based biomarkers in liver disease.  
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1.2 CIRRHOSIS. DIAGNOSIS, COMPLICATIONS AND TREATMENT 
Published as  
Cirrhosis: Reviewing the literature and future perspectives 
Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe 
European Medical Journal (Hepatology) 2016;1:111-117   
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1.2.1 ABSTRACT 
Cirrhosis is the final stage of chronic liver disease and has many causes, including viral hepatitis, 
excessive alcohol intake, and non-alcoholic steatohepatitis. When decompensated cirrhosis develops, 
complications occur that affect quality of life and patient survival. Cirrhosis has a large burden of 
disease and is responsible for almost 2% of deaths in Europe. Cirrhotic patients are in need of early 
diagnosis and a careful follow-up for the prevention and detection of complications. The ultimate 
treatment for end-stage cirrhosis is liver transplantation. This review will cover clinical aspects of 
cirrhosis and uncover future trends in the care of these patients. 
1.2.2 INTRODUCTION 
Cirrhosis is the final stage of chronic liver disease. It results in distortion of the hepatic architecture 
by fibrosis, and the formation of regenerative nodules1. It is the result of progressive liver fibrosis 
caused by chronic liver diseases, including viral hepatitis, alcoholic liver disease, NASH, autoimmune 
liver disease, and genetic disorders, amongst others. Recent reports support the finding that the 
early stages of cirrhosis are reversible on a microscopic level with adequate treatment of the 
underlying liver disease2. However, at more advanced stages, cirrhosis is considered irreversible. 
Cirrhosis is the source of a variety of complications, which result in a reduction in the life expectancy 
of these patients.  At this stage, liver transplantation is the only curative treatment option4. 
1.2.3 EPIDEMIOLOGY AND ETIOLOGY 
Cirrhosis has a large burden of disease. It is the eighth leading cause of death and is responsible for 
1.2% of all deaths in the USA5.  According to the Global Burden of Disease study, the worldwide 
prevalence of cirrhosis is increasing6. In the USA, the most common causes of cirrhosis are chronic  
hepatitis C virus (HCV), alcoholic liver disease, and non-alcoholic liver disease7. In Europe, liver 
cirrhosis accounts for 1.8% of all deaths, amounting to 170,000 deaths per year3. Worryingly, the 
reported incidence of cirrhosis remains stable or is increasing in several countries, including both the 
UK8 and Ireland3. In Europe, the main causes are alcoholic liver disease, NASH, and HCV3. The four 
most frequent causes of cirrhosis worldwide are chronic hepatitis B virus (HBV) and HCV, alcoholic 
liver disease, non-alcoholic fatty liver disease (NAFLD), and haemochromatosis. A variety of other 
diseases can result in cirrhosis, although these are less frequent9.  
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Alcohol  
Excessive alcohol intake remains the number one cause of cirrhosis in Western countries. A daily 
intake of ?60 g/day for men, and ?40 g/day for women is considered harmful. Chronic intake of 
alcohol can also accelerate the natural progression of chronic HBV or HCV10, and haemochromatosis. 
Alcohol abstinence is the cornerstone of treatment and can reverse the disease course11.  
Viral Hepatitis 
Chronic HBV and HCV are leading causes of cirrhosis, especially in endemic regions like South East 
Asia and Sub-Saharan Africa. According to the disease stage, finite treatment with pegylated 
interferon or long-term therapy with nucleos(t)ide analogues is appropriate in HBV patients12. The 
introduction of interferon-free treatment for HCV has been important, as it has resulted in improved 
treatment response without significant side effects13. However, access to these new direct-acting 
agents remains a challenge due to high costs. Hepatitis A and E do not develop into chronic hepatitis 
in immunocompentent patients and are not considered risk factors for cirrhosis.  
Non-Alcoholic Fatty Liver Disease 
NAFLD is related to the presence of metabolic syndrome in association with obesity, diabetes, and/or 
arterial hypertension. A subset of these patients will develop signs of NASH, which can lead to the 
development of fibrosis and subsequently cirrhosis14,15. It is an increasing health problem, especially 
in the Western world6. Treatment is based on dietary measures and exercise14.  
Haemochromatosis  
Hereditary haemochromatosis is an autosomal recessive disorder characterised by excessive 
intestinal absorption of dietary iron, which results in a pathological increase in total body iron 
stores16. End-organ liver damage can occur, in turn leading to cirrhosis. Phlebotomy has been 
indicated to remove excessive iron stores17.  
Autoimmune Hepatitis  
Autoimmune hepatitis is a rare disease affecting 16–18 cases per 100,000 inhabitants in Europe. 
More than 30% of adult patients and ~50% of children have cirrhosis at diagnosis, due to an insidious 
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disease course18. Treatment is based on immunosuppressive agents including corticosteroids and 
azathioprine18.  
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis 
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are autoimmune diseases 
that affect the small and the large bile ducts, respectively. PBC can lead to progressive fibrosis 
resulting in cirrhosis. In PSC patients, prolonged extrahepatic cholestasis can induce the development 
of portal fibrosis leading to cirrhosis19. Ursodeoxycholic acid can slow down disease progression in 
PBC and can be used in PSC20. In PBC, newer agents, like obeticholic acid, are promising treatment 
options21.  
Rare Causes of Cirrhosis 
Other causes of cirrhosis include a reaction to drugs, Budd-Chiari syndrome, Wilson’s disease, alpha-
1 antitrypsin deficiency, granulomatous liver diseases, right-sided heart failure, and veno-occlusive 
disease amongst others9. A specific aetiology can be determined in 85–90% of patients22.  
1.2.4 CLINICAL MANIFESTATIONS 
Cirrhosis can be compensated without overt complications, or decompensated with the appearance 
of complications. The three major complications of cirrhosis are the consequences of portal 
hypertension (e.g. ascites, variceal bleeding, etc.), hepatocellular insufficiency (e.g. icterus), or the 
appearance of hepatocellular carcinoma (HCC).  
Patients with compensated cirrhosis may present with nonspecific symptoms or may even be 
asymptomatic. They can complain of anorexia, weight loss, or fatigue. When decompensation 
develops, patients may present with jaundice, pruritus, signs of upper gastrointestinal bleeding, 
abdominal distension due to ascites, or confusions due to hepatic encephalopathy23. Hypogonadism 
may occur in men, which can manifest as impotence, infertility, or loss of libido24. In women, 
amenorrhoea or irregular menstrual bleeding are common25. Typical signs at clinical examination 
include jaundice, stellate angiomas, palmar erythema, foetor hepaticus, asterixis, signs of 
hypogonadism, and feminisation in males. Other signs include indicators of portal hypertension such 
as ascites, cutaneous collateral venous circulation, and splenomegaly23.  
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1.2.5 DIAGNOSIS 
Laboratory Findings 
Laboratory abnormalities may be the first indication of liver cirrhosis. Though bilirubin levels may be 
normal in compensated cirrhosis, the levels rise as cirrhosis progresses. Levels of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) are moderately elevated in cirrhosis; 
however, normal aminotransferase levels do not exclude cirrhosis. Alkaline phosphatase is usually 
mildly elevated in cirrhosis. Levels higher than 2 or 3-times the upper limit of normal suggest an 
underlying cholestatic liver disease, such as PSC or PBC20. Gamma-glutamyl transpeptidase levels 
correlate well with alkaline phosphatase, but are more elevated in alcohol induced chronic liver 
disease26.  
Once the synthetic function of the liver is affected, albumin levels decrease and prothrombin time 
levels increase as key proteins involved in the coagulation cascade are produced in hepatocytes. Low 
platelets can appear in the case of hypersplenism27. 
Imaging  
Ultrasonography is the first step in liver imaging. It is non-invasive, widely available, affordable, and 
well accepted by patients. Liver volume can be normal, enlarged, or diminished, especially in 
advanced cirrhosis28. Often a nodular deformation of the liver can be observed. Other typical signs 
include atrophy of the right lobe of the liver, and hypertrophy of the caudate or left lobes.  
When portal hypertension develops, Doppler imaging can reveal an enlarged portal vein, enlarged 
collateral veins, and decreased portal flow29. Ultrasonography is useful for the detection of hepatic 
nodules and is the backbone of screening programmes for the early detection of HCC30,31. Detection 
of hepatic nodules demands further characterisation using computed tomography or magnetic 
resonance imaging. 
Non-Invasive Markers of Cirrhosis 
Hepatologists are increasingly adopting the use of non-invasive markers of fibrosis and cirrhosis. 
These include biological markers and transient elastography (TE). Liver fibrosis can be staged using 1-
dimensional ultrasound (FibroScan®, Echosens, France) 32, which measures the velocity of a low-
frequency (50 Hz) elastic shear wave propagating through the liver. The stiffer the tissue, the faster 
the shear wave propagates. Ultrasound elastography can currently be performed based on two 
physical principles: strain displacement/ imaging, and shear wave imaging and quantification33. The 
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latter includes point shear wave elastography (pSWE), also known as acoustic radiation force impulse 
imaging (ARFI; Virtual touch tissue quantification™, Siemens Healthcare; elastography point 
quantification, ElastPQ™, Philips) and 2D-shear wave elastography (2D-SWE; Aixplorer™ Supersonic 
Imagine, France). A major advantage of pSWE/ARFI is that it can be easily implemented on modified 
commercial ultrasound machines (Acuson 2000/3000 Virtual Touch™ tissue quantification, Siemens 
Healthcare, Germany; ElastPQ, iU22xMATRIX, Philips, Netherlands). This results in a combined 
approach of conventional ultrasonography with TE34. Correct interpretation of pSWE/ARFI results 
should systematically take into account potentially confounding parameters: fasting for at least 2 
hours, levels of transaminases (<5-times the upper limit of normal), absence of extrahepatic 
cholestasis, and absence of right heart failure33. According to the European Association for the Study 
of the Liver (EASL) clinical practice guidelines, TE is a reliable method for the diagnosis of cirrhosis in 
patients with chronic liver diseases. TE is generally better at ruling-out rather than suggesting 
cirrhosis and has a negative predictive value >90%34.  
FibroTest©, a patented biomarker (combining six serum markers with the age and gender of the 
patient: alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, 
total bilirubin, and ALT), and APRI (AST to Platelet Ratio Index calculator) are the most widely used 
and validated biological markers35. Fibrotest and APRI show an area under a receiver operating 
characteristic curve (AUROC) of 0.86 and 0.8436, respectively, for the diagnosis of cirrhosis. 
Liver Biopsy 
The gold standard for the diagnosis of cirrhosis is a histological examination. However, this should 
not be performed in all cirrhotic patients. A biopsy should be considered in patients in whom the 
diagnosis is in question, and when knowledge of a specific diagnosis is likely to alter the management 
of the disease37. A liver biopsy can be performed percutaneously, transjugularly, or laparoscopically. 
There is an inherent risk of bleeding, and severe bleeding occurs in between 1 in 2,500 and 1 in 
10,000 biopsies performed using an intercostal percutaneous approach37. 
1.2.6 MAJOR COMPLICATIONS 
Cirrhotic patients are at risk for the development of complications, therefore cirrhotic patients 
should be observed more closely for decompensated cirrhosis. Once decompensation develops, the 
patient should be considered for liver transplantation4. Many complications of cirrhosis develop as a 
result of portal hypertension, an increased pressure in the portal circulation defined as an elevation 
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of the hepatic venous pressure gradient to >5 mmHg38. The haemodynamic abnormalities associated 
with portal hypertension cause the most severe complications of cirrhosis, including ascites, hepatic 
encephalopathy, and bleeding from gastro-oesophageal varices. Ascites is the accumulation of fluid 
in the peritoneal cavity. It is treated with diuretics and sodium restriction. Some patients require 
repeated therapeutic paracentesis, or transjugular intrahepatic portosystemic shunt (TIPS) 
placement39. In patients with ascites, spontaneous bacterial peritonitis (SBP) may occur. Patients may 
be asymptomatic, present with altered mental status, or be seriously ill with a high fever, abdominal 
tenderness, and pain. The diagnosis is established by an elevated ascitic fluid absolute 
polymorphonuclear leukocyte count (?250 cells/mm³). The mortality is high if prompt antibiotic 
treatment and albumin substitution are not initiated39. 
Hepatorenal syndrome (HRS) can develop in patients with advanced cirrhosis. HRS is the 
development of renal failure in patients with advanced chronic liver disease who have portal 
hypertension and ascites40. Around 40% of these patients will develop HRS during the natural history 
of their disease. It is caused by vasoconstriction of the renal circulation and intense systemic 
arteriolar vasodilatation, which results in reduced systemic vascular resistance and arterial 
hypotension. Following liver transplantation, the histological appearance of the kidneys is normal 
and the kidneys often resume normal function39. Treatment of HRS is based on the treatment of the 
precipitating factors; adequate volume replacement with albumin and vasoconstriction therapy with 
vasopressin analogues, such as terlipressin39.  
Variceal haemorrhage is a dramatic event that typically presents as haematemesis and/or melaena. 
The mortality rate is high (20%, 30-day mortality) and treatment requires a multidisciplinary 
approach41 including antibiotic treatment and endoscopic haemostasis. In selected patients, early 
TIPS placement can increase survival42. 
A typical complication of cirrhosis is the occurrence of portal vein thrombosis (PVT). According to a 
large prospective trial in France, the 5-year cumulative incidence of PVT was 10.7%41. PVT is 
associated with the severity of liver disease at baseline and anticoagulation is indicated in patients 
waiting for liver transplantation43. 
Hepatic encephalopathy encompasses a spectrum of potentially reversible neuropsychiatric 
abnormalities including confusion, altered level of consciousness, and coma44. Signs can easily be 
overlooked when they are limited to psychomotor slowing, a lack of attention, or sleep disturbances. 
Hepatic encephalopathy can be scored using the West Haven criteria. A typical sign of 
encephalopathy is the presence of asterixis. Treatment is based upon addressing the precipitating 
factors using synthetic disaccharides (e.g. lactulose) and nonabsorbable antibiotics (e.g. rifaximin) 44.  
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Liver cirrhosis is the most important risk factor for the development of HCC. HCC represents up to 
85% of the primary liver cancer burden45. In patients with compensated cirrhosis the annual 
incidence of HCC ranges from 1–8%46. It is mandatory for an ultrasonography to be taken every 6 
months to ensure early detection of HCC47-48. 
1.2.7 FOLLOW UP, PREVENTION OF COMPLICATIONS AND TREATMENT 
The natural course of cirrhosis is variable and can be well tolerated for many years. In these patients 
the primary goal should be to prevent the occurrence of complications. Slowing or even reversing the 
progression of liver disease can be achieved by addressing the underlying liver disease. Abstinence 
from alcohol improves survival in alcoholic cirrhosis49. Achieving a sustained viral response in HCV 
with antiviral treatment lowers liver-related mortality50. 
The presence of impaired hepatic metabolism and renal excretion denotes a need for caution with 
many medications, which may subsequently necessitate dose adjustments or should even be 
avoided49,51. Nephrotoxic agents can precipitate HRS and should be used cautiously. Careful 
monitoring for the development of complications and, if possible, the prevention of complications, is 
the cornerstone of the treatment of a cirrhotic patient. Cirrhotic patients should undergo screening 
for oesophageal varices with upper endoscopy. However, according to the recent Baveno VI 
guidelines52, patients with a liver stiffness <20 kPa, and a platelet count >150,000 can avoid 
screening.  Patients with medium or large varices require primary prevention with non-selective beta 
blockers or endoscopic band ligation. The role of carvedilol remains unclear52. Furthermore, platelet 
levels <100,000 can increase risk for surgery. 
In a study, it was demonstrated that in patients with ascitic fluid protein <15 g/L and without prior 
SBP, norfloxacin (400 mg/day) reduces the risk of SBP and improves survival. In these patients, long-
term primary prophylaxis should be considered41. Empirical antibiotics should be started immediately 
following the diagnosis of SBP. Furthermore, albumin (1.5 g/kg at diagnosis and 1 g/kg on Day 3) 
should be administered in order to decrease the risk of HRS41.  
The presence of hepatic encephalopathy can be extremely subtle. Precipitating factors including 
dehydration, infection, and variceal bleeding should be avoided or addressed as soon as possible. The 
ultimate treatment for cirrhosis is liver transplantation, and excellent long-term results have been 
demonstrated53. It should be considered in patients with decompensated cirrhosis. The final decision 
depends upon the severity of the liver disease and the absence of contraindications4. 
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Patients who develop HCC should be managed according to the Barcelona Clinic Liver Cancer (BCLC) 
staging system31. Single HCC lesions in Child–Pugh A patients are eligible for resection or ablation. 
Intermediate stage disease patients are offered locoregional therapy including transarterial 
chemoembolisation or radioembolisation. In advanced or metastatic disease, sorafenib is the only 
remaining option; it improves median overall survival from 6 to 9 months. In patients with lesions 
that meet the ‘Milan criteria’ liver transplantation should be considered31. 
1.2.8 PROGNOSIS 
The prognosis of patients with compensated cirrhosis is excellent. Transition from the compensated 
to the decompensated stage occurs at a rate of 5–7% per year11. The median survival rate in 
compensated cirrhosis is >12 years11. Once patients develop complications of cirrhosis, such as 
ascites, variceal bleeding, or HRS, they are considered to have decompensated cirrhosis and their 
prognosis is worse.  
Two models are commonly used for prognosis evaluation: the Child–Pugh classification and the 
Model for End-Stage Liver Disease (MELD). The Child–Pugh classification includes the variables serum 
albumin and bilirubin, ascites, encephalopathy, and prothrombin time54. The ranges from 5 to 15, 
and patients are divided into Child–Pugh A (score 5–6), B (score 7–9), or C (score 10–15). One-year 
survival rates for Child– Pugh A, B, and C patients are 100%, 80%, and 45%, respectively55. MELD 
score is calculated using bilirubin levels, creatinine, and international normalised ratio56. It is now 
used for prioritising patients on the liver transplant waiting list. Patients with a MELD score of >10 
should be referred to a liver transplant centre for evaluation. 
There is a growing interest in the use of non-invasive tests for the prognosis of chronic liver disease, 
particularly for TE in patients with cirrhosis34. The Baveno VI consensus paper52 introduced the term 
‘compensated advanced chronic liver disease’ (cACLD). This term applies to patients with chronic 
liver disease at increased risk of developing clinically significant portal hypertension, defined as a 
hepatovenous pressure gradient of ?10 mmHg. TE values <10 kPa in the absence of other known 
clinical signs rule out cACLD. Values between 10–15 kPa are suggestive of cACLD but need 
confirmation. Values >15 kPa are highly suggestive of cACLD. Patients with cACLD are at an increased 
risk for complications and should be referred to a liver disease specialist52. 
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1.2.9 CONCLUSION 
Cirrhosis is the final stage of chronic liver disease. The aim of a clinician dealing with cirrhosis should 
be to prevent the development of major complications. A new trend in this field is the adoption of 
non-invasive techniques, e.g. TE for diagnosis of cirrhosis and follow-up of cirrhotic patients, as they 
are an emerging tool for risk stratification. In cirrhotic patients the performance of an ultrasonograph 
every 6 months remains of utmost importance for early detection of HCC. Decompensated patients 
have a dismal prognosis and should be referred to a specialised hepatological centre, as liver 
transplantation should be considered in these patients. 
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1.3 LIVER TRANSPLANTATION 
1.3.1 GENERAL INTRODUCTION 
The first liver transplantation was performed by Thomas Starzl in the United States in 19631. After a 
challenging start, liver transplantation has become the standard of care for acute and chronic liver 
failure and selected patients with hepatocellular carcinoma with more than 80 000 liver 
transplantations performed to date2. The breakthrough of liver transplantation has been possible 
after the introduction of immunosuppressive agents like cyclosporine3 and in the improvement of 
surgical techniques and peri-operative intensive care4. In the eighties and the nineties the number of 
liver transplantations showed an exponential growth which has stabilized since the start of this 
century2 (Figure 1). Nowadays a major challenge in liver transplantation, which hampers its further 
expansion, is the shortage of donor organs.  
Figure 1. Evolution of 93,634 LTs performed in Europe since May 1968. Arrows indicate the year the 
first LT was performed in indicated countries. ?This decrease is owed to the fact that some centers did 
not yet send their updating further to the recent changes of the questionnaire.Source: Adam et al.2 
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1.3.1.1 Indications for liver transplantation 
Liver transplantation is indicated in patients with end-stage liver disease, hepatocellular carcinoma 
(selected patients) and acute liver failure (Figure 2).  
The most common indication is decompensated cirrhosis with the occurrence of major complications 
such as variceal haemorrhage, ascites, encephalopathy etc5. Liver transplantation can be considered 
in these patients if liver transplantation would extend the life expectancy beyond what can be 
expected from the natural history of the underlying liver disease or if it is likely to improve the quality 
of life.  The major causes of cirrhosis are chronic alcohol intake, chronic hepatitis C and B and non-
alcoholic fatty liver disease. The primary cause of cirrhosis should be treated if possible. This includes 
abstinence of alcohol for at least 6 months and appropriate treatment of HBV and HCV patients with 
antiviral drugs5. Other causes of end-stage liver disease are cholestatic liver diseases, eg. primary 
biliary cholangitis or primary sclerosing cholangitis and metabolic diseases2. 
Acute liver failure develops in healthy, often young patients without underlying liver disease and can 
be caused by toxic agents (eg. paracetamol) or viruses (hepatitis A or B)6. These patients show a rapid 
deterioration of their general status with the development of encephalopathy. Some of these 
patients require urgent liver transplantation, within 48 hours after the development of the clinical 
syndrome. Liver transplantation has revolutionized the prognosis of these patients causing survival to 
increase from 10-20% to 78-80% at 1 year7.  
Figure 2: Primary diseases leading to liver transplantation in Europe (01/1988-12/2011). Others: 
Budd-Chiari, Benign liver tumours or polycystic diseases, parasitic diseases, other. Source EASL 
Clinical practice Guidelines Liver Transplantation. 
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The third major indication for liver transplantation is hepatocellular carcinoma (HCC). HCC is the 
most common primary malignancy of the liver8.  It occurs on the background of cirrhosis in the 
majority of patients. Liver transplantation is the treatment of choice in early unresectable HCC. Low 
rates of recurrence have been reported when Milan criteria are applied for patient selection (solitary 
HCC with diameter < 5 cm or up to 3 nodules with diameter < 3 cm)9.    
In cirrhotic patients, the severity of liver disease is assessed by the MELD score (based on creatinine, 
bilirubin and INR) which is a good predictor of short-term pre-transplant mortality risk10.  If a liver 
transplantation is considered in a patient, an assessment will also include the presence of 
comorbidities, a nutritional assessment, a screening for infections and (pre)malignant lesions and a 
socio-psychiatric assessment with a special focus on the presence of addictions5. All transplant 
candidates should be discussed in multidisciplinary transplant meetings.  
1.3.1.2 Organ donation and allocation 
In the EU, organs cannot be procured without the consent of donors and/or their relatives. This can 
be a presumed consent, where every citizen is an organ donor unless “opting-out” actively. In other 
countries potential donors need to opt-in actively and register as an organ donor.  
Donation after brain death (DBD) is the most common type of deceased donation, while donation 
after circulatory death (DCD) is increasingly used as an additional source of organs for 
transplantation. DCD is a graft donation from a donor who has suffered an irreversible cardiac arrest 
and has suffered devastating and irreversible brain injury and may be near death, but does not meet 
formal brain death criteria. After consent of the relatives, care is withdrawn and donor organs are 
recovered in the operating room after circulation has seazed. This type of donation does not cause or 
hasten death. Organs recovered from a donor after cardiac death have some degree of oxygen 
deprivation during the time after the heart stops beating which can lead to diminished graft 
survival11. Living donation represents only a small part of liver transplantation in the EU2.  
Belgium is a member of Eurotransplant (ET)12, an organ exchange organization that cooperates with 
Austria, Croatia, Germany, Hungary, Luxembourg, the Netherlands and Slovenia for organ allocation. 
Since 2006, allocation is based on the “sickest-first” principle using the MELD scoring. Patients whose 
severity is not adequately reflected by lab MELD can be requested for an exceptional MELD. The 
most frequent, eg. HCC, have been identified as standard exceptions12.  
Several strategies have been tried to increase the donor organ pool. A first strategy is the use of 
extended criteria donors (ECD), also called marginal donors. These donor organs represent 
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unfavorable characteristics associated with suboptimal post-transplant outcome due to higher risk of 
poor graft function or due to potential disease transmission13.  ET defines marginal liver donors as 
donor age > 65 years, ICU stay with ventilation > 7 days, BMI > 30, steatosis of the liver > 40%, serum 
sodium > 165 mmol/l, increased transaminases (AST >105 U/L;ALT> 90U/L) and serum bilirubin >3 
mg/dl.  
Another strategy is the use of DCD liver grafts, as mentioned before, and liver grafts from donors of 
older age. Transplantation of livers from septuagenarian and octogenarian donors can achieve 
excellent long-term patient and graft survival for selected HCV negative patients14. Steatotic liver 
grafts show an increased risk of ischemia-reperfusion injury. Although mild macrosteatosis (<30% 
volume) is not considered to affect the transplant outcome, moderate and severe steatosis can be a 
contraindication for use of the donor organ15. The use of extracorporeal normothermic machine 
perfusion and machine perfusion-based defatting protocols might change this approach in the near 
future16. Finally the use of HBcAb positive donors grafts is safe in HBsAg positive patients and 
requires prophylaxis in HBsAg negative patients13. The use of HCV positive donor graft is considered 
safe in HCV positive patients but should be avoided in non-HCV positive recipients as outcome can be 
affected17. However, the implementation of direct acting antiviral drugs might generate arguments 
to change this approach18. The use of organs from donors with previous or current malignancies can 
occur and is often fatal in immunosuppressed transplant patients. Each case should be carefully 
considered depending on the exact tumour stage and the disease-free interval5. 
A scoring system based on donor characteristics, the donor risk index (DRI) was developed in 2006 in 
order to assess the risk of graft failure after liver transplantation19. A European variant, the ET-DRI 
has been developed since20. 
1.3.1.3 Immunosuppression 
In contrast to other organs, the liver requires less immunosuppression than other organs. The 
occurrence of acute cellular rejection (ACR) does seldom lead to graft loss and thus a less strict 
approach towards immunosuppression is allowed, especially after the first year after liver 
transplantation13. 
The cornerstone of immunosuppression are calcineurin-inhibitors. Both cyclosporine (CsA) and 
tacrolimus (Tac) bind to cytoplasmic receptors and the resulting complexes inactivate calcineurin, a 
pivotal enzyme in T cell receptor signaling21. Tac is the drug of choice in 90% of liver transplant 
patients. Mycophenolic acid is the active metabolite of mycophenolate mofetil (MMF) and is a 
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selective, non-competitive inhibitor of inosine monophosphate dehydrogenase, and reduces purine 
synthesis, affecting lymphocyte proliferation. It is used in combination with CNI in order to reduce 
dosage and side effects of CNI. These side effects will be addresses in the next section. Sirolimus and 
everolimus are inhibitors of the mammalian target of rapamycin (mTOR) and interact with IL-2 
signaling. The side-effects include aftosis, skin lesions, decreased wound-healing and 
hyperlipidemia22. In contrast to CNI mTOR inhibitors do not induce nephrotoxicity.  
Figure 3: Mechanisms of action of immunosuppressive agents. CNIs (ciclosporin and tacrolimus) bind to 
their respective immunophilins, and inhibit calcineurin. Calcineurin is then unable to dephosphorylate NFAT, 
which will prevent translocation of NFAT to the nucleus and thereby production of IL-2. Sirolimus is an mTOR 
inhibitor. It binds to FKBP and inhibits mTOR, which in turn inhibits transition of the cell cycle from G1 to S 
phase. MPA and LFL are also cell-cycle inhibitors, and act via inhibition of nucleotide synthesis. Abbreviations: 
CNI, calcineurin inhibitor; FKBP, FK506-binding protein; IL-2, interleukin-2; LFL, leflunomide; MHC, major 
histocompatibility complex; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin; NFAT, nuclear 
factor of activated T cells; TCR, T cell receptor. Source Samaniego et al.21 
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Corticosteroids have classically been added to CNI and MMF during the first 3 to 6 months after liver 
transplantation at the cost of increasing corticoid-related side-effect23. Induction agents like IL-2 
receptor monoclonal antibodies (daclizumab and basiliximab) are attractive corticoid-sparing 
alternatives, especially in patients with pre-transplant renal impairment24.  
1.3.1.4 Graft and patient survival 
Graft and patient survival after liver transplantation are excellent over the last several years. The 
chance of one-year survival is close to 90% and the 5-year survival rate is around 70%2.  
Early graft loss can be due to primary non function (PNF). PNF occurs after 2-10%25–27 of liver 
transplantations and was first described by Shaw et al.28 as a situation where “a graft never 
demonstrated evidence of initial function following transplantation” after exclusion of technical 
causes and acute cellular rejection needing an urgent retransplantation. PNF requires urgent 
retransplantation.  
In the early post-transplant period surgical complications and infections account for the majority of 
deaths and graft losses. Surgical complications after transplantation include vascular complications 
and biliary complications. Vascular problems are mainly arterial and range from acute hepatic artery 
thrombosis, which can affect graft survival on the short term or more modest vascular impairments 
that can cause ischemic biliary lesions which can affect the graft survival on the long term2930 and 
often lead to retransplantation. In contrast to these non-anastomotic ischemia-type bile duct lesions, 
anastomotic stenosis  can be seen in 4-9% of patients. It is often observed in the first year after liver 
transplantation. Conventional endoscopic treatment with ERCP with balloon dilatation and use of 
prosthesis has a success rate of 70-100%31. Overall, graft loss occurs in 7-10% of patients and liver 
retransplantation is the only definite solution for these patients32.   
On the long term, de novo malignancies and cardiovascular diseases are the major reason for death2. 
Recurrence of the underlying liver disease, in particular hepatitis C infection has had a dramatic 
effect on transplant outcome. The advent of newer DAA’s has the potential to eliminate this 
problem33. ACR occurs in 15-30% of liver transplant recipients34 but can be successfully treated in the 
majority of patients. In contrast, chronic ductopenic rejection is difficult to treat and can lead to graft 
loss35.   
This has lead to a paradigm shift in liver transplantation. The discovery of cyclosporine in 1971 
enabled the development of liver transplantation from an experimental procedure to the standard of 
care for end stage liver disease as ACR could be treated effectively. Today, over-immunosuppression 
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is inducing (opportunistic) infections in the early post-transplant period and the side-effects of CNI 
cause cardiovascular disease and cancer development in the late posttransplant period, both leading 
to impaired patient survival.  
One of the keys to bring liver transplantation to a higher level and to improve patient survival in the 
next years will be the development of strategies to identify patients who are tolerant and who can 
survive without any immunosuppression. Indeed, up to 20% of patients show spontaneous 
tolerance36. Another strategy will be the development of biomarkers that can guide clinicians in the 
use of immunosuppression, in order to use the lowest possible dosage. Finally, strategies for 
induction of tolerance could radically change our medical practice37.  
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1.3.2 BIOMARKERS FOR ACUTE CELLULAR REJECTION 
The current gold standard for the diagnosis of acute cellular rejection (ACR) is a liver biopsy and this 
has remained unchanged until now, despite many attempts to develop non-invasive biomarkers that 
could diagnose ACR with a high accuracy. Unfortunately, after performing a literature review we had 
to conclude that the perfect biomarker has not been found (yet). 
Biomarkers for the diagnosis of acute cellular rejection in 
liver transplant recipients: A review 
Xavier Verhelst, Roberto Troisi, Isabelle Colle, Anja Geerts, Hans Van Vlierberghe 
Hepatol Res. 2013 Feb;43(2):165-78.  
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1.3.2.1 ABSTRACT 
The gold standard for the diagnosis of acute cellular rejection (ACR) is a liver biopsy. The quest for an 
alternative non-invasive biomarkers has been long and is ongoing. However, an efficient and useful 
biomarker has not been developed yet. In this manuscript, we review all possible candidate 
biomarkers that have been studied in recent years, starting with cytokines and ending with an 
overview of different newly discovered “omics”. Promising paths are being explored but a valid non-
invasive biomarker has not been discovered yet. 
1.3.2.2 INTRODUCTION 
Since the first liver transplantation in 1963 by Starzl1, liver transplantation has been considered a 
standard of care treatment for end-stage liver diseases with excellent long-term survival and 
accepted morbidity and mortality rates. However, the early post-transplant period can be troubled 
by a variety of complications, including delayed graft function, hepatic artery and vein thrombosis 
and biliary complications. The most common complication in this period is acute cellular rejection 
(ACR), occurring in 20–40% of patients2. Diagnosis of ACR is based upon clinical suspicion on one 
hand, raised by nonspecific symptoms like malaise, fever, abdominal pain, hepatomegaly and 
increasing ascites, and by laboratory abnormalities on the other hand, including elevation of serum 
aminotransferases, alkaline phosphatases, g-glutamyl transferases and bilirubin levels. However, 
these signs and symptoms are non-specific and do not correlate with the severity of rejection3. 
Confirmation requires a liver biopsy, considered the gold standard4, which is costly and causes 
morbidity and mortality5. Despite correct counseling, a liver biopsy can cause anxiety in many 
patients. Furthermore, even if a liver biopsy is the gold standard, diagnostic accuracy is challenged by 
sampling error and interpretation is not always straightforward6. In this manuscript, we review the 
possible non-invasive diagnostic tools for the diagnosis of ACR. Animal studies will not be discussed 
in this review. 
1.3.3.3 ACUTE CELLULAR REJECTION 
ACR is a T-cell-dependent immune response directed against donor tissues resulting from the 
recognition of alloantigens by recipient T cells7 followed by T-cell activation and proliferation. The 
primum movens of the ACR is the binding of foreign antigens from newly transplanted organs to 
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antigen-presenting cells of the recipient resulting in an activation of recipient T cells. The activated T 
cells in turn release interleukin 2 (IL-2) which binds to the IL-2 receptors (IL-2R) only expressed on the 
surface of activated T cells. The IL-2R is composed of three transmembrane protein subunits, a (CD 
25), b (CD 122) and g (CD 132). The first is specific to IL-2R. Binding to a and b subunits is a crucial  
step in T-cell activation and propagation7,8. This explains why IL-2 can be considered a catalyzer of 
the cellular immune response and is an attractive therapeutic target. For instance, basiliximab (a 
chimeric monoclonal antibody targeting CD25) and daclizumab (a humanized monoclonal antibody 
with the same target) are used as prophylactic agents in the early post-transplant period9,10. In this 
cascade of events, an interaction between the CD28 molecule and the B7 ligand is necessary as a 
second signal for optimal T-cell activation and IL-2 production11. This ultimately leads to infiltration of 
the graft by host T cells and damage of the graft, as can be appreciated by histological assessment of 
a liver biopsy. This is typically characterized by portal inflammation, bile duct inflammation damage 
and venous endothelial inflammation.  
1.3.3.4 BIOMARKERS FOR ACR 
The first question should address what a good biomarker is. The Biomarkers Definitions Working 
Group defined a biomarker as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention”12. A perfect diagnostic biomarker for ACR should be highly sensitive and 
specific, non-invasive, rapidly available and budget-friendly. The second question should answer if a 
potential biomarker has proven clinical utility and has been externally validated. Indeed, many 
potential biomarkers have been reported to have diagnostic potential, but few have been validated. 
Validation criteria for ACR are not available, but we were inspired by the minimal requirements for 
the validation of noninvasive fibrosis markers according to the French National Authority for Health 
(Haute Autorité de Santé) as adapted by Ratziu13. Based on this, we propose a set of five criteria 
assessing the intrinsic quality of the biomarker for ACR and the quality of the study report. These 
criteria are: (i) sensitivity, specificity, area under the receiver–operator curve (AUROC); (ii) 
discrimination from other events, including cytomegalovirus (CMV) infection and recurrence of 
hepatitis C virus (HCV) infection in the liver graft; (iii) easily available high throughput test; (iv) 
sufficiently large sample size with prospectively analyzed patients; and (v) one independent 
validation. 
Both biomarkers that are diagnostic for ACR and biomarkers that are prognostic for ACR and identify 
patients at increased risk for ACR development can be identified.  
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PAST AND PRESENT BIOMARKERS FOR ACR 
Serum markers related to inflammation 
Rising of liver enzymes after transplantation is often the first reason to suspect ACR. However, 
sensitivity and specificity of liver enzymes are low and these enzymes cannot differentiate ACR from 
others complications. The AUROC for aspartate aminotransferase, alanine aminotransferase (ALT), g-
glutamyltransferase, total bilirubin and conjugated bilirubin is approximately 0.5. For alkaline 
phosphatase, the AUROC is slightly better (0.69) and although this value reached statistical 
significance, the clinical significance remains doubtful3. The first potential biomarkers studied were 
cytokines and other proteins related to the inflammatory response. Growing insight into the 
immunological basis of ACR accompanied the study of these cytokines as biomarkers for ACR. For 
example, a rise of CD28 expression up to 6 days before diagnosis of ACR has been observed14,15. A 
French group studied the expression of CD25, CD28 and CD38 on CD3+, CD4+ and CD8+ cells, 
respectively. The mean frequencies of CD28 and CD38-expressing T cells (in peripheral blood 
mononuclear cells) were significantly higher in patients with acute rejection, whereas the frequency 
of CD25-expressing T cells did not differ significantly between ACR and non-ACR patients16. This 
expression decreased after anti-rejection therapy. Although in this study the CD28 and CD38 
expression levels did not change in patients suffering from an acute CMV infection, other data report 
an expression of this same CD28 and CD38 expression during CMV infection17, limiting its clinical use. 
Soluble IL-2R (sIL-2R) levels in serum are increased as early as 10 days before the diagnosis of ACR 
but also increase in cases of CMV infection18,19, bacterial infections and cholangitis20,21. However, if 
the ratio of the post-transplant level divided by the pre-transplant level of SIL-2R was measured in 
combination with the levels of CD8, a more pronounced elevation of both levels was observed during 
CMV infection in comparison with ACR, where levels of CD8 are not increased22. Soluble tumor 
necrosis factor (TNF) receptor II (sTNF-RII), released upon stimulation of T-helper (Th)1 lymphocytes, 
and IL-10, a counter regulatory Th2 cytokine, increase as well during ACR as during serious infections. 
Neopterin, an intermediate of tetrahydrobiopterin synthesis produced by interferon (IFN)-g-activated 
macrophages, increased at the onset of ACR only in steroid resistant patients. The pro-inflammatory 
cytokines IFN-g, IL-1b, IL-4 and IL-6 were not of any use20. IL-6 is an inducer of the hepatic synthesis 
of a myriad of acute phase proteins. Kita et al. observed in contrast a marked rise of IL-6 during ACR 
and during infection, however, the rise pattern was distinguishable between both23. Interleukin-15 is 
produced by non-lymphatic cells including macrophages, dendritic cells and epithelial cells. Its 
biologic activities are similar to those of IL-2. Plasma levels of IL-15 are increased during ACR, 
particularly during steroid-resistant ACR and during chronic rejection24. Also, TNF-a, currently used 
on a daily basis in clinical settings as a marker of infection, once was proposed as a potential 
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biomarker for ACR. Levels of TNF-a are elevated during ACR but cannot discriminate ACR from 
infection25. Beta2-Microglobulin is a low molecular weight protein included in the major 
histocompatibility complex class I complex required for its expression. ACR in cardiac and renal 
transplant patients is associated with increased levels of b2-microglobulin. The same was observed in 
liver transplantation, but this marker could not differentiate ACR from infectious complications26-28. 
The infiltration of leukocytes into the allograft during ACR is regulated by the expression of adhesion 
molecules29. An increase of intercellular adhesion molecule 1 (ICAM-1) and E-selectin in serum was 
observed in relation to ACR. However, neither E-selectin30,31 nor ICAM-132 could differentiate ACR 
from an infectious episode. A differentiation was seen between patients with ACR and CMV 
infection, where ICAM-1 levels did not increase33. Serum vascular cellular adhesion molecule 1 
(VCAM-1) and E-selectin were associated to the extent of preservation and reperfusion injury in one 
study33, but were also attributed to ACR in another group31. These data could not be reproduced by 
other research groups34. We also have to take into account that these values do increase during the 
first days after transplantation, probably due to a rebound phenomenon that reflects immunological 
activation due to surgery and organ conservation31,34. In pediatric patients, a rise in plasminogen 
activator inhibitor 1 was noticed before ACR and was suggested as a candidate biomarker. Validation 
in a larger cohort has not been reported.  
A Japanese group developed an enzyme-linked immunoassay (ELISA) for the measurement of serum 
human myeloid-related protein complex (MRP8/14). MRP8/14 is expressed in activated human 
granulocytes and monocytes in the inflammatory phase and is involved in the inflammation-related 
calcium-dependent activation. In liver transplant recipients, a clear association was observed 
between serum levels and ACR, however, sensitivity and specificity were not published. Furthermore, 
there is no information regarding the expression of MRP8/14 during infectious complications36. 
However, in kidney transplant recipients, MRP8/14 was also increased during non-viral infections, 
but in combination with procalcitonin a discrimination was possible37. It seems obvious that the role 
of the adaptive immune response is well established in the occurrence of ACR. On the other hand, 
the role of the innate immunity is less clear. The role of Toll-like receptors (TLR), mediators of innate 
immunity, was studied in ACR. Patients experiencing ACR had significantly higher levels of TLR4 and a 
greater capacity to produce the pro-inflammatory cytokines TNF-a and IL-6 before transplantation, 
but had a downregulation of the TLR4 pathway if they experienced rejection. In contrast, there was 
no correlation between TLR2 levels and rejection38. Apoptosis is an important mechanism of cell 
death during ACR and this is mediated via Fas ligand. Increased serum levels of soluble Fas antigen 
have been detected in patients during ACR39. Finally, several studies illustrate that blood eosinophilia 
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could be an interesting biomarker for ACR40,41. In one study, a positive predictive value of 82% was 
found but, more interestingly, a negative predictive value of 86%42. However, the response was less 
clear in patients who received steroids and in HCV-infected patients. Although most of these markers 
do prove a relationship with ACR, only five could be retained as valuable because these showed a 
clear relationship with the appearance of ACR, could differentiate from other post-transplant 
complications and were performed on prospective patient series. The characteristics are summarized 
in Table 1. 
Serum markers not related to inflammation (Table 2) 
Other potential biomarkers were a-glutathione S-transferase (a-GST) and p-glutathione S-transferase 
(p-GST). GST are a family of multifunctional detoxifying enzymes that are implicated in the 
conjugation of glutathione with several compounds. a-GST is a low molecular weight protein widely 
present in the hepatocyte cytosol with a short half-life. Plasma values increase rapidly in case of ACR 
but lack sensitivity and specificity to claim clinical usefulness46-49. p-GST is an isoenzyme exclusively 
found in the biliary epithelium of the liver that was also tested but was not found to be related to 
ACR49. A single report mentions the elevation of carbohydrate antigen (CA)-19.9, routinely used as a 
tumor marker for pancreatic and bile duct malignancies50. The rise of CA-19.9 might be explained by 
the release of CA-19.9 due to cell damage caused by the inflammatory reaction. In a rat model, 
ceruloplasmin was shown to be reduced during ACR. The underlying physiopathology is unclear55. A 
group from Kings College London observed an increase of acid-labile nitrosocompounds (NOx) during 
ACR which correlated with rejection severity and with response to treatment; in contrast, there was 
no correlation with nitrate (NO3 –) levels51. However, another group found a clear relationship 
between ACR and nitrate levels52. The clinical usefulness remains unclear. In a small patient series, 
serum amyloid A protein (SAA) was significantly increased during the appearance of ACR53, but SAA 
could not differentiate ACR from infections21. N-protein-bound conjugated bilirubin has been 
reported as a helpful biomarker for the diagnosis of ACR, however, sensitivity and specificity were 
not satisfactory26,54. These data are summarized in Table 2. 
Bile markers 
Conflicting results (summarized in Table 3) have been published regarding the validity of bile 
markers. Umeshita et al. found a clear rise of bile IL-6 after ACR and a decrease in the case of a 
successful treatment56, but this was also seen in cholangitis. Biliary IL-8 also increases in the early 
stage of ACR but specificity is not higher than serum cytokine markers44. Adams et al. reported 
elevated IL-2R in the bile of patients with ACR, with higher sensitivity and specificity than in serum19. 
Elevated levels of ICAM-1 in bile have been observed in ACR32,45 but in another study the same was 
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observed during the appearance of infectious complications44. On the other hand, another group 
could not find a relationship between ICAM-1 and VCAM-1 in bile and ACR. A Japanese group 
discovered (in a small group of five patients with biopsy-proven ACR) a raise of alanine 
aminopeptidase N 3 days before the appearance of ACR57. A major drawback in clinical practice is the 
bile collection that requires the position of a T tube. 
Ascites markers 
In a small series of pediatric liver transplant patients, an increase of the IL-1R antagonist was 
observed in ascites 48 h before rejection (see Table 4) 58. Ascites collection after transplantation 
requires puncture or the position of a peritoneal drainage which can cause infections. Furthermore, 
ascites is not always present after transplantation. 
FUTURE BIOMARKERS 
The perpetual advance of the last decade has opened new perspectives for the discovery of 
biomarkers, particularly in the field of genomics, transcriptomics, proteomics and metabolomics. 
Today, two non-invasive tests are US Food and Drug Administration approved and commercially 
available in the field of organ transplantation. The first, AlloMap (XDx, South San Francisco, CA, USA), 
predicts the absence of ACR after heart transplantation59. The second, the immune function test 
ImmuKnow (Cyclex Incorporated, Columbia, MD, USA), provides a preliminary evaluation of the 
degree of activation of CD4 T cells by measuring the ability of CD4+ T cells to respond to in vitro 
mitogenic stimulation by quantitating adenosine triphosphate production. This result can help to 
titrate the immunosuppressive therapy after kidney transplantation60. This announces a paradigm 
shift from measuring serum drug levels, only providing an estimation of the immunosuppressive 
state to the direct measurement of the in vivo actual immune function. For transplant hepatologists,  
ImmuKnow has not been approved yet, but data are exciting. Several trials have demonstrated that 
this assay could identify patients with a low immune response (at risk of infections) and patients with 
a high immune response (at risk of ACR)61-63. Immuknow also can distinguish between ACR and 
recurrent HCV infection64, where patients experiencing HCV recurrence showed a significantly lower 
immune response than patients developing ACR. 
Genomics 
Genome-wide association studies have identified loci associated with an increased susceptibility to 
ACR, for example, the copy number variation in the CCL3L1 gene65 or to poor allograft survival66, but 
biomarkers associated with the acute event of ACR are not available at this moment, in contrast to  
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the field of kidney transplantation where different promising agents have been identified (see Table 
5) 67.
Proteomics 
A plethora of proteins are involved in the immune response of ACR. Proteomic analysis of serum 
seems a very attractive and promising path to the identification of valid biomarkers. Proteomic 
research in this field has contributed to the better understanding of these processes. Numerous 
patents have been taken for diagnostic proteomic-based tools, recently reviewed by Fiorini et al. 73, 
indicating the momentum present in this research area. Massoud et al.68 identified 41 serum proteins 
differentially abundant in the serum of ACR patients. Seven of them (serum amyloid A, complement 
component 4 [C4], fibrinogen, complement component 1q [C1q], complement component 3, heat  
shock protein [HSP]-60 and HSP-70) were turned into an ELISA-based assay. C4 and C1q were both 
independent predictors of ACR. The best diagnostic performance was achieved by C4. Using a cut-off 
level determined by the researchers, sensitivity was 97%, specificity 62% with a positive predictive 
value of 74% and a negative predictive value of 94%. Combining C4 levels with ALT levels higher than 
70 IU/mL improved these results to 96%, 81%, 86% and 94%, respectively. However, the study cohort 
included only 16 patients and should be confirmed in larger multicenter trials. 
In rats undergoing liver transplantation, eight proteins involved in metabolism were downregulated 
in rats with ACR, including sulfite oxidase, adenosine triphosphate (ATP) synthase subunit-a, 
aldehyde dehydrogenase, ATP synthase subunit-b, NADH dehydrogenase-1a, putative L-aspartate 
dehydrogenase, ketohexokinase and 3-hydroxyisobutyrate dehydrogenase74. 
Transcriptomics 
Kobayashi et al. observed that the mRNA level of IFN regulatory factor 1 and guanylate-binding 
protein 2 (GBP2) in leukocytes, both related to T-cell-mediated immune response, were upregulated 
during ACR but only GBP2 showed statistical significance71. The same research group also discovered  
different transcriptome patterns for ACR in patients with concomitant hepatitis C recurrence, 
compared to patients with isolated hepatitis C recurrence. Liver injury is associated with release of 
hepatocyte-derived microRNA (miR). ACR is associated with a rise of miR-122 and miR-148a in serum. 
Their elevation is high during ACR and starts before the rise of transaminases70. Reverse transcription 
polymerase chain reaction in cells obtained from the organ perfusate revealed lower levels of HSP-70 
mRNA expression in patients experiencing ACR, in comparison to patients without ACR, suggesting a 
protective role of HSP-70 expression. There was a correlation between the amount of HSP-70 mRNA 
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expression in these cells and liver biopsies69. This may represent a prognostic factor, but has no 
diagnostic potential at this moment. 
Metabolomics 
Metabolomics is the quantitative measurement of dynamic multiparametric metabolic responses of 
living systems to pathophysiological stimuli or genetic modification75. Wu et al. found distinct 
metabolomic profiles in rats with ACR after allogenic transplantation correlating with histological 
changes76. In a case report, very distinct metabolomic profiles obtained by proton nuclear magnetic 
resonance spectroscopy were observed during primary dysfunction of the liver, as early as 2 h after 
transplantation72. 
1.3.3.5 DISCUSSION 
We reviewed all potential biomarkers that have been evaluated as a diagnostic marker for ACR. In 
the first category of “older” biomarkers, we identified 31 molecules in serum, six in bile and three in 
ascites. Neither bile- nor ascites-based biomarkers performed better than serum-based biomarkers 
and should not be taken into account considering the practical concerns for sample collection. The 
first group of older serum biomarkers was related to inflammation, and contained mainly  
inflammatory cytokines. Although many of these cytokines show a rise during ACR, they are not 
useful as biomarkers because they cannot differentiate ACR from other complications, especially 
infections, that occur during the early post-transplant period and require tailored treatments. We 
could retain only five valuable biomarkers in this group (CD28, CD38, IL-4, ICAM-1 and eosinophilia), 
summarized in Table 1. However, even these markers demonstrate important shortcomings, for 
example, results for ICAM-1 were conflicting. The main shortcoming is the lack of validation in large 
multicenter studies. In the newer biomarkers of the different “omic” families, the situation is more 
promising. Only a few reports are available, but they show promising high sensitivity and specificity 
values, the best being the combination of a proteomic-based ELISA focusing on the appearance of 
C4 in combination with ALT68. This combination claims a sensitivity of 96% and a specificity of 81% 
with an AUROC of 0.88. However, this trial was based on only 16 patient samples and was not 
externally validated. Another important clinical concern is the differentiation of ACR from other post-
transplantation events like CMV infection, sepsis and HCV recurrence. In the majority of tests, these  
data are not reported or yield conflicting results. A particular clinical problem is HCV recurrence. The 
development of fibrosis and cirrhosis in transplanted patients occurs at an accelerated rate 
compared to immunocompetent patients. As a result, cirrhosis occurs in approximately 25% of those 
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transplanted for HCV within a median of 5 years77. It can be challenging to differentiate ACR from 
HCV recurrence. However, only six out of all the markers reviewed in this article were tested for their 
ability to differentiate patients with ACR from patients with HCV recurrence15,25,27,42,64,71. Only 
Immuknow was able to differentiate between both64. CD28 yielded conflicting results15,43. 
Measurement of guanylate-binding protein 2/glyceraldehydes 3-phosphate dehydrogenase showed a 
trend toward differentiation, but this was not statistically significant71. Microarray studies are a 
promising path to distinguish between ACR and HCV recurrence. Differential gene expression has 
been observed in liver tissue between patients with ACR, HCV recurrence78 and the absence of 
both79. These different gene expression patterns reflect distinct pathophysiological pathways. 
Genomic analysis will be helpful for the further elucidation of these pathways. However, at this 
moment, microarray-based tests performed on serum are not available. A rare clinical entity is 
antibody-mediated rejection (AMR). It is caused by preformed donor-specific human leukocyte 
antigen antibodies (DSA) and complement activation, and is defined by graft dysfunction, histological 
evidence of acute tissue injury, complement component 4 deposition in the vascular walls and 
elevated DSA mean fluorescence intensity (MFI) 80. AMR is often treatment resistant due to the 
combination of both cellular and humoral mechanisms and often results in graft loss in kidney and 
heart transplant recipients81,82. The clinical significance of AMR after liver transplantation is still a 
matter of debate. Recent work observed DSA in 22.2% of a large prospective liver transplant cohort, 
without affecting rejection rates83. However, several case reports in ABO blood group-compatible 
liver transplants have been reported with poor graft outcome84-86. These data suggest that in steroid-
resistant patients with acute rejection, measurement of DSA titers can lead to the identification of 
AMR and trigger appropriate treatment87. If a promising biomarker has been identified, it should be 
rapidly validated in large multicenter trials that are able to recruit a sufficient amount of patients and 
events to achieve enough power. Discrimination from other events should be tested as well. This is 
probably where former research groups have failed. 
1.3.3.6 CONCLUSION 
THE SEARCH FOR novel biomarkers for the diagnosis of ACR after liver transplantation has progressed 
in parallel with the discovery of new insights in the pathogenesis of rejection. From cytokines over 
genomics to metabolomics, the perfect biomarkers able to challenge the liver biopsy have not been 
discovered yet. However, new techniques and the discovery of new insights in all kind of “omics” 
have the potential of bearing this long-awaited non-invasive biomarker. 
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1.4  PROTEIN N-GLYCOSYLATION AND GLYCOMICS 
1.4.1 GENERAL INTRODUCTION 
1.4.1.1  Protein N-Glycosylation 
In eukaryotic cells, proteins are frequently modified with complex glycan structures. This process, 
called glycosylation, is the most frequent posttranslational modification1. Three major types of 
glycosylation have been observed : N-linked glycosylation of asparaginases1, O-linked glycosylation of 
serine and threonine2 and glycosylphosphatidyl inositol derivatization of the carboxyl-terminal 
carboxyl groups3. Here, we will focus on the N-glycosylation of humans.  
N-glycosylation is essential for cell viability. It is strictly regulated by a multitude of enzymes4 and at
least half of the genes functioning in this biosynthetic pathway have been conserved through
evolution. N-glycosylation is the principal posttranslational modification of serum proteins. These
glycan structures are involved in diverse biological processes including protein folding and
conformation, cell structure and stability and cell-matrix and cell-cell interaction5. 
Alterations in the abundance of particular N-glycans reflect an altered physiological state. This makes 
N-glycans particularly attractive for biomarker development. Furthermore, N-glycoproteins are highly
regulated during growth and differentiation and alterations in protein N-glycosylation patterns
correlate with developmental programs like morphogenesis, proliferation and apoptosis6.
1.4.1.2 Biosynthesis of N-Glycans 
Protein N-glycosylation occurs along the secretory pathway and is localized in the endoplasmic 
reticulum (ER) and the Golgi apparatus7. N-glycan synthesis can be divided in 3 major steps (Figure 1). 
? Formation of a lipid-linked precursor oligosaccharide 
? en bloc transfer of the oligosaccharide to the polypeptide 
? processing of the oligosaccharide8 
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Figure 1. Overview of the pathway for glycoprotein biosynthesis and its location within a cell. 
(Source : Taylor and Drickamer. Introduction to Glycobiology. Oxford 2011).    
Formation of a lipid-linked precursor oligosaccharide 
The donor that initiates N-linked glycan synthesis is a Glc3Man9GlcNAc2 structure attached to the lipid 
dolichol through a pyrophosphate linkage9. Assembly of a glycan on the dolichol head group takes 
place in two phases. The first phase occurs on the cytoplasmic side of the ER membrane, whereas the 
second phase occurs in the lumen. UDP-GlcNAc and guanosine diphosphate mannose (GDP-Man) are 
used as sugar donors for the attachment of the two GlcNAc residues and the first 5 mannose 
residues. Then, the lipid-linked glycan is translocated across the membrane and becomes 
inaccessible to cytoplasmic enzymes (Figure 2)7,9.  
On the luminal side of the ER membrane, further sugars are added using dolichol-linked sugars as 
donors. These are synthesized on the cytoplamic face of the ER membrane and translocated across 
the membrane. 
INTRODUCTION 
65 
Figure 2. Pathway for generation of the dolichol-linked oligosaccharide donor for protein N-
Glycosylation. (Adapted from Taylor and Drickamer. Introduction to Glycobiology. Oxford 2011).    
En bloc transfer of the oligosaccharide to the polypeptide 
The dolichol-linked precursor oligosaccharide is transferred to a asparagine residue in the sequence 
Asn-X-Ser or Asn-X-Thr, where X can be any amino acid except proline. N-linked glycans are found at 
the surface of proteins. Considering that N-linked glycosylation only is initiated in the lumen of the 
ER, N-glycans are only found in secreted proteins and in the portions of transmembrane proteins that 
face the lumen1.  
The completed dolichol-bound precursor glycan is transferred to a polypeptide acceptor by 
oligosccharyltransferase (Figure 1). Exoglycosidases remove monosaccharides from the non-reducing 
end on the glycan7.  This proces is located in the endoplasmic reticulum. 
Lysosomal proteins are also synthesized in the ER and specifically transported through the Golgi 
apparatus to the trans-Golgi network, from which transport vesicles bud to deliver them to the 
endosomal/lysosomal compartment. These lysosomal proteins are tagged with a unique marker: the 
mannose-6-phosphate (M6P) group, which is added exclusively to the N-linked oligosaccharides of 
lysosomal soluble hydrolases, as they pass through the cis-Golgi network. The M6P groups are then 
recognized by two independent transmembrane M6P receptors, present in the trans-Golgi network: 
the cation-independent M6P receptor and/or the cation-dependent M6P receptor. These proteins 
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bind to lysosomal hydrolases on the lumenal side of the membrane and to adaptins in assembling 
clathrin coats on the cytosolic side. In this way, the M6P receptors help package the hydrolases into 
vesicles that bud from the trans-Golgi network to deliver their content to endosomes that ultimately 
will develop into mature lysosomes, where hydrolases may start digesting the endocyted material10.  
Protein folding and N-glycosylation 
In the ER, carbohydrates are added primarily to newly synthesized unfolded proteins. As a result, 
cells can use glycosylation to promote and regulate protein folding and quality control. Protein 
folding is a highly reliable process and is evolutionarily conserved11. Nonetheless, a small proportion 
of proteins misfold and the accumulation of aberrant proteins can be toxic. Proteins that fail to fold 
must be retained and recognized by the ER-associated degradation (ERAD) mechanism for turnover12.  
The first steps in glycan-directed protein folding are trimming of 2 terminal glucose residues from the 
A-branch of the glycan. The lectin-like ER proteins calnexin and calreticul bind to the remaining
glucose residue in the Glc1Man9GlcNAc2 structure. Calnexin is a type I integral membrane protein. Its
lectin domain binds to the glycan and to the A-branch of the N-glycan that interacts with chaperones
and with other parts of the substrate molecule. Calreticulin  is the soluble homologue of calnexin,
and is retained in the ER. This is a transient interactions, that allows the cleavage of the last glucose
by glucosidase II, thereby preventing re-engagement  of calnexin13. The UDP-glucose:glycoprotein
glucosyltransferase (UGGT) inspects the released proteins and those still bearing unfolded domains
are re-glucosylated by UGGT restoring the calnexin-binding site for another round of binding and
release12. This process continues until the protein is fully folded or until it is degraded at the
proteasome14. Well folded proteins all carry a GlcNAc2 Man8-9 structure. 
Processing of the oligosaccharide 
The structure remaining is subject to the action of a series of mannosidases that remove mannose 
residues in alfa 1-2 linkage (Figure 3). These enzymatic actions occur in the Golgi appartus. Some 
glycans will be processed to more complicated structures1,9. These are built on a common core that 
consists of just three mannose residues and two GlcNAc residues attached to the glycoprotein. This 
process is initiated by the attachment of a GlcNAc residue to the 1-3 arm of the core while it still 
contains five mannose residues. GlcNAc –transferase I initiates the re-elongation followed by a 
removal of two additional mannose residues from the 1-6 arm of the core by mannosidases.  
Bi-antennary glycans are most abundant, but tri-antennary and tetra-antennary glycans are also 
common. The branched structures are typically extended by the addition of a single galactose and 
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sialic acid residue to each GlcNAc residue. Building steps for these structures are catalysed by 
galactosyltransferase and sialyltransferases7.   
It cannot be stressed enough that the exact glycan structure is defined by strictly regulated 
enzymatic processes that drive glycosylation. In contrast to glycation, the non-enzymatically driven 
binding of glucose to for example HBa1c, which is used in diabetes monitoring, glycosylation is 
dependent on the substrate itself (in casu a protein) and the enzymes, whose expression is strictly 
regulated. Each cell at a certain time or in a certain condition expresses a specific set of enzymes and 
thus glycans.  
Figure 3. Processing of an initial high mannose N-linked glycan to generate a complex glycan. 
(Source : Taylor and Drickamer. Introduction to Glycobiology. Oxford 2011).    
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Subdivision of N Glycans 
The final result of N-glycan formation can be divided in high mannose, hybrid and complex type 
glycans (Figure 4). Complex type glycans are the most common type for secreted proteins.  
Figure 4. N-glycans can be divided into high mannose type glycans, hybrid type glycans and 
complex type glycans. All share a common core structure. Square : beta-linked GLcNAc; Green circle : 
mannose; yellow circle : galactose; red triangle: fucose; purple diamond: sialic acid 
1.4.1.3 Glycomics  
Glycomics is the comprehensive study of the glycome, which is the entire complement of sugars, 
whether free or present in more complex molecules of an organism. It includes genetic, 
physiological, pathological, and other aspects. It can also be defined as "the systematic study of all 
glycan structures of a given cell type or organism" and is a subset of glycobiology715.  
CORE Structure 
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1.4.2  GLYCOMICS-BASED BIOMARKERS AND LIVER DISEASES : AN INTRODUCTION 
Over the last decade the analysis of the glycome and the subsequently developed glycomics based 
biomarkers have received increasing attention and have evolved from an unknown rarity to a mature 
field of biomarker development. Glycomics is the “systematic study of all glycan structures of a given 
cell type or organism" and is a subset of glycobiology16.  Protein glycosylation is regarded as one of 
the most common posttranslational modifications and is involved in 'specific recognition' events e.g. 
interaction between cells and the modulation and control of crucial biological processes e.g. protein 
folding17.  
N-Glycans are bound to proteins through an amide linkage to the Asparagine (Asn) (N) side chain in
the sequence Asn-X-Serine/Threonin, where X is any amino acid except Proline, by a series of
reactions catalyzed by a complex enzymatic machinery localized in the endoplasmic reticulum (ER)
and Golgi compartments18. Alterations in N-linked glycosylation have been observed during the
development of various diseases including cancer, infections and autoimmune diseases19. Emerging
high-throughput (semi)-automated platforms have catalyzed the development of glycomics-based
biomarkers that measure these posttranslational modifications.
1.4.2.1 Glycomics  
Liver disease is a potential interesting field for serum glycomics-based biomarker discovery because 
the majority of N-glycans found in whole serum are attached to serum proteins produced in the 
liver20 and to a lesser extent to immunoglobulins (Ig), being produced in B-cells21. Interestingly, 
consistent alterations in serum glycan structures have been described in liver diseases including viral 
hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma4. 
For the last ten years, many potential glycomics-based biomarkers for various liver diseases have 
been developed. A first strategy is to measure alterations of the glycome on the total serum protein 
content22, the second is to study glycoalterations on specific proteins, e.g. fucosylation of alpha foeto 
protein (AFP-L3)23.    
However, none of them have been adopted by clinicians for daily clinical use, due to lack of 
validation24 and the use of expensive and labour-intensive technology, although most of these 
markers have a strong pathophysiological rationale. Furthermore, recently new techniques have 
been reported on more accessible platforms e.g. high throughput microfluid systems25 or ELISA 
based techniques, which could accelerate clinical implementation.  
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Histologic assessment of liver tissue obtained by liver biopsy remains the gold standard for the 
diagnosis of liver diseases. However, liver biopsy has been challenged by non-invasive biological 
markers and by measurement of liver stiffness e.g. by transient elastrography26. Non invasive 
techniques are more comfortable for the patient and might overcome interobserver variability27 and 
sampling error28. 
The goal of this review is to summarize the advances in the development of glycomics based markers 
and to identify biomarkers that have potential for clinical use.  
1.4.2.2 Liver fibrosis and cirrhosis 
Liver fibrosis is the result of excessive extracellular matrix deposition in the liver in response to 
chronic inflammatory injury and is determined by the replication balance between fibrogenesis and 
fibrosis degradation. When this balance favours fibrogenesis, there is a resulting accumulation of 
collagen and extracellular matrix, leading eventually to cirrhosis29. The gold standard for evaluation 
of fibrosis is a liver biopsy.  
The whole serum N-glycome shows typical alterations in patients with liver fibrosis or cirrhosis. In 
2004 Callewaert et al. described 8-aminopyrene-1,3,6-trisulfonic acid (APTS)-labeled (N-glycan) 
profiling on a high-throughput DNA sequencer (DNA sequencer-assisted fluorophore-assisted 
capillary electrophoresis or DSA-FACE)3020 to generate profiles of serum protein N-glycans. In a typical 
desialylated serum protein N-glycan profile, 14 glycans were detectable and identified. A biomarker 
was developed named GlycoCirrhoTest20 that distinguished compensated cirrhotic from non-cirrhotic 
chronic liver disease patients, with 79% sensitivity and 86% specificity. GlycoCirrhoTest is based on 
the increase in the proportion of bisecting GlcNac containing N-Glycans and a decrease in the 
proportion of triantennary N-Glycans. Diagnostic capacity was comparable to Fibrotest. Combining 
GlycoCirrhoTest with Fibrotest resulted in an increased diagnostic accuracy for compensated 
cirrhosis to 100% specificity and 75% sensitivity20. These glycoalterations were unrelated to etiology 
of liver disease31. Since 2010 sample preparation has been simplified and can be used on cheap high-
throughput microfluidics CE platforms including the MCE-202 MultiNA, 2100 Bioanalyzer and eGene 
system32. 
The same technique was applied for the development of a marker for progressive fibrosis in chronic 
HCV33 and chronic HBV patients3435, called GlycoFibroTest, based on a gradual increase of the 
proportion of undergalactosylated bisecting GlcNac containing core fucosylated N-Glycans and a 
INTRODUCTION 
71 
decrease in the proportion of triantennary N-Glycans33.  IgG depletion of sera33, demonstrated that 
the undergalactosylation in the whole serum N-glycome is caused by undergalactosylation of 
immunoglobulins and not by liver derived proteins.  Mehta et al.21 also support the hypothesis that 
N-glycome changes in patients with fibrosis are partially derived from immunoglobulins. They
observed alterations in glycosylation of an IgG reactive to galactose with increasing levels of fibrosis.
Again, the main alterations were alpha1,6-core fucosylation and the increase of a bisected
fucosylated biantennary N-glycan21. Sensitivity and specificity were more than 80%.
In contrast to these fibrosis markers, both glycan structures that form the GlycoCirrhoTest are not
IgG related20. Thus, the GlycoCirrhoTest, that is highly specific for cirrhosis but not for increasing
stages of fibrosis is based on glycans on liver secreted proteins and not changes in glycosylation of
IgG.
In chronic HBV infected patients with various degrees of fibrosis, quantitative glycome profiling using 
Maldi-Tof MS identified 4 N-glycans that were incorporated into the Fibro-Glyco index36. Three of 
them were core-fucosylated or showed a bisecting GlcNac. Area under the curve (AUC) for detection 
of fibrosis (Ishak >3) was 0.912 (Sensitivity 85%; Specificity 84%) and for cirrhosis 0.911 (Sensitivity 
88%; Specificity 83%).  
All these biomarkers measure glycomic changes in the total serum protein content. Other biomarkers 
are based on the glycosylation of targeted serum proteins. 
Glyco-alterations including fucosylation and desialylation on the acute-phase protein alpha1-acid 
glycoprotein (AGP) occur during progression of liver fibrosis. Fucosylation appears upon development 
of cirrhosis37. Kuno et al. developed a multiple lectin-antibody sandwich assay to study glyco-
alterations in serum AGP. A combinations of 3 lectins, Aspergillus oryzae lectin (AOL), Maackia 
amurensis lectin (MAL) and Datura Stramonium agglutinin (DSA) was distinctive for the detection of 
severe fibrosis and cirrhosis38. This was followed by the development of an automated triplex lectin-
antibody sandwich immunoassay assisted by an automated protein purification system (ED-01) and a 
bedside clinical chemistry analyzer (HISCL) for the acquisition of two glyco-parameters reacting 
against Aspergillus oryzae lectin (AOL) and Maackia amurensis lectin (MAL)39. This LecT-Hepa test 
correlated with fibrosis stage (R=0,68) and showed an AUC of 0,86 for the diagnosis of severe 
fibrosis. These findings were confirmed in a multicenter study with an AUC of 0,882 for significant 
fibrosis40.  
Another lectin immunoassay, FastLec Hepa, measures quantitative and qualitative alterations of 
serum 90 K/Mac-2 binding protein (M2BP) using the Wisteria floribunda agglutinin (WFA). WFA+-
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M2BP detects hyperfucosylation41. Again, diagnostic performance showed an AUC of more than 0,8 
for significant fibrosis. These data were confirmed recently in a heterogeneous population42. 
Colony stimulating factor 1 receptor (CSF1R) also appears to increase in sera of cirrhotic patients.  An 
antibody-lectin sandwich ELISA was developed for detection of Wisteria floribunda agglutinin-
reactive CSF1R (WFA+- CSF1R)43.  Interestingly, results for WFA+-M2BP and WFA+- CSF1R were 
concordant (R=0,59). CSF1R and M2BP were both expressed in hepatic parenchymal cells and 
macrophages in regenerating nodules.   
Recently, a sandwich ELISA assay was reported measuring fucosylated fetuin A. In patients with 
chronic HBV, decreasing levels of fucosylated fetuin A levels, a negative acute phase protein 
synthesized in hepatocytes, were described in respectively cirrhosis, HCC and healthy controls. 
However, an important overlap was present between cirrhosis and HCC patients44.  
In conclusion, the development of fibrosis and cirrhosis results in typical glycoalterations. Fibrosis is 
an inflammatory driven process with progressive liver damage, which is highlighted by the 
undergalactosylation of IgG related glycans. In established cirrhosis, altered glycan expression is 
primarily hepatocyte driven, as is reflected by the GlycoCirrhoTest20. The GlycoCirrhoTest defining 
glycan is a bisecting GlcNac, which is the product of N-acetylglucosaminyltransferase III (GnT-III)45. 
This enzyme is not expressed in hepatocytes in physiological conditions, but is expressed in 
hepatocytes in the regenerating liver45. Furthermore, GnT-III activity is increased in sera and liver 
tissue of cirrhotic patients46,47. As mentioned before, GCT is increased in cirrhotic patients, but not in 
patients with progressive stages of liver fibrosis, which supports the hypothesis that GCT increase is 
related to upregulation of GnT-III in regenerative nodules, which are the histological hallmark of liver 
cirrhosis and are not present in earlier stages of liver fibrosis. 
In liver fibrosis repeated monitoring in order to assess fibrosis progression or response to therapy is 
an attractive strategy for the assessment of disease prognosis.  Clinicians should keep in mind that 
biomarkers are expressed as continuous variables in contrast to histologic fibrosis staging systems 
(eg. Metavir), that turn a continuous variable into a categorical variable. Comparison between the 
new biomarkers and the histologic gold standard inevitably results in a large overlap between the 
different categories. However, this should be seen as a strength of the biomarker, and not as a 
weakness.  This was nicely illustrated by the HALT-C trial study group, who studied computer-assisted 
morphometry in order to provide precise Histologic measurement of hepatic fibrosis on a continuous 
scale48.  
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Table 1. Glycomics based biomarkers for liver fibrosis and cirrhosis. All patients had histologic 
grading of liver disease unless mentioned otherwise. Legend: AGP : alpha1-acid glycoprotein 
Population Number of 
patients 
Technique Diagnostic Glycan Diagnostic performance 
(Fibrosis level Metavir) 
Reference 
>=F2 F4 
Chronic liver 
disease 
F0-F3: n = 52 
F4: n = 48 
DSA-FACE GlycoCirrhoTest 
?NA2FB, ?NA3 
AUC 0,87 Callewaert et al.20 
Chronic HCV N = 400 DSA-FACE GlycoFibroTest 
?NGA2FB,?NA3 
F2-F4: AUC 
0.71 
Vanderschaeghe 
et al. 33 
Chronic HBV N = 173 
Ishak 0-2 : 87 
Ishak 3-6: 86  
DSA-FACE GlycoFibroTest 
?NGA2FB,?NA3 
AUC 0,710 Gui et al.34 
Chronic HBV N = 128 DSA-FACE ?NGA2FB, ?NA3 AUC 0,736 AUC 0,754 Qu et al.35 
Chronic HBV N = 46 
Ishak 1 : 10 
Ishak 2 : 9 
Ishak 3-4 : 10 
Ishak 5 : 8 
Ishak 6 : 9 
Maldi-Tof 
MS 
Fibro-Glyco Index 
Increase of 2 core-
flucosylated glycans 
and 1 penta-
antennary glycan 
Decrease of NA2.      
AUC 0.912 AUC 0.911 Kam et al. 36 
Chronic HCV 
Non HCV 
cirrhosis 
HCC  
Ishak 1-2 :24 
Ishak 3-5 :1 9 
Ishak 6 : 57 
N = 34 
N=87 
Lectin FLISA ?Anti Alpha-Gal 
epitope on IgG 
Based on ?serum 
glycans 
NGA2F  NA2F NA2FB 
AUC 0.900 AUC 0.930 Mehta et al.21 
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Chronic HBV 
and HCV 
N=125 
F0-1:33 
F2: 32 
F3: 31 
F4: 29 
Multilectin  
assay (12 
lectins) 
Cirrhosis : 
Increased ?-1,3 
fucosylation of the 
Lewis X antigen on  
AGP 
AUC 0.760 AUC 0.900 Kuno et al.38 
Chronic HCV N = 175 Lectin 
Antibody 
immunoassa
y  
LectHepa 
Increased ?-1,3 
fucosylation of the 
Lewis X antigen on 
AGP 
AUC 0.730 AUC 0.950 Kuno et al. 39 
Chronic HCV N = 183 Lectin 
Antibody 
immunoassa
y 
LectHepa 
Increased ?-1,3 
fucosylation of the 
Lewis X antigen on 
AGP 
AUC 0.802 AUC 0.929 Ito et al.40 
Chronic HCV N=209 
F0–F1 : n=82 F2 
: n = 52  
F3 : n = 40  
F4 : n = 35 
Automated 
chemilumine
scence 
enzyme 
immunoassa
y (HISCL) 
FastLec-Hepa 
Increased ?-1,3 
fucosylation of the 
Lewis X antigen on 
AGP. 
Fibrosis > F2 
AUC 0.797 
AUC 0.910 Kuno et al. 41 
Chronic HCV 
(n=160) and 
HBV (n=21) 
Alcohol 
(n=12) 
N=160 
F0–F1 : n=82 F2 
: n = 52  
F3 : n = 40  
F4 : n = 35 
Automated 
chemilumine
scence 
enzyme 
immunoassa
y (HISCL) 
FastLec-Hepa 
Increased ?-1,3 
fucosylation of the 
Lewis X antigen on 
AGP. 
AUC 0.812 AUC 0.795 Toshima et al. 42 
Fibrotest Meta-analysis 
(HCV, HBV, 
alcohol, NASH) 
AUC 0.66 AUC 0.69 Poynard et al.50 
FIB-4 
HCV (n=592) 
F0 : n= 73 
F1: n= 470 
F2: n = 185  
F3 : n = 85  
F4 : n = 61 
Age,  platelets, ALT, 
AST 
>F3:
AUC 0.85
AUC 0.91 Vallet-Pichard et 
al.51 
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Glycomics based test for fibrosis and cirrhosis are based on whole serum or specific serum proteins 
and show a diagnostic accuracy of at least 80% for advanced fibrosis (F3-F4), which is comparable to 
a commercialized test like Fibrotest. The main issue is the lack of external validation, with exception 
of the FastLec-Hepa test. In the validation cohort however, the diagnostic performance did not reach 
0,8049.    
The question remains whether glycomics-based biomarkers for liver fibrosis and liver cirrhosis could 
challenge currently used biomarkers. Recently published EASL Clinical Practice Guidelines Non-
invasive tests for evaluation of liver disease severity and prognosis26 do not mention any glycomics-
based biomarkers. The proposed biomarkers by EASL show a good diagnostic accuracy (AUC > 0.80%) 
for cirrhosis but are far less robust for detection of significant fibrosis (>= F2). FibroTest® and  APRI 
are the most widely used and validated tests for fibrosis/cirrhosis and are being integrated in clinical 
practice. According to our overview (table 1), glycomics-based biomarkers might challenge FibroTest 
and APRI for detection of cirrhosis. Furthermore, a combination of FibroTest and GlycoCirrhoTest 
showed an increased performance for the diagnosis of cirrhosis20. However, confirmation in larger 
trials is necessary. 
1.4.2.3 NAFLD and NASH 
Non alcoholic fattly liver disease (NAFLD) encompasses the entire spectrum of fatty liver disease in 
individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis 
(NASH) and cirrhosis52. The burden of NASH is increasing and NASH has become the second leading 
cause for liver transplantation in the USA53. There is an urgent need for biomarkers that can 
distinguish NAFLD from NASH54, as a liver biopsy is still required55. Hence, this ideal biomarker could 
identify NASH patients among NAFLD patients, a subgroup that needs a more careful follow up 
regarding the increased risk for progression to fibrosis54.  
The glycomic approach has generated interesting answers to this question (Table 2).  In a first study 
the glycomic analysis using DSA-FACE according to Callewaert et al.20 was applied in sera of 47 NAFLD 
patients including 82% NASH patients. Desialylated sera of NASH patients contained significantly 
higher relative abundance of NGA2F (a core fucosylated agalactosylated biantennary glycan) and 
lower relative abundance of NA2 (a galactosylated non fucosylated biantennary glycan). The 
logarithmic transformation of this proportion was called the GlycoNashTest and could identify NASH 
patients among NAFLD patients with an accuracy of 74,3%56. In contrast to earlier studies, the 
authors did not observe an increase of bisecting GlcNac carrying biantennary glycans in NASH 
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patients with fibrosis, as we observed in patients with chronic liver disease (viral hepatitis and 
alcoholic liver diseases) with increasing levels of fibrosis22,33.  
The GlycoNashTest was validated in a multicentre Belgian study of 275 obese patients undergoing 
bariatric surgery57. The AUC to distinguish NASH from borderline NASH and steatosis varied between 
0,66 and 0,75, which was equal to K18F. Interestingly, the value of the GlycoNashTest increased 
significantly according to the level of lobular inflammation but not to the fibrosis stage.  
GlycoNashTest showed the lowest p-value57. The N-glycan profile of IgG that was isolated from sera 
of these patients confirmed the increased undergalactosylation in NASH patients.  The diagnostic 
utility of GlycoNashTest was also demonstrated in a pediatric population58. Considering that the 
hallmark of NASH is the presence of an inflammatory infiltrate, it makes sense that the observed 
glycoalteration in NASH is immunoglobulin driven.   
A Japanese group developed a so called ”Sweetblot” technique, an automated protocol for 
integrated glycoblotting and MS59. In contrast to Callewaert et al20, these glycans are not desialylated 
before analysis. In NASH patients, among 41 glycans examined, 8 glycans were increasingly 
expressed, 2 hybrid type, 3 bisected biantennary type and 2 triantennary type glycans. Among those, 
3 glycans m/z 1955 (a bisected biantennary type fucosylated glycan), m/z 2032 (a hybrid type glycan) 
and m/z 2584 (a triantennary fucosylated glycan) showed an UAC above 0,8360. These glycans 
showed a positive correlation with the level of lobular inflammation, ballooning and steatosis.      
The glycoalteration of specific glycoprotein has proven helpful in the diagnosis of NASH. Measured by 
a lectin-antibody ELISA kit, serum Fucosylated Haptoglobin (Fuc-Hpt) levels have been reported as a 
marker for NASH (AUC 0,734)61. Fuc-Hpt levels showed a significant increase according to increasing 
hepatocyte ballooning score. In almost 900 NAFLD patients (without histologic grading of liver 
disease) serum Fuc-Hpt increased stepwise with increasing FIB-4 index61. In the mean time, the same 
group developed an ELISA assay based on glycoalterations in Fuc-Hpt and Mac2BP. The latter was 
initially developed as fibrosis marker. The combination of both yielded a diagnostic performance for 
distinguishing NAFLD from NASH of 0,854 in a pilot cohort and 0,844 in a large validation cohort62. As 
reported earlier, Fuc-Hpt reflects hepatocyte ballooning and Mac2BP detects the presence of 
fibrosis. 
The current gold standard for diagnosis for NASH remains liver biopsy. A promising alternative would 
be the measurement of cytokeratin-18 (CK-18) that showed an AUC of 0.711 to distinguish simple 
steatosis from NASH63. However, subsequent cohorts showed disappointing diagnostic values (AUC 
of 0.631 and 0.500)64. In our analysis, the glycan based GlycoNashTest showed a higher diagnostic 
accuracy than CK-1857. 
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Table 2 : Glycomics based biomarkers for NAFLD and NASH. All patients had histologic grading of 
liver disease unless mentioned otherwise. 
 
Population Number of 
patients 
Technique Diagnostic 
Glycan 
Diagnostic 
performance 
Reference 
NAFLD and 
NASH 
NAFLD : n=9 
NASH : n = 38 
DSA-FACE GlycoNashTest 
?NGA2F,?NA2 
             
NASH : AUC 0.743 Chen et al.56 
NAFLD and 
NASH 
NAFLD : n=199 
NASH : n=76 
DSA-FACE GlycoNashTest 
?NGA2F,?NA2 
            
NASH : AUC 0.66 – 
0.75 
Blomme et al.57 
Paediatric 
NAFLD and 
NASH 
NAFLD : n=5 
NASH : n=46 
DSA-FACE GlycoNashTest 
?NGA2F,?NA2 
             
NASH : AUC 0.72 Blomme et al.58 
NAFLD and 
NASH 
NAFLD : n=15 
NASH : n=42 
Sweetblot 
(integrated 
glycoblotting 
and MS) 
m/z 1955 m/z 2032 
        
m/z 2584 
 
NASH : AUC 
0,833 
0,863 
0,866 
Yamasaki et al.60 
NAFLD and 
NASH 
NAFLD : n= 19 
NASH : n= 107  
Lectin Ab 
ELISA 
Fucosylated 
Haptoglobin 
NASH : AUC 0,734 
 
Kamada et al.61 
NAFLD and 
NASH 
Training cohort 
NAFLD : n= 29 
NASH : n= 95 
Validation 
cohort 
NAFLD : n= 169 
NASH : n= 213 
Lectin Ab 
ELISA 
Fucosylated 
Haptoglobin and 
Mac2bp 
AUC : 0,854 Kamada et al.62 
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In conclusion, a biomarker to identify NASH patients among NAFLD patients is an unmet clinical need. 
Glycomic changes in whole serum or on targeted glycoprotein (eg. Fuc-Hpt and Mac2BP) are 
promising markers for NASH.  
1.4.2.4 Hepatocellular carcinoma 
Diagnostic biomarkers 
Alterations in glycosylation of glycoproteins has been reported in several cancers, e.g. ovarian 
cancer65, colorectal cancer66 and prostate cancer67 amongst others. They are involved in the entire 
spectrum of carcinogenesis, from tumor progression, tumor cell differentiation, over cell- cell 
interaction and tumor cell adhesion to metastasis68.  For example, the histoblood group Lewis (Le) 
antigens are found in most human epithelial tissues attached to glycolipids and glycoproteins. The 
expression of the sialylated antigens, SLea (a branch alfa-1,4-fucosylated tetrassacharide) and SLex (a 
branch alfa-1,3-fucosylated tetrassacharide) is significantly enhanced in cancer. Both SLea and SLex 
contribute to hematogenous metastasis, in which blood-invading cancer cells adhere to blood vessels 
endothelial cells in requiring the presence of carbohydrate ligands on cancer cells and at the same 
time E-selectin receptors on endothelial cells. SLea mediates adhesion of cancer cells derived from 
the lower digestive organs (colon and rectum), pancreas and biliary tract, while the SLex mediates 
adhesion of breast, ovarian and pulmonary cancer cells69.  
HCC has been the first focus of glycobiomarker development. Similar glycoalterations in serum and in 
HCC tissue suggest that glycans are involved in tumor formation and development70.  For decades 
alfafoetoprotein (AFP) has been used as a diagnostic marker for HCC and it remains the best 
diagnostic and prognostic biomarker for clinical use, despite the overall disappointing accuracy71. AFP 
is a glycoprotein produced by the yolk sac and the fetal liver45.  AFP has a single N-linked 
oligosaccharide with a biantennary complex-type structure. During cancer development altered 
terminal sialylation and core fucosylation appear. This fucosylation is detectable using Lens culinaris 
agglutinin (LCA) lectin and the LCA-reactive fraction of AFP (AFP-L3) is an improved diagnostic 
accuracy for HCC compared to AFP levels72.  Using a cut off of 10 ng/ml, sensitivity for detection of 
(early) HCC was 60% and specificity 90%73.  
The technique developed by Callewaert20 for high-throughput analysis of N-glycans was also applied 
on HCC patients. In HBV-related HCC patients NA3Fb, a branch alfa-1,3-fucosylated triantennary 
glycan (involving the SLex epitope) was more abundant than in patients with cirrhosis or fibrosis 
without HCC. On the other hand the abundance of a bisecting core alpha-1,6-focusylated biantennary 
glycan (NA2FB) was lowered74. The logarithmic transformation of this ratio was renamed 
INTRODUCTION 
 
79 
 
GlycoHCCTest and reached a diagnostic accuracy of 81%, equal to AFP in this cohort and showed a 
clear correlation with tumor stage. A Chinese group applied the same technique  in HBV related HCC 
patients and reported that in an increase of NA3Fb, an alfa-1,3-fucosylated  triantennary glycan and a 
decrease of NG1A2F, an agalacto monogalactosylated core-1,6-fucosylated biantennary glycan, was 
associated with HCC with a diagnostic accuracy of 0,87375. Furthermore, this glycomarker compared 
to AFP showed more diagnostic accuracy for the presence of vascular invasion.  
An integrated platform using “glycoblotting” and MS was developed for N-glycan profiling of whole 
serum76. This group claims a 100% diagnostic accuracy for HCC using a subset of 4 glycans (Man5, 
NGA2, NA2G1 and NA2). Interestingly, none of these glycans are fucosylated. 
In a set of 83 N-glycans in human serum, 53 glycans were altered in HCC patients compared to a 
control population77. In a multivariate logistic regression, 3 glycans remained significantly associated 
with HCC. The combination of these glycans in a blinded validation set showed an AUC of 0,960. An 
increase was seen in the abundance of a biantennary bisecting glycan and a decrease in triantennary 
and tetra-antennary complex glycans. None of these glycans were fucosylated. In contrast, in a 
exploratory analysis of 27 HCC patients, HCC patients could be identified with a high diagnostic 
accuracy (AUC 0.811) due to increased fucosylation of 5 serum proteins (C3, CE, HRG, CD14 and 
HGF)78.  
Using LC-ESI-MS, compared to cirrhotic patients without HCC,  8 N-glycans were upregulated and 3 
N-glycans were downregulated in HCC patients79.  These glycans could be grouped in 4 clusters: a 
cluster of 3 biantennary glycans (upregulated), a cluster of 4 beta-1,6,GlcNAc branching glycans 
(upregulated), a cluster of 5 other beta-1,6,GlcNAc branching glycans (downregulated) and a cluster 
of 5 tetra-antennary glycans (upregulated). Cluster 3 and 4 are downstream products of GnT-V.  
The Sweetblot technology, also used for NASH biomarkers, was applied on a larger cohort of 114 HCC 
patients on a background of viral hepatitis80. The ratio of m/z 3195, a tri-sialylated triantennary 
complex type glycan with fucose residue on m/z1914 (a bigalactosylated biantennary fucosylated 
glycan) showed an AUC of 0,810 for the distinction of HCC from liver cirrhosis and chronic viral 
hepatitis80. Both glycans were similar to those represented by the GlycoHCCTest74. 
Beside these whole serum protein content glycomic fingerprinting, glycoalterations on specific serum 
proteins in HCC were also studied.  
Debruyne et al.81 isolated Hemopexin, a liver secreted protein, from human serum. Specific glycomic 
patterns on Hemopexin showed increased branching ?-1,3-fucosylated multi-antennary glycans in 
HCC. A Chinese group reported an increase of fucosylation and sialylation of paraoxonase 1  
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Table 3 : Glycomics based biomarkers for HCC. All patients had histologic grading of liver disease 
unless mentioned otherwise. Exploratory studies with low number of patients and/or lack of HCC size 
were excluded from the table.  
Population Number of 
patients 
HCC size Technique Diagnostic Glycan Diagnostic 
performance 
Reference 
Diagnostic Biomarkers 
HCC in 
Chronic 
HBV 
N= 227 TNM 
classification
: 
T1 : n=6 
T2 : n= 28 
T3 : n=59 
T4 : n=5 
DSA-FACE GlycoHCCTest 
?NA3FB  ?NA2FB 
AUC : 
0.81 
Significan
t 
correlatio
n with 
TNM 
stage  
Liu et al.74 
HCC in 
chronic 
HCV 
N=73 Stage I/II: 
n=18 
Stage III/IV: 
33 
(AJCC 
staging) 
MALDI-
TOF MS 
Increased 
abundance 
Decreased 
abundance 
AUC 
0.960 
Goldman et al.77 
HCC N=20 Not reported DSA-FACE Hemopexin Glycan 
marker: 
?NA3Fcb ?NA4Fb 
?NA2 
AUC 
0.920 
Debruyne et al.81  
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Liu et al.78  
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Fang et al.75 
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lectin 
affinity 
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?fucosylation 
and sialylation 
of serum 
PON1 
AUC 
0.902 
Sun et al.82 
HCC N=110 Not reported Lectin 
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?fucosylation 
serum PON1 
AUC 
0.803 
Zhang et al.84 
HCC 
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HBV/HCV/
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N=50 
(18/42/40) 
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StageIV:n=  8 
MALDI-
QIT-TOF 
Increased 
Bifucosylation 
of 
Haptoglobin 
AUC 
0.821-
0.843 
Zhu et al.87 
 
 
heteroplasmon (PON1) in sera of early HCC patients82 (AUC 0.902). PON1 is a calcium-dependent 
hydrolase protein synthesized mainly by liver cells and secreted in the circulation and contains 3 
identified glycosylation sites83. Recently, an ELISA was reported for measuring fucosylation index of 
PON1. AUC for the diagnosis of early HCC was 0.80384.  
Analysis of site specific glycans on the serum haptoglobin beta chain revealed increased sialylation on 
the NLFN207HSEN211ATAK site and an overall increased fucosylation85. Another study reported 
increased fucosylation on plasma haptoglobin and vitronectin (VTN)86. Quantitative analysis of serum 
haptoglobin fucosylation unequivocally showed that the presence of core and branch fucosylation 
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could differentiate between HCC and cirrhosis (AUC > 0.80)87. In HBV and alcohol related liver but not 
in HCV related liver disease, total fucosylation index was also discriminative for HCC. This finding 
however should be interpreted with caution considering the limited number of patients in every 
subgroup.  
In summary, consistent alterations of glycosylation have been observed in HCC : increased 
fucosylation, increased presence of bisecting GlcNac residues and increased branching leading to the 
accumulation of triantennary and tetra-antennary glycans4.  These processes are the result of the 
upregulation of fucosyltransferases and the N-acetylglucosaminyltransferases III and V4,88,89. 
Targeting glycoalterations on specific proteins is not superior to whole serum protein N-glycan 
analysis for HCC diagnosis90.   
1.4.3.5 Discussion 
Biomarkers are playing an increasingly important role in the management of patients with chronic 
liver diseases. The last decade, we witnessed an exponential increase in glycomics-based biomarkers 
in the field of hepatology. This review summarized data regarding glycobiomarkers for liver 
fibrosis/cirrhosis, NAFLD/NASH and HCC.  
The first observation is the important number of studies regarding glycobiomarkers by several groups 
using different techniques. Diagnostic markers were developed for fibrosis/cirrhosis, NAFLD/NASH 
and HCC with a good diagnostic performance (AUC >0,8). Unfortunately,  most biomarkers lack 
external validation. However, consistent glyco-alterations were observed according to the underlying 
condition. We expect validation studies in the upcoming years.  
Second, the observed glyco-alterations are supported by a pathophysiological rationale, eg. the 
increased presence of fucosylatransferases in HCC, reflected by the increased fucosylation of several 
glycoproteins9161,928,84,88. Three glycosyltransferases deserve further attention: N-
acetylglucsaminyltransferase V (GnT-V), N-acetylglucosaminyltransferase III (GnT-III) and alfa,1-6 
fucosyltransferase (alfa,1-6FT). GnT-V catalyzes beta1-6 branching of N-acetylglucosamine on 
asparagines (N)-linked oligosaccharides of cell proteins, GnT-III catalyzes the formation of the 
bisecting GlcNac in a beta 1,4 linkage 45,47,93 and alfa,1-6,FT moves a fucose residue from GDP-fucose 
to N-linked type complex glycopeptides with an alfa,1-6 linkage94. Both GnT-III and GnT-V are 
increased in HCC and compete for the same substrate.  In HCC, Beta1-6,GlcNac branching catalysed 
by GnT-V correlates with TNM classification of HCC95 and with metastasis96. On the other hand, an 
increase of GnT-III might suppress GnT-V activity and subsequent GlcNac beta,1-6, branching, what 
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could counteract tumor progression34,96,97, which was the rationale for the GlycoHCCTest74 and 
confirmed by Fang et al34.  
Although hyperfucosylation has been reported in cirrhosis21 and NASH61, hyperfucosylation seems to 
be preferentially related to HCC91. The majority of glycomics based biomarkers for HCC are based on 
increased fucosylation, preferentially core fucosylation. Two markers are not based on an increase of 
fucosylation, although increased fucosylation was seen in HCC sera in one study77 and not reported 
nor denied in the other study76. 
However, Methta et al. studied core fucosylation levels in HCC tissue and surrounding non-tumoral 
liver tissue. In 16 samples, fucosylation was not consistently increased in HCC tissue compared to 
adjacent tissue and tissue of healthy controls98. In contrast, increased levels of a tetra-antennary 
glycan (A4F4) were observed in HCC tissue98. In this study this same glycan was also statistically 
increased in a small set of 18 HCC sera compared to serum of 9 cirrhotic patients.  
The third observation is that these glycoalteration can be studied on whole serum proteins or on 
isolated proteins eg. haptoglobin, PON1, fibronectin etc. Diagnostic performance is not increased by 
targeting single proteins. Clinical application requires a rapid high throughput automatised 
technique, what could favor whole serum analysis. Several markers could fulfill this requirement 
including the GlycoHepatoTest (including the GlycoCirrhoTest20, GlycoFibroTest25, GlycoNashTest57 
and GlycoHCCTest74) in a single analysis and the Sweetblot59 technique.   
 
If we take a closer look at the specific domains where these biomarkers have been tested, interesting 
conclusions can be drawn regarding the application in clinical practice.  
LIVER FIBROSIS AND CIRRHOSIS 
The first observation is that increasing levels of fibrosis correlate with inflammatory changes. Our 
group33 amongst others90 formerly showed that fibrosis was associated with increasing levels of 
undergalactosylated IgG related glycans. Probably, these changes reflect the ongoing inflammation 
rather than the established fibrosis.  A Japanese team developed the Fast-Lec Hepa, an automated 
immune-assay that measures hyperfucosylation on Mac 2 Binding protein using a lectin 
immunoassay. However, the underlying characteristics of the test have not been revealed41. All these 
markers show excellent correlation with fibrosis stage. Although these markers show excellent 
diagnostic accuracy (AUC > 0.900 for advanced fibrosis) these are not superior to other non glycomic 
serum fibrosis markers like fibrotest99 or FIB451 that have now been adopted by clinicians. 
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A special test in this series is the GlycoCirrhoTest. It is not a marker of fibrosis but a specific marker of 
cirrhosis. In contrast to the GlycoFibroTest that measures inflammation, the GlycoCirrhoTest is 
defined by an increase of a bisecting GlcNAc, which is the product of GnT-III20. The activity of this 
enzyme is increased in cirrhotic nodules and absent in normal resting hepatocytes45. Given that the 
cirrhotic nodule is the hallmark of cirrhosis, this pathophysiological rationale supports the strong 
diagnostic performance for established compensated and decompensated cirrhosis with a high 
specificity (>90%) at a specificity of more than 60%.  
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
There is a real unmet medical need for non-invasive markers of NAFLD. For the differentiation 
between simple steatosis and NASH a liver biopsy is required. Specific glycomic signatures have been 
observed in patients with NASH compared to simple steatosis. The GlycoNASHTest used the same 
technology as the GlycoFibroTest and the GlycoCirrhoTest. The GlycoNASHTest is based on an 
increase of undergalactosylated glycans and correlates with lobular inflammation, ballooning and 
steatosis but not with fibrosis57. Although the AUC for differentiation between NASH and steatosis 
was adequate (AUC = 0.750), an important overlap was seen between both groups, hampering the 
use in clinical practice. A Japanese group developed an automated protocol for integrated 
glycoblotting and MS (Sweetblot technique) and defined another glycomic signature that correlated 
with lobular inflammation, ballooning and steatosis60. Increased fucosylation of Haptoglobin was also 
associated hepatocyte ballooning62 in another study. 
The field for biomarker development in NAFLD is huge. In Western countries it affects 17–46% of 
adults100. The current EASL guidelines on the management on NAFLD that have been published only a 
few months ago advocate that NASH “has to be diagnosed by a liver biopsy showing steatosis, 
hepatocyte ballooning and lobular inflammation (A1)”100. This illustrates the total lack of efficient 
biomarkers for the diagnosis of NASH. This is a real opportunity for research groups to refine and 
improve glycomics-based biomarkers for the diagnosis of NASH.  
HEPATOCELLULAR CARCINOMA 
The field of HCC shows the largest research in glycomics-based biomarkers. Glycomic alterations can 
be summarized as increased fucosylation, increased bisecting GlcNAc residues, and increased 
branching with complex tri- and tetra-antennary glycans.  
In the evolution towards personalized medicine, the real medical need for HCC biomarkers is limited 
to (1)  the very early diagnosis of HCC where cure is still possible and (2)  as markers of response to 
therapy and relapse. This overview shows that most glycomics-based biomarkers have excellent 
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results in large established tumours, but have not adequately been tested in very small tumours. This 
proves that it makes sense to measure glycomic alterations in serum of HCC patients as these 
changes are reflected by an altered glycosylation machinery in HCC tumours. However,  these 
findings need to be refined in early tumours in order to prove a real clinical benefit.  
Interestingly, probably the best glycomic biomarker for HCC is probably the oldest: AFP-L3. AFP-L3 is 
the fucosylated L3 fraction to total AFP ratio. It is superior to classic AFP measurement for early 
diagnosis of HCC and it has been shown that pre-treatment AFP-L3 levels in HCC patients undergoing 
a treatment have a prognostic value101.  The use of these marker is however not advocated by 
current guidelines102.   
In conclusion, glycomics are a sweet and promising field of biomarker development with robust 
biomarkers for several liver diseases. Although most markers have not been externally validated, 
consistent findings amongst different research groups and the well described pathophysiological 
rationale of these glycoalterations could shine a new light on glycobiomarkers that remain a hidden 
gem.  
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II. Study Goal
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The introduction of this work reviews the current knowledge of glycomics-based biomarkers for the 
diagnosis of chronic liver disease. The goal of this PhD thesis was to explore new horizons in the 
application of glycomics-based biomarkers, with a focus on prognostic markers in liver disease and 
liver transplantation.  
Indeed, in this era of personalized medicine, prognostic markers will gain tremendous importance in 
the development of the therapeutic strategy of a given patient. 
The prognostic potential of glycomics-based biomarkers was explored in several areas of liver 
disease.  
1. The potential of serum glycomics-based biomarkers to predict the risk of hepatocellular
carcinoma development in compensated cirrhosis.
Liver cirrhosis is the major risk factor for development of HCC. The current strategy used by
clinicians is to screen cirrhotic patients using ultrasonography (with or without serum AFP
measurement) every 6 months in order to detect early and treatable HCC lesions. We
explored the role of the GlycoCirrhoTest, a non invasive serum marker, as a glycomarker to
stratify between high- and low risk patients for the development of HCC.
Potential clinical relevance : A specific glycomic signature (GlycoCirrhoTest) of cirrhotic
patients with a high-risk for development of HCC could lead to the implementation of
personalized surveillance protocols for patients, according to the GlycoCirrhoTest value. This
could increase awareness among patients with a high risk for HCC development to adhere to
screening programs and could reassure low-risk patients. Futhermore, it could prove cost-
effective as the number of visits in a significant number of low-risk patients might be
reduced.
2. The potential of glycomics-based biomarkers to assess the quality of the donor liver graft
before liver transplantation using perfusate analysis. 
In liver transplantation, the quality of the donor liver graft has a major impact on the
outcome of the patient after transplantation. The goal of this work was double: 
STUDY GOAL 
95 
(1) Evaluation of the technical feasibility of glycomic analysis of perfusate 
We evaluated whether the method for N-glycan analysis in serum developed by
Callewaert et al.1 is applicable in perfusate, the preservation fluid in which the liver is
transported, often for many hours, from donor to recipient. 
(2) Development of glycomic-based biomarkers for primary non function after liver
transplantation. 
We explored the role of the glycomics signature in perfusate of different outcomes
after liver transplantation, including normal liver function, early allograft dysfunction
and primary non function. In patients suffering from primary non function a specific
and highly discriminative glycomic signature was discovered, leading to the
development of a new biomarker.
A patent application PCT /EP2016/ 065383 was filed for this biomarker. 
Potential clinical relevance : The identification of a specific glycomic signature in perfusate of 
patients with a high risk of PNF development enables transplant physicians to make 
evidence-based decisions in organ allocation. A high risk for PNF development can guide the 
removal of high-risk organs from the organ donor pool or reassure the transplant physician 
that the risk for PNF using this specific organ will be low.  
3. The potential of glycomics-based biomarkers to assess the outcome after liver
transplantation in the early transplant period using serum analysis 
In this project we performed a sequential glycomic analysis of serum in the immediate peri-
transplant period. The goal was to study the evolution of the serum glycome in the first 2
weeks after liver transplantation and to explore glycomic signatures predictive for survival of
the liver graft and the patient.
Potential clinical relevance : A specific glycomic signature that identifies patients with a high
risk of organ loss or even death during the first year after liver transplantation is a valuable
tool for decision-making in the post-transplant period.  It could allow a closer follow-up of
these patients and could endorse the decision to perform a retransplantation in a particular
patient with problematic liver function after LT and a high GlycoTransplantTest value. 
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4. The potential of glycomics-based biomarkers to assess the appearance of acute cellular
rejection after liver transplantation using a non-invasive serum analysis.
Acute cellular rejection (ACR) is a frequent complication after liver transplantation and
requires liver biopsy for diagnosis. The goal of this work was double:
(1) A literature review regarding potential non-invasive diagnostic markers for ACR was
performed (included in the introductory section). 
(2) The potential of glycomics-based markers for the non-invasive diagnosis of ACR was
explored.
Potential clinical relevance : Reliable non-invasive markers for ACR are an unmet clinical 
need. If a specific glycomic signature could be found during the occurrence of ACR, it could 
lead to the development of a non-invasive biomarker for ACR and thus avoid liver biopsies in 
patients after liver transplantation. 
5. The potential of glycomics-based biomarkers to assess outcome in acute liver failure using
serum analysis 
Acute liver failure is a serious liver condition occurring in otherwise healthy often young
patients without underlying liver disease. In some patients urgent liver transplantation is
required.
The goal of this work was to explore the dynamic glycomic changes in serum during the
occurrence of acute liver failure. Furthermore, we provide a proof of concept that the
glycomic signature at admission can predict transplant-free survival.
Potential clinical relevance : A glycomic signature that can predict transplant-free survival in
ALF patients could allow to withhold patients from liver transplantation and guide only those
patients to liver transplantation who need it in order to survive the ALF episode.
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III. The potential of glycomics-based
biomarkers to predict the risk of
hepatocellular carcinoma development in
compensated cirrhosis
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3.1 ABSTRACT 
Purpose: Cirrhosis is a major risk factor for the development of hepatocellular carcinoma (HCC), but 
remains underdiagnosed in the compensated stage. Fibrosis progression and cirrhosis are associated 
with changes in blood serum glycomic profiles. Previously, the serum glycomics-based 
GlycoCirrhoTest  was shown to identify 50-70% of compensated cirrhosis cases in chronic liver 
disease cohorts, at >90% specificity. This study assessed GlycoCirrhoTest for the risk of HCC 
development in compensated cirrhosis. 
Experimental Design: Serum glycomics were analysed in sera of 133 patients with compensated 
cirrhosis collected between 1995 and 2005 in a surveillance protocol for HCC using an optimized 
glycomic technology on a DNA sequencer. 
Results: Baseline GlycoCirrhoTest values were significantly increased in patients who developed HCC 
after a median follow-up of 6.4 years as compared to patients who did not. For patients with a 
baseline GlycoCirrhoTest exceeding 0.2, the hazard ratio for HCC development over the entire study 
(Cox regression) was 5.1 (95% CI 2.2-11.7;p<0.001), and the hazard ratio for HCC development within 
7 years was 12.1 (95% CI 2.8-51.6;p=0.01) based on cut-off value optimized in the same cohort. An 
absolute increase in GlycoCirrhoTest of 0.2 was associated with a hazard ratio of 10.29 (95% CI 3.37-
31.432.11;p<0.001)  for developing HCC. In comparison, the hazard ratio for the development of HCC 
within 7 years for AFP levels above the optimal cutoff in this study (5.75 ng/ml) was 4.65 (95% CI 
1.588-13.607).   
Conclusions: This prognostic study suggests that GlycoCirrhoTest is a serum biomarker that identifies 
compensated cirrhotic patients at risk for developing HCC. Screening strategies could be guided by a 
positive test on GlycoCirrhoTest. 
3.2 INTRODUCTION 
Hepatocellular carcinoma (HCC) represents up to 85% of the primary liver cancer burden2. In recent 
years, an increasing number of biomarkers have been proposed for the diagnosis of HCC3. Other 
markers have been proposed to better assess the prognosis of the outcome of HCC4. However, to 
increase the effectiveness of screening aimed at detecting HCC at the early stage that is amenable to 
curative therapy, it is important to accurately identify the main risk groups. In this regard, it is well 
established that liver cirrhosis is the most important risk factor for HCC development. Indeed, in 
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Figure 1 : The glycomic analysis and GlycoCirrhoTest 
Panel A: The structures of the N-glycan peaks in the total serum of a cirrhotic patient as obtained using capillary 
electrophoresis yields 13 peaks. From left to right : Peak 1 is an agalacto, core-alpha-1,6-fucosylated 
biantennary (NGA2F), peak 2 is an agalacto, core-alpha-1,6-fucosylated bisecting biantennary (NGA2FB), peak 3 
and peak 4 are single monogalacto, core-alpha-1,6-fucosylated biantennary structures (NG1A2F), peak 5 is the 
bigalacto biantennary glycan NA2, peak 6 is the bigalacto, core-alpha-1,6-fucosylated biantennary glycan NA2F, 
peak 7 is the bigalacto, core-alpha-1,6-fucosylated bisecting biantennary glycan NA2FB, peak 8 is the 
triantennary glycan NA3, peak 9 is the branching alpha-1,3-fucosylated triantennary glycan NA3Fb, peak 9 is 
the core-alpha-1,6-fucosylated triantennary glycan NA3Fc, peak 10 is the branching alpha-1,3-fucosylated and 
core alpha-1,6-fucosylated triantennary glycan NA3Fbc, peak 11 is a tetra-antennary (NA4) and peak 12 is a 
branching alpha-1,3-fucosylated tetra-antennary (NA4Fb) glycan. The symbols used in the structural formulas 
are: square indicates beta-linked N-acetylglucosamine (GlcNAc); yellow circle indicates beta-linked galactose, 
triangle indicates alpha/beta-1,3/6-linked fucose; green circle indicates alpha/beta-linked mannose.  
Panel B: The GlycoCirrhoTest  profile of patients with cirrhosis is characterized by an increase in the relative 
expression of NA2FB, a bisecting N-acetylglucosamine containing N-Glycan, and a decrease in the relative 
expression of NA3, a triantennary N-glycan on glycoproteins in serum. The upper glycomic profile shows a 
patient with a low GlycoCirrhoTest, who did not develop HCC during follow-up. The lower glycomic profile 
shows a patient with a high GlycoCirrhoTest, who did develop HCC during follow-up. In this patient, the relative 
expression of NA2FB is increased while the relative expression of NA3 is decreased.  
Panel C: N-acetyl-glucosaminyltransferase III (GnT- III) catalyzes the addition of an N-acetylglucosamine 
(GlcNAc) residue from the uridinediphosphate (UDP)-GlcNAc donor to core-mannose in a ? 1-4 configuration 
and forms bisecting GlcNAc. 
 
most prevalent aetiologies of chronic liver disease, the vast majority of HCC cases originate on a 
background of cirrhosis5678, likely because hepatocellular cell proliferation in the inflammatory 
context of cirrhotic nodules provides a strongly enlarged pool of dividing hepatocytes in which 
mutagenesis can result in tumour formation.  In patients with compensated cirrhosis the annual 
incidence of HCC ranges from 1% to 8%9. EASL and AASLD guidelines advocate systematic ultrasound-
based screening for HCC in any patient with cirrhosis on the basis of ultrasonography (US) every 6 
months1011. The aim of screening is to detect small tumours with more chance of curative therapy12. 
This screening strategy in cirrhotic patients showed a reduction in HCC mortality rates13 and it is cost-
effective14. Unfortunately, the proportion of cirrhosis patients who do have screening remains low. 
For instance, in a North American cohort, less than 20% patients with HCC reported to have received 
regular screening before diagnosis15. An important reason for this is that the compensated stage of 
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liver cirrhosis remains underdetected. The current diagnosis of compensated cirrhosis is through liver 
biopsy in chronic liver disease patients. However, biopsy is unsuited for regular patient monitoring 
and a reliable and specific non-invasive biomarker that identifies the cirrhosis-characteristic 
hepatocyte proliferation that predisposes to HCC development could fill this gap. 
We have previously shown that the GlycoCirrhoTest, a “glycomics” biomarker based on profiling of 
the N-glycans from the total serum protein using capillary electrophoresis (CE), could distinguish 
chronic liver disease patients with compensated cirrhosis from those with earlier stages of fibrosis. 
Furthermore, GlycoCirrhoTest has been optimized for use in clinical laboratories, using high-  
throughput DNA sequencers or CE-based analysers16,17, including those that are in use in clinical 
chemistry for routine serum protein electrophoresis (unpublished results).  
The GlycoCirrhoTest profile of patients with cirrhosis is characterized by an increase in the proportion 
of bisecting N-acetylglucosamine (GlcNAc)- containing N-glycans and a decrease in the proportion of 
triantennary N-glycans on glycoproteins in serum (Figure 1). The enzyme N-
acetylglucosaminyltransferase III (GnT-III) catalyzes the addition of a bisecting GlcNAc residue in ?1,4 
linkage to the ?-linked mannose of the trimannosyl core structure of N-linked oligosaccharides of 
glycoproteins, using UDP-GlcNAc as donor substrate18. This leads to the formation of the defining 
sugar moiety of the GlycoCirrhoTest (Figure 1). Neither bisecting GlcNAc residues nor GnT-III activity 
are detectable in a rat model in non-nodular liver tissue surrounding liver nodules or in livers of age 
and sex matched control rats19,20. On the other hand, in 2 different rat models of HCC (induced by 
1,2-dimethyl-hydrazine or diethylnitrosamine) significant levels of GnT-III expression were observed 
in hepatic non-malignant cirrhotic nodules as well as in HCC nodules. Significantly increased GnT-III 
activity was also observed in sera and liver tissue of patients with  nodular cirrhosis and HCC but not 
in patients with chronic hepatitis without cirrhosis21,22. After treatment of HCC with transarterial 
chemoembolization or percutaneous ablation, serum GnT-III levels decreased markedly21,22. 
Altogether, these data suggest that GnT-III is produced in the liver in (pre)neoplastic states but not in 
non-cirrhotic chronic liver diseases or normal liver tissue. 
Because of this biology, in the present study we had the aim of investigating the hypothesis that a 
high GlycoCirrhoTest value may identify those compensated cirrhosis patients with the highest risk of 
progressing to HCC during follow-up. For comparison, we also studied the prognostic value of FIB-423 
and alpha foetoprotein (AFP). 
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3.3 PATIENTS AND METHODS 
3.3.1 STUDY COHORT 
The study population consisted of 133 consecutive cirrhotic patients. Serum samples were 
prospectively collected between 1995 and 2005 at the Department of Hepatology of Beaujon 
Hospital (Clichy, France) and stored at -20°C. These patients were part of a large French multicentric 
prospective randomised trial on behalf of the “Groupe d’Etude et de traitement du carcinome 
hépatocellulaire” (GRETCH) that compared ultrasonographic surveillance of HCC in cirrhosis at 3- 
versus 6-month interval24.  The study conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki and was approved by the Ghent University Hospital ethics committee.   
 
 
 
Figure 2: Flowchart with overview of inclusion- and exclusion criteria.  
 
 
All patients had biopsy proven Child-Pugh A (n=116) or B (n=10) cirrhosis at the time of serum 
sampling. None of the patients had evidence of HCC at enrolment based on imaging (ultrasound [US] 
and, where needed, computed tomography [CT] and/or magnetic resonance imaging [MRI]). 
Demographic data were retrieved from the patient’s files. Seventy percent of the patients had 
CHAPTER 3 
104 
chronic hepatitis C virus (HCV) infection. Other causes of cirrhosis included chronic hepatitis B virus 
(HBV) infection, alcohol abuse and autoimmune diseases (Table 1). After enrolment, all patients had 
careful screening for HCC based on Doppler-US every 6 months or 3 months according to 
randomization. A standardized report was completed by each operator, mentioning the presence or 
absence of focal lesions. If focal lesions were present, the localization, number, echogenicity and 
diameter of nodules were recorded. After the termination of this trial (with a mean follow-up of 4 
years), patients were followed according to EASL guidelines25 with abdomen US every 6 months with 
or without alpha foetoprotein (AFP) measurement according to center policy. One patient who 
developed HCC during the first year and six patients with a follow-up shorter than one year were 
excluded from further analysis (Figure 2). 
3.3.2 DESIGN 
A glycomic fingerprint including the GlycoCirrhoTest  was obtained on serum samples collected at 
enrolment in this prospective cohort study24 and stored. Alpha-Foetoprotein (AFP) levels were 
measured on the same serum samples. FIB-4 was calculated using available laboratory values from 
the medical records.  Diagnosis of HCC was established according to the 2001 EASL criteria25. When 
imaging was not conclusive, patients had a US guided-biopsy. Patient characteristics and routine 
laboratory values at inclusion are summarised in Table 1.  
3.3.3 GLYCOMIC ANALYSIS 
Five microliter of serum were processed according to the in-solution deglycosylation method 
described by Vanderschaeghe et al.16. Briefly, denaturing buffer containing SDS was added to the 
serum and incubated for 5 min at 95°C. Then, the samples were treated with Peptide N-glycosidase F 
to release the N-glycans from their denatured carrier proteins. After enzymatic removal of the 
terminal sialic acid residues, the glycans were labeled with 8-aminopyrene-1,3,6-trisulphonic acid 
and analysed using an ABI3130 DNA sequencer as described26. The result of this analysis is a total 
serum protein electropherogram (Figure 1), which consists of 13 peaks. Each peak represents a well-
identified glycan17. The numerical height of every peak is quantified and normalised to the sum of all 
peak heights, thus represented as a percentage of total peak height.  The GlycoCirrhoTest is 
calculated as the logarithmic transformation of the abundance ratio of a bigalacto core-?-1,6-
fucosylated bisecting biantennary glycan (NA2FB) to a triantennary glycan (NA3)1.  
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3.3.4 ALPHA-FOETOPROTEIN ANALYSIS 
All serum samples were diluted in 0.9% NaCl and analysed by Electro-chemiluminescence 
immunoassay (ECLIA) in a MODULAR E module (ROCHE). 
 
3.3.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using IBM©SPSS©Statistics Version 22.0. Based on a two sample t-
test, mean serum levels of biomarkers were compared between patients that developed HCC and 
those who did not. For every marker a  cox regression analysis was performed with the development 
of HCC as outcome variable. For cox regression analysis, an internal validation of the model was 
performed by applying a bias-corrected and accelerated (BCa) bootstrap  (n=1000).  Based on the 
relative change in abundance of the 6 glycans that were different (p ?0.1) at baseline between the 
group of patients that developed HCC and those who did not, we designed a new composite score, 
the GlycoHCCRiskScore, based on multivariable logistic regression. GCT, based on two single glycans 
as described above, was also calculated. For both the GlycoHCCRiskScore and the GCT a ROC analysis 
was performed and Youden index was used to select an optimal cut-off. The patients were classified 
according to these cut-offs, and Cumulative Incidence (One minus cumulative survival) was 
calculated with the Kaplan-Meier method. Cox regression analysis was used to estimate the hazard 
ratio for HCC development in the biomarker-positive vs. biomarker-negative patient groups.  A 
multivariable cox regression analysis was performed including GlycoCirrhoTest and AFP . Using the 
validate function of the rms package in R (version 3.2.3) cross-validation was applied to the logistic 
and cox regression models to adjust for the optimism in C-Index estimation.  Statistical significance 
was set at the alpha level = 0.05. 
 
3.4 RESULTS 
3.4.1 BASELINE CHARACTERISTICS 
After exclusion of patients (n=6) with a follow-up of less than 1 year and patients who developed HCC 
less than 1 year after enrolment (n=2), 125 patients were included for final analysis (Figure 2). Among 
these patients, 34 (27.2%) developed HCC during follow-up after a mean interval of 66.67 months (SD 
29.30). Baseline characteristics of patients who developed HCC were comparable to those who did 
not, except for time at risk (Table 1). Time at risk was defined as the duration of follow-up until 
appearance of HCC, liver transplantation, death or loss to follow-up. Six patients died during follow 
up. Three deaths were related to HCC. Time at risk was higher in the patients who did not develop 
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HCC, compared to those who did (7.6 years vs. 5.7 years, p=0.012). However, this is inherent to the 
study design, as follow-up was stopped as soon as the patients developed HCC.  
 
3.4.2 ASSOCIATION OF GLYCOCIRRHOTEST WITH THE  DEVELOPMENT OF HCC 
GlycoCirrhoTest is calculated as the logarithmic transformation of the ratio NA2FB to NA3 (Figure 1) 
and was initially developed as a diagnostic marker for cirrhosis1. Baseline GlycoCirrhoTest values 
were significantly higher (Figure 3) in patients who developed HCC during follow-up compared to 
patients who did not develop HCC (mean GlycoCirrhoTest value : 0.33 vs 0.16, p<0.001). 
A cox regression analysis was performed with baseline GlycoCirrhoTest as a single predictor for the 
risk for developing HCC. The hazard ratio (HR) of GlycoCirrhoTest of 1 for developing HCC was 10.294 
(95%CI: 3.37231.426, p<0.001) . Each more modest increase of GlycoCirrhoTest of 0.2, which is more 
clinically relevant, showed a hazard  ratio of 1.59 (95%CI: 1.275-1.993, p<0.001).  A bootstrap analysis 
confirmed these data (p<0.001). The estimated C-Index of this regression analysis was 0.69, after 
cross-validation the estimated C-Index was 0.69.  
A ROC analysis (Figure 3) showed an area under the curve of 0.71 (p=0.001 – 95% CI 0.59-0.80) for 
the association with  HCC development. Based on the Youden index a cut off of 0.2 was defined, 
yielding a sensitivity of 79% and a specificity of 62%. After cross-validation the estimated c-index was 
0.70. 
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Table 1: Baseline characteristics of cirrhotic patients developing HCC and patients without HCC  
 All Patients No HCC HCC  
    p-value (Fisher’s Exact 
Test) 
Gender (M/F) 96/29 
(76.8/23.2%) 
68/23 
(74.7/25.3%) 
28/6(82.3/17.6%) 0.388 
Etiology    0.830 
HCV 72 51(56%) 21(61%)  
HBV 27 22(24%) 5(14%)  
Alcohol 8 5(6%) 3(9%)  
Alcohol+HCV 8 8(9%) 0(0%)  
Alcohol+HBV 6 1(1%) 5(15%)  
Other 4 4(4%) 0(0%)  
     
 Mean (+/- SD) Mean (+/- SD) Mean (+/- SD) p-value (Mann Whitney U 
test) 
Age 53.1 (11.1) 52.6 (11.2) 53.9 (10.2) 0.528 
Time at risk 
(years) 
6.76 (3.8) 7.6 (3.9) 5.6 (2.6) 0.018 
Child Pugh  5.3 (0.7) 5.3 (0.7) 5.3 (0.6) 0.825 
Total Bilirubin 
(mg/dl) 
1.1 (0.6) 1.1 (0.6) 1.2 (0.4) 0.087 
Albumin (g/l) 38 (5.4) 38 (5.7) 38 (4.9) 0.889 
Creatinine 
(mg/dl) 
0.81 (0.14) 0.80 (0.1) 0.85 (0.1) 0.109 
AST (U/l) 67 (50) 66 (51.9) 67 (46.6) 0.340 
ALT (U/l) 75 (69) 74 (68.3) 74 (75.3) 0.872 
GGT (U/l) 149 (147) 144 (147.6) 150 (131.5) 1.000 
PAL (U/l) 99 (57) 90 (51.2) 122 (77.9) 0.100 
Platelets (/?l)  143689 
(55860) 
143150 (53445) 152125 (53285) 0.618 
INR 1.21 (0.21) 1.20 (0.19) 1.22 (0.22) 0.974 
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As illustrated in figure 4, in patients with a GlycoCirrhoTest value <0.2 at enrolment, the Kaplan-
Meier cumulative incidence of HCC after enrolment was 23% for the complete duration of the study. 
In patients with a GlycoCirrhoTest value ?0.2 at enrolment, the cumulative incidence of HCC after 
Figure 3. Overview of results  Panel A:  Baseline values of GlycoHCCRiskScore and GlycoCirrhoTest 
are significantly increased in patients who developed HCC during follow-up (tested by Mann Whitney 
U test). This was not the case for AFP and FIB-4 values. Panel B:  ROC analysis showed a AUC for the 
development of HCC during follow-up of respectively 0.73 (95% CI: 0.063-0.083) and 0.70 (95% CI : 
0.59-0;80) for GlycoHCCRiskScore and GlycoCirrhoTest. AFP and FIB-4 failed to show a significant 
association with HCC occurrence (AUC respectively 0.66 (95% CI 0.59-0.77) and 0.56 (95% CI 0.449-
0.65)).  
enrolment was 57%. The cumulative incidence of HCC after 5, 7 and 10 years in patients with a 
GlycoCirrhoTest value above or equal to 0.2 at enrolment was 22.2%, 41.9% and 57.0%. In patients 
with GlycoCirrhoTest below 0.2 cumulative incidence rates were respectively 3.3, 3.3 and 22.6%. It is 
clear from visual inspection of these curves that the predictive power for HCC risk of GlycoCirrhoTest 
stretches is mainly valid for a remarkably long 5-7 years upon serum sampling, upon which the 
discriminatory power wanes. This is confirmed using ROC analysis for HCC occurrence over different 
length of monitoring time upon serum sampling. In this cohort, the highest AUC values were reached 
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for the prediction that a patient would develop HCC within the next 5-6 years (Table 2). After this, 
the AUC trended downwards again.  
 
Table 2. Time-dependent prognostic value of GlycoCirrhoTest and  GlycoHCCRiskScore. Values 
reflect the area under the curve using ROC analysis with 95% CI (between brackets). 
 Number of HCC 
cases 
GlycoHCCRiskScore  GlycoCirrhoTest 
HCC within 2 years 3 0.605 (0.274-0.896) 0.438 (0.223-0.829) 
HCC within 3 years 6 0.703 (0.401-0.896) 0.643 (0.392-0.869) 
HCC within 4 years 10 0.798 (0.633-0.901) 0.742 (0.534-0.902) 
HCC within 5 years 14 0.803 (0.566-0.899) 0.766 (0.612-0.889) 
HCC within 6 years 17 0.771 (0.610-0.881) 0.742 (0.569-0.871) 
HCC within 10 years 34 0.729 (0.602-0.856) 0.691 (0.564-0.791) 
 
 
Overall hazard ratio for HCC development based on Cox regression analysis was 5.05 (95% CI 2.2-
11.7; p<0.001) for the total duration of the study. Taking into account only the first 7 years of follow 
up, the hazard ratio was 12.1 (95% CI 2.8-51.6; p=0.01).  
 
3.4.3 PROGNOSTIC VALUE OF AFP, FIB-4  AND OTHER BASELINE BIOCHEMICAL VARIABLES 
Mean serum AFP levels were slightly increased in the group of patients who developed HCC, as 
compared to the group of patients who did not (16.09 vs. 10.79 ng/ml; p=0.008). A cox regression 
analysis showed a significant increase of HCC risk according to baseline AFP value with a hazard  ratio 
equal to 1.018 (95%CI: 1.005-1.031, p=0.008).  A bootstrap analysis confirmed these data (p<0.001).  
A ROC analysis showed an area under the curve of 0.67 (p=0.005 – 95% CI 0.59-0.77) for the 
association with HCC occurrence (Figure 3). Again, we defined the cut off using the Youden index. 
The optimal cut off value for AFP was 5.75, yielding a sensitivity of 76% and a specificity of 55%. In 
patients with AFP levels below 5.75 at enrolment, the cumulative incidence of HCC was 6.4%. In 
patients with AFP levels above or equal to 5.75 at enrolment, the cumulative incidence of HCC was 
19%.  
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Overall hazard ratio for HCC development based on Cox regression analysis was 3.21 (95% CI 1.47-
7.07; p=0.04) for the total duration of the study. Taking into account only the first 7 years of follow 
up, the hazard ratio was 4.65 (95% CI 1.59-13.61; p=0.005).  
Mean FIB-4 values were comparable between the patients who developed HCC and those who did 
not (4.01 vs. 3.93, p=0.545). Baseline Child-Pugh score, MELD score, platelets, INR, bilirubin and 
albumin level were not different between patients who developed HCC and those who did not (Table 
1). Using univariable cox regression analysis, none of these markers were significantly related to HCC 
occurrence.  
 
3.4.4 MULTIVARIABLE COX REGRESSION MODEL INCLUDING GLYCOCIRRHOTEST AND AFP . 
Only GlycoCirrhoTest and AFP were significantly associated with HCC occurrence in univariable cox 
regression analysis. Both were included in a multivariable cox regression analysis. This  model 
confirmed the strong association of GlycoCirrhoTest with HCC development (HR 8.77: 95% CI 2.74-
28.08; p<0.001). In contrast, in this multivariable regression model, AFP showed no significant 
association with HCC development (p=1.165).  
 
3.4.5 TOTAL BASELINE GLYCOMIC FINGERPRINT AND RISK FOR DEVELOPING HCC 
The blood serum N-glycan electropherogram yields 13 glycans that have been identified before26 
(Figure 1). The GlycoCirrhoTest is based on only two glycans. Next, we wanted to investigate whether 
changes in the other 11 glycans generated in the N-glycan analysis could provide additional HCC-
predictive information that was not captured by the two glycans of the GlycoCirrhoTest. In the 
patients who developed HCC during follow up, a significant increase in the relative abundance of 
NA2FB (p=0.028) and NA3Fb (p=0.023) as well as a significant decrease in the relative abundance of 
NA3 (p=0.01) and NA4 (p<0.001) were observed. The relative abundance of the remaining glycans did 
not differ significantly between both groups, although NA3Fbc (p=0.066) and NGA2FB (p=0.056) 
showed a trend to increase at the ?-level of 0.05 (Mann Whitney U-test throughout).  
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Figure 4: Cumulative incidence curve representing the risk for developing hepatocellular carcinoma 
according to value of the GlycoCirrhoTest. The cohort was divided according to the GlycoCirrhoTest 
threshold and monitored for the appearance of hepatocellular carcinoma. The blue line represents 
patients with a GlycoCirrhoTest value <0.2; the green line represents patients with a GlycoCirrhoTest 
above or equal to the threshold of 0.2. These patients show an increased risk for HCC development 
(Hazard ratio = 5.1; 95% CI 2.2-11.7; p<0.001). Censored cases (as indicated by crosses on the 
cumulative incidence curves) died, underwent liver transplantation or were lost to follow-up. 
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Based on the relative change in abundance of these 6 glycans that differed at baseline between the 
group of patients that developed HCC and those who did not (p ? 0.1) (Mann Whitney U) we 
designed a new composite score (GlycoHCCRiskScore) via logistic regression analysis.  
GlycoHCCRiskScore=[(NGA2FB*0.137)+(NA2FB*-0.044)+(NA3*-0.216) 
+(NA3F*0.158)+(NA3Fbc*0.796)+(NA4*-0.764)]. 
The algorithm includes the relative increase or decrease of every glycan (beta-value) given by logistic 
regression analysis. As expected, the mean baseline GlycoHCCRiskScore is significantly increased in 
cirrhotic patients (-0.69  vs. -1.39, p<0.001) that developed HCC during follow-up (Figure 3). 
A cox regression analysis was performed (univariable analysis) to further evaluate the value of 
baseline GlycoHCCRisk score for association with  the risk for HCC development.  An increase of 
GlycoHCCRiskScore with 1 showed a HR of 2.72 (CI 1.69-4.38, p<0.001) for HCC occurrence. An 
internal bootstrap validation confirmed the statistical significance of this finding (p < 0.001). The 
estimated C-Index of this cox regression was 0.75, after cross-validation the estimated C-Index was 
0.67. 
A ROC analysis (Figure 3) was performed for the HCC-prognostic value of GlycoHCCRiskScore and 
showed an area under the curve of 0.730 (95% CI 0.63-0.83; p<0.001). After cross-validation the 
estimated C-Index was 0.640. This is not significantly better than the value obtained for 
GlycoCirrhoTest, indicating that this simple marker comprehensively captures the HCC-hazard 
relevant information in the total serum N-glycome. 
3.5 DISCUSSION 
Although many biomarkers have recently been developed for the diagnosis of (early) HCC3, 
prognostic markers to stratify patients with compensated cirrhosis with higher and lower risk for HCC 
are lacking.  
We here find that a simple serum glycomics-based biomarker (GlycoCirrhoTest) can be used to assess 
the risk for the development of HCC in patients with compensated cirrhosis. The role of the liver in 
the glycosylation of serum proteins is central. GlycoCirrhoTest is based on the ratio of abundance of 
a  bisecting GlcNAc-modified N-glycan and a triantennary glycan on the total mixture of serum 
proteins. We previously showed that this marker could help identify patients with compensated 
cirrhosis among patients with chronic liver diseases, with a 79% sensitivity and a 86% specificity1 in 
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the discovery cohort at the statistically optimal cutoff value. At the slightly higher cutoff of 0.2 which 
was found in the present study to be optimal for use of GlycoCirrhoTest as an HCC risk predictor, 
about 50% of compensated cirrhosis cases surpass this threshold in an aggregate analysis of three 
independent cohorts from multiple clinical centers (total number of included chronic liver disease 
patients >600; manuscript in preparation). This corresponds well with the 50% cumulative long-term 
incidence of HCC observed in the present study for compensated cirrhosis patients with a 
GlycoCirrhoTest value of higher than 0.2. Although these findings require further validation, this 
strongly indicates that GlycoCirrhoTest-based monitoring of chronic liver disease patients would 
reliably and non-invasively detect almost all compensated cirrhosis patients who are at real risk for 
HCC development. This answers a major medical need in current tools for cirrhosis and HCC 
monitoring. 
The cut-off of 0.2 favours sensitivity above specificity, as the implications of a false positive screening 
results, which would lead to a supplementary imaging of the liver, is more acceptable than a false 
negative result. Patients who expressed a GlycoCirrhoTest above 0.2 experienced a significantly 
increased cumulative HCC incidence of 42% versus 3% after 7 years (p<0.001). Overall hazard ratio 
for HCC development based on Cox regression analysis was 5.1 (95% CI 2.2-11.7; p<0.001)  for 
patients who had a baseline GlycoCirrhoTest higher than 0.2, and at this same cutoff the hazard ratio 
for HCC development within 7 years was 12.1 (95% CI 2.8-51.6; p=0.01). In contrast, AFP showed a 
hazard ratio of 4.65 (95% CI 1.588-13.607; p=0.005). In a multivariable cox regression model 
including GlycoCirrhoTest and AFP , only GlycoCirrhoTest showed a significant association with the 
occurrence of HCC.  Similarly, the prognostic value of the whole glycomic fingerprint including all 13 
glycans, as expressed in the  GlycoHCCRiskScore was not superior to the value of the GlycoCirrhoTest. 
Of note, all of the glycans that had higher abundance in the patients with increased HCC risk were 
modified with either a fucose, a bisecting GlcNAc or both, whereas the glycans with decreased 
abundance are the unmodified precursors. This overall glycome change is most simply and robustly 
captured in GlycoCirrhoTest (AUC = 0.70, which is very similar to the one of the full complexity 
GlycoHCCRiskScore, AUC = 0.73).  
The underlying pathophysiological rationale of the GlycoCirrhoTest is partially elucidated. The 
enzyme responsible for the formation of bisecting GlcNAc residues, N-acetylglucosaminyltransferase 
III (GnT-III) is not expressed in hepatocytes in normal physiological conditions, but is increasingly 
expressed in rat liver dysplastic and malignant nodules during hepatocarcinogenesis19,20. 
Furthermore, GnT-III activity is gradually increased in sera and nodular liver tissue of cirrhotic 
patients without and with HCC22,21. Importantly, we previously showed that GlycoCirrhoTest is 
specifically increased in cirrhotic patients, but not in patients with earlier stages of liver fibrosis1, 
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which supports the hypothesis that GlycoCirrhoTest increase is related to upregulation of GnT-III in 
regenerative nodules, which are the histological hallmark of liver cirrhosis and are not present in 
earlier stages of liver fibrosis. It is conceivable that with more hepatocytes actively dividing in such 
nodules, the risk for propagation of oncogenic mutations increases and hence the risk for HCC rises. 
Therefore a true marker for such nodular regeneration in liver cirrhosis should also be a good risk 
marker for HCC, as validated here for GlycoCirrhoTest1. 
Alternative biomarkers for HCC risk have been proposed. FIB-4, a composite biomarker based on AST, 
ALT, platelet count and age, has been suggested as a prognostic marker for HCC development among 
chronic hepatitis C infected patients; however, this study included a majority of non-cirrhotic 
patients, and was not designed to assess risk within a cirrhotic cohort27. In contrast, our cohort 
included only patients with compensated cirrhosis. Within this cirrhotic population, the HCC 
prognostic power of FIB-4 could not be confirmed. Risk models for the prediction of HCC risk have 
been developed. Abu-amara et al.28 recently perfomed an external validation of 5 risk models for HCC 
development and showed a good prognostic performance, especially for the identification of low risk 
patients. However, these models have only been developed for chronic hepatitis B patients. It is well 
known that hepatitis B is an oncogenic virus with appearance of HCC before the cirrhotic stage has 
been reached in a larger fraction of patients29. Hung et al.30 developed a risk scoring system in an 
Asian population based on routine clinical parameters, that detects more incident HCC patients as 
compared to current guidelines, within 10 years. Again, 62% of patients included in this cohort were 
HBsAg positive. Our cohort covers primarily patients with chronic hepatitis C and alcohol related liver 
disease, which reflects the European or North American epidemiology. The value of GlycoCirrhoTest 
in predicting HCC risk in HBV-infected patient populations remains to be determined in future 
studies. 
Current EASL and AASLD guidelines1011 recommend biannual screening of cirrhotic patients with 
ultrasonography for the appearance of HCC, which is cost-effective as it results in the detection of 
more cases of HCC in a stage that can be effectively treated using existing interventions. However, 
such screening requires the prior diagnosis of cirrhosis, and this is often not the case for patients 
with early-stage, compensated cirrhosis. Inclusion of GlycoCirrhoTest in the monitoring scheme for 
chronic liver disease patients can fill this gap, which should ultimately lead to the detection of more 
HCC cases at a curable stage of the disease than is presently achievable. 
Furthermore, using the 0.2 cut-off, GlycoCirrhoTest offers a high 7-year negative predictive value for 
HCC development of 97%, allowing for the selection of low risk patients. We might imagine that 
these patients could be offered a less stringent follow-up which is not only more convenient for the 
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patients but might prove a cost-saving strategy. These observations demand a prospective validation 
with GlycoCirrhoTest measurement as part of the monitoring strategy for chronic liver disease 
patients, preferably in current standard clinical practice. The immediate utility of GlycoCirrhoTest 
may also be to use it as an  inclusion criterion for cirrhotic patients in HCC-preventing clinical trials. 
With a 12 fold increase of 7 year HCC incidence in the GlycoCirrhoTest positive group, the required 
number of patients for  clinical trials could be very significantly reduced, saving cost and time in 
organising such trials.  
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4.1 ABSTRACT  
Introduction : Primary non function (PNF) is a rare but major complication after liver transplantation 
requiring urgent retransplantation. It is associated with the use of extended-criteria donors. The 
donor risk index is a clinical score that can guide the estimation of graft quality but lacks the power 
to predict PNF risk in individual patients. Perfusate analysis is an attractive tool for assessment of 
donor liver function before implantation. Glycomic assessment of serum has proven useful in the 
diagnosis of liver disease. Here, we performed a comprehensive analysis of perfusate in relation to 
the appearance of PNF. 
Methods: In this prospective monocentric study 66 consecutive liver transplantations between 
October 2011 and July 2013 were included. Perfusate samples were collected after flushing of the 
hepatic veins before implantation of the liver graft. All donor grafts were transported using cold 
static storage. Based on an optimized DNA sequencer technology we performed glycomic analysis of 
these perfusate samples and searched for glycomic alterations in PNF patients. 
Results:  The relative abundance of one single glycan, an agalacto core-alpha-1,6-fucosylated 
biantennary glycan (NGA2F) was significantly increased in the perfusate of the 3 patients that 
developed PNF after liver transplantation. It could identify PNF patients with 100% accuracy. This 
glycomarker, called GlycoPNFTest, was the only predictor of PNF in a multivariate analysis 
(p<0.0001). 
Conclusion: In this cohort, patients who developed PNF after liver transplantation showed a specific 
glycomic signature in perfusate (before liver transplantation) that could distinguish them from non-
PNF patients with 100% accuracy. This approach could guide the removal of donor grafts at risk for 
PNF from the donor pool, especially when the use of high-risk organs is considered. 
 
4.2 INTRODUCTION 
Liver transplantation is the treatment of choice for end-stage liver disease, acute liver failure and 
selected patients with hepatocellular carcinoma1 with excellent long term results2.  A major challenge 
in the expansion of organ transplantation is shortage of donor organs, which is reflected in a 
unacceptably high waiting list mortality3. This bottleneck has led to the use of expanded criteria 
donors (ECD) donors in order to increase the donor pool4–6. Marginal livers or ECD livers carry an 
increased risk of liver failure or an increased risk of disease transmission. Scoring systems have been 
developed to predict the organ quality based on clinical characteristics of the donor including the 
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donor risk index (DRI)7, and the more recently developed European variant, the Eurotransplant donor 
risk index (ET-DRI)8. However, although these instruments are of great value for population based 
studies, they fail to predict the outcome of a single donor9 and cannot yet be included in allocation 
strategies.  
A particular problem associated with the use of these low quality grafts is primary non function 
(PNF)10. PNF occurs after 2-10%11–13 of liver transplantations and was first described by Shaw et al.14 
as a situation where “a graft never demonstrated evidence of initial function following 
transplantation” after exclusion of technical causes and acute cellular rejection needing an urgent 
retransplantation. A more frequent but less dramatic phenomenon is early allograft dysfunction 
(EAD), which is a functional insufficiency after orthotopic liver transplantation characterized by a 
constellation of findings that may include hyperbilirubinemia, coagulopathy, encephalopathy or 
ascites15. It occurs in up to 1 in 4 liver transplantations15. In contrast to PNF it does not require urgent 
retransplantation. Nevertheless, EAD is associated with increased graft loss and patient mortality 
within the first 90 days15,16 after liver transplantation.    
Reliable prognostic clinical scores or biomarkers to predict the appearance of PNF or EAD after liver 
transplantation are not available. Here, we performed a comprehensive analysis of N-glycans in 
perfusate in relation to the appearance of PNF and EAD after LT.  
Indeed, during the last ten years it has become clear that N-glycan analysis of serum, also called 
glycomics, is useful for the diagnosis of various liver diseases17. After the discovery that a glycomic 
based serum biomarker can reliably distinguish different stages of liver fibrosis from liver 
cirrhosis18,19, glycomics-based biomarkers for the diagnosis of hepatocellular carcinoma (HCC)20,21 and 
a biomarker to distinguish simple liver steatosis from non-alcoholic steatohepatitis22,23 based upon N-
glycan analysis have been developed. 
The aim of this study was to explore the feasibility of N-glycan analysis of glycoproteins in graft 
perfusate after flushing of the donor liver graft. The second aim was to search for distinct N-glycan 
profiles in patient that developed PNF, EAD and patients with a good liver graft function, in order to 
develop biomarkers to monitor organ quality and predict PNF.  
The results of the present study provide a strong proof of concept that the analysis of N-glycans in 
preservation fluid can predict the appearance of PNF after liver transplantation.  
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4.3 MATERIALS AND METHODS 
4.3.1 STUDY POPULATION 
This monocentric study was performed at the Liver Transplant Unit of Ghent University Hospital 
(Belgium) between October 2011 and July 2013. In this period, 85 orthotopic liver transplantations 
were performed in 74 adult patients at Ghent University Hospital. In this cohort of patients, 
perfusate from 66 liver transplantations in 64 patients could be sampled prospectively. Recipient and 
donor characteristics are summarized in table 1.  
PNF was defined as the need for urgent retransplantation when a graft did never demonstrate any 
evidence of initial function following transplantation after exclusion of other causes like hepatic 
artery thrombosis or acute cellular rejection. It was accompanied by high transaminases, low PT, high 
bilirubin and high lactate within 24 hours after liver transplantation.  
EAD was defined according to Olthoff et al.15 as the presence of one or more of the following 
previously defined postoperative laboratory analyses : bilirubin >= 10 mg/dl on day 7, INR >= 1.6 on 
day 7, alanine or aspartate aminotransferases (AST or ALT) > 2000 UI/l within the first 7 days.  
Donor risk index was calculated according to Feng et al.7. 
 
4.3.2 DESIGN 
Every liver transplant patient was eligible as described before.  The perfusate samples were collected 
upon arrival at the recipient hospital during the backtable procedure, after transport of the donor 
liver. A glycomic analysis of these perfusate samples was performed and the glycomic profile was 
related to the outcome parameters PNF and EAD.  
 
4.3.3 SAMPLE COLLECTION AND PROCESSING 
The perfusate sample was obtained during the back-table procedure. Liver grafts were procured 
according to local practices and transported to our center in Histidine-trypotophan-ketoglutarate 
(Custodiol HTK, Franz Köhler Chemie GmbH, Bensheim, Germany) or Wisconsin solution (UW Belzer, 
Costorsol, Bridge to Life, London, United Kingdom). During the back-table procedure, the left hepatic 
vein was flushed with a syringe of 20 ml of perfusate in which the graft had been transported under 
normal hydrostatic pressure. Perfusate samples were collected and immediately stored at -21°C.  
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Table 1. Patient Characteristics. Patients were divided according to the occurrence of PNF or EAD. 
Variables between groups were compared using Kruskal-Wallis test. Continous variables are 
expressed as means followed by standard deviation (SD) between brackets.  *Highest INR value 
betweed postoperative day 2 and day 7. **Highest total bilirubin value between postoperative day 2 
and 7 
  No PNF/EAD 
(n =44) 
EAD (n=19) PNF (n=3) p-value 
Recipient 
Characteristics 
    
     
Demographic 
data 
    
Age  49.68 (13.64) 52 (15.09) 50 (19.16) p=0.704 
Sex (M/F) 26/18 13/6 2/1  
     
Biochemical data     
AST at 48 hours 
(U/L)  
594 (446) 2194 (2138) 5488 (6195) 0.001 
ALT at 48 hours 
(U/L)  
592 (456) 1574 (1461) 1384 (1271) 0.004 
INR* 1.58 (0.76) 2.17 (1.13) 3.52 (0.96) 0.001 
Total bilirubin** 
(mg/dl)   
2.91 (3.06) 6.06 (6.55) 11.73 (8.40) 0.006 
     
Donor 
Characteristics 
    
Age    74.89 (17,69) 47.68 (16.88) 47.67 (18.23) 0.989 
Sex (M/W)   2/1  
Length (cm)    172.80 (6.75) 174.32 (7.42) 171 (7.8) 0.310 
Weight (cm)    77.08 (11.76) 84.84 (23.41) 60.50 (6.34) 0.093 
Perfusate 
(HTK/UW) 
33/10 12/6 2/1  
CIT (minutes)  422.18 
(121.68) 
389.42 
(102.338) 
493 (9.90) 0.763 
WIT (minutes)    36.73 (12.23) 42.26 (19.36) 40 (11.31) 0.473 
AST (U/L)    55.43 (51.91) 63.05 (61.85) 22.50 (3.53) 0.705 
ALT (U/L)  42.08 (39.65) 53.53 (65.67) 25.50 (19.09) 0.611 
GGT (mg/dl)    69.53 
(101.94) 
59.26 (44.20) 20.50 (7.79) 0.704 
Total Bilirubin 
(mg/dl)   
2.43 (5.77) 2.14 (3.85) 0.72 (0.17) 0.925 
DRI   1.67 (0.36) 1.69 (0.41) 1.71 (0.35) 0.897 
DCD  0 3 0  
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4.3.4 N-GLYCOSYLATION ANALYSIS 
All samples were defrosted and analysed in one run. The glycomic analysis was performed in duplo. 
Perfusate samples were prepared using the 96 well on membrane deglycosylation method, that has 
been described in detail previously24. In summary, N-glycans bound to proteins in 500 ?l of 
preservation solution were denatured using 1 ml of denaturing buffer (10 mM Ammonium 
Bicarbonate pH 8.3, containing 3.5% SDS). Then, N-glycans were released from the proteins, using 
Peptide N-glycosidase F (PNGase F- provided by the laboratory of Prof. Nico Callewaert, Unit for 
Medical Biotechnology, Department for Molecular Biomedical Research, VIB—Ghent University, 
Ghent, Belgium) and labeled with 8-aminopyrene-1,3,6-trisulphonic acid (ATPS - Molecular Probes, 
Eugene, OR,USA).  Subsequently, the glycans were desialylated overnight at 37° C by the addition of 2  
?l of 10mM ammonium acetate pH 5.0 containing 40 mU of Arthrobacter ureafaciens -2,3/6/8-
sialidase (also provided by the laboratory of Prof. Nico Callewaert). Samples were resuspended to 10 
?l with ultrapure water. Two microliters of the desialylated N-glycan samples were analyzed with a 
multicapillary electrophoresis-based ABI3130 sequencer.  
A desialylated serum protein N-glycan profile was obtained for the study objects. We quantified 13 
peaks that were detectable in all samples using Peak Scanner 2 Version 2.0 software (Applied 
Biosystems, Foster City, CA, USA), and normalized their abundance to the total peak height intensity. 
The nature of these peaks has been identified before by structural analysis18.  
4.3.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using IBM©SPSS©Statistics Version 22.0. Continuous variables were 
compared between the group of patients who developed PNF, EAD and those who did not using a 
Kruskal-Wallis test. Comparison of two non parametric variables was performed using Mann Whitney 
U test. The prognostic value of potential biomarkers was assessed using exact logistic regression. 
Multivariate analysis was performed using a multivariate logistic regression model. Statistical 
significance was set at the alpha level = 0.05. 
 
4.3.6 ETHICS 
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved 
by the Ghent University Hospital ethics committee.   
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4.4 RESULTS 
4.4.1 PATIENT POPULATION 
N-glycan analysis was performed in perfusate from 66 liver transplantations in 64 patients. Three
patients developed a PNF, 19 patients developed EAD and the remaining 44 patients showed a
normal liver function after transplantation (No PNF/EAD) patients. In this last group, 2 patients
needed an urgent early retransplantation, both due to a hepatic artery thrombosis, and were not
considered as PNF. Recipient and donor characteristics are summarized in table 1. Significant
differences were observed between the three patients groups regarding recipient ALT and AST values 
on postoperative day 2, and peak INR and bilirubin levels in the first week after liver transplantation,
reflecting the presence of EAD and/or PNF. Interestingly, there were no DCD donors in the PNF group
(table 1 and 2). 
Table 2. Patient Characteristics. Pairwaise comparison of statistically significant different values 
between patients with normal recovery after liver transplantation, EAD and PNF. Variables between 
groups were compared using Mann Whitney U test.  
Variable Comparison between groups p value 
Recipient AST at 48 hours  No PNF-PNF 0.507 
No PNF-EAD 0.001 
PNF-EAD 1 
Recipient ALT at 48 hours No PNF-PNF 0.763 
No PNF-EAD 0.003 
PNF-EAD 1 
Recipient INR No PNF-PNF 0.011 
No PNF-EAD 0.019 
PNF-EAD 0.347 
Recipient Total Bilirubin No PNF-PNF 0.079 
No PNF-EAD 0.027 
PNF-EAD 0.982 
4.4.2 N-GLYCAN ANALYSIS OF PERFUSATE 
The technique used for N-glycan analysis is based on a DNA sequencer-assisted fluorophore-assisted 
capillary electrophoresis that was initially developed and validated for serum analysis21 and has been 
used for urine analysis22. Now, this technique was applied on perfusate from liver transplant patients. 
Using the standard protocol, we obtained electropherograms with 13 peaks, identically as what has 
been observed in serum and urine.  
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Figure 1. The structures of the N-glycan peaks in a human perfusate sample.  
A. The structures of the N-glycan peaks in a human perfusate sample as obtained using capillary
electrophoresis yields 13 peaks. From left to right : Peak 1 is an agalacto, core-alpha-1,6-fucosylated
biantennary (NGA2F), peak 2 is an agalacto, core-alpha-1,6-fucosylated bisecting biantennary
(NGA2FB), peak 3 and peak 4 are single monogalacto, core-alpha-1,6-fucosylated biantennary
structures (NG1A2F), peak 5 is the bigalacto biantennary glycan NA2, peak 6 is the bigalacto, core-
alpha-1,6-fucosylated biantennary glycan NA2F, peak 7 is the bigalacto, core-alpha-1,6-fucosylated
bisecting biantennary glycan NA2FB, peak 8 is the triantennary glycan NA3, peak 9 is the branching
alpha-1,3-fucosylated triantennary glycan NA3Fb, peak 10 is the core-alpha-1,6-fucosylated
triantennary glycan NA3Fc, peak 11 is the branching alpha-1,3-fucosylated and core alpha-1,6-
fucosylated triantennary glycan NA3Fbc, peak 12 is a tetra-antennary (NA4) and peak 13 is a
branching alpha-1,3-fucosylated tetra-antennary (NA4Fb) glycan. The symbols used in the structural
formulas are: square indicates beta-linked N-acetylglucosamine (GlcNAc); yellow circle indicates
beta-linked galactose, triangle indicates alpha/beta-1,3/6-linked fucose; green circle indicates
alpha/beta-linked mannose. 
B. This graphs shows the perfusate analysis of a patient without PNF (upper panel) and a patient who
developed PNF (lower panel). Note the increased abundance of peak 1, 2 and 3 (green). The increase
of peak 1 alone is discriminative of PNF versus no-PNF.
4.4.2.1 Development of a glycomic based biomarker 
A desialylated serum protein N-glycan profile was obtained for the 66 samples in the study (Figure 1). 
We quantified 13 peaks that were well detectable in all samples and normalized their abundance to 
the total peak height intensity per patient. Peak 1, 2, and 3 showed discriminative changes according 
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to development of PNF and EAD (Figure 2). However, as can be appreciated from figure 2, PNF 
patients have a discriminative glycomic signature compared to non-PNF patients, whereas for EAD 
patients a specific glycomic signature was not apparent.  For further analysis, we focused on PNF and 
pooled the EAD and non-PNF patients.  
A more detailed analysis (table 3) disclosed that the perfusate N-glycan profile of PNF patients was 
highly discriminative from non-PNF patients based on the increased abundance of peak 1, an  
agalacto, core-alpha-1,6-fucosylated biantennary glycan (NGA2F )(Figure 2) compared to the EAD and 
non-PNF/EAD patients (p<0.0001) with an accuracy of 100%.  
Using exact logistic regression (univariable analysis), the odds ratio (OR) for PNF development for an 
increase of peak 1 with an absolute value of 1 was 1.801 (p<0.0001; 95% CI 1.321-infinity). This 
marker was called the GlycoPNFTest. 
4.4.2.2 AST and ALT in perfusate  
AST and ALT levels were determined in perfusate. Comparable levels of AST (p = 0.661) and ALT 
levels (p=0.617) were found in PNF, EAD and other patients. 
4.4.2.3 Prognostic markers for PNF 
Next we analyzed whether other donor- or recipient parameters were predictive for the occurrence 
of PNF using an univariable analysis (Mann Whitney U test). None of the clinical donor parameters 
were predictive for the development of PNF after liver transplantation, nor was AST and ALT analysis 
in perfusate (Table 3). In a multivariate logistic regression model including NGA2F, DRI, AST and ALT 
in perfusate, only the glycomarker NGA2F was an independent predictor of PNF (p<0.0001).  
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Figure 2. Overview of the relative abundance of relevant glycans in patients that developed PNF 
afterward. Peak 1 (NGA2F) shows 100% accuracy for prediction of PNF.  P values were calculated 
using Mann Whitney U- test. * p< 0.05, ** p<0.001 
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Table 3. Prognostic markers for the development of PNF. A. Univariable analysis (Mann Withney U 
test) was performed in order to look for prognostic markers for PNF development. B. Multivariate 
logistic regression model. *Highest INR value betweed postoperative day 2 and day 7. **Highest total 
bilirubin value between postoperative day 2 and 7 
A.  
Univariable analysis p-value 
Donor Characteristics 
Age    0.954 
Sex (M/W) 0.772 
Length (cm)    0.269 
Weight (cm)    0.175 
Perfusate (HTK/UW) 0.858 
CIT (minutes)  0.794 
WIT (minutes)    0.518 
AST (U/L)    0.641 
ALT (U/L)  0.908 
GGT (mg/dl)    0.871 
Total Bilirubin (mg/dl)  0.734 
NHBD 0.908 
DRI  0.772 
Perfusate analysis  
AST 0.653 
ALT 0.589 
Peak 1  <0.0001 
Peak 2 0.042 
Peak 3 0.010 
Peak 4 0.817 
B.  
p-value 
NG1A2F <0.0001 
AST perfusate 0.800 
ALT perfusate 0.818 
Donor Risk Index 0.818 
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4.5 DISCUSSION 
We propose a new biomarker, the GlycoPNFTest, based on glycomic analysis of perfusate that might 
be able to identify donor livers at risk for the development of PNF. This biomarker could be a tool to 
safely select high-risk organs (eg. ECD organs) for liver transplantation that otherwise would be 
discarded from the donor pool based on a conventional assessment. Secondly, this glycomic marker 
could prevent futile transplantations. Indeed, in this cohort, not any clinical parameter was able to 
predict PNF, in contrast to the glycomarker that could with 100 % sensitivity and specificity 
differentiate between PNF and non-PNF patients. To our knowledge, not a single biomarker has 
proven the same utility today. We are however aware that PNF was only present in only 3 patients 
(what does reflect the low prevalence of PNF). A validation study is ongoing in order to study these 
findings in a larger amount of patients in a multiple transplant centers. Interestingly, this biomarker 
has a high negative predictive value for the occurrence of PNF, as the non-PNF patients are clustered 
within a small range, thus raising arguments to be able to transplant a patient safely without a major 
risk for PNF development.  
Perfusate biomarkers are an attractive alternative for liver biopsy or serum markers, because 
perfusate is believed to represent the condition of the entire liver parenchyma and is easy to collect 
in large volumes. However, only few perfusate markers have previously shown any utility in the 
prediction of PNF25. Conventional transaminases and lactate dehydrogenase (LDH) are increased in 
the perfusate of patients developing PNF and EAD, reflecting hepatocellular injury. Unfortunately, 
high enzyme activity in the effluent did not necessarily predict a malfunction of the graft as the 
specificity for PNF was only 42%, making it a sensitive marker for safe livers at a cost of excluding 
many potential clinically acceptable  livers26. In our cohort, AST and ALT levels showed a wide range 
among all patients, without distinct correlation with EAD or PNF.  Xanthine, an adenine nucleotide, 
was shown to be increased in the effluent perfusate of PNF patients, but was not able to discriminate 
between the patients of both groups in a clinical study27.  In the same patients, adenine nucleotides 
were decreased in liver tissue after transplantation, reflecting irreversible injury and necrosis of the 
liver and the retardation of the recovery of cellular adenoside triphosphate (ATP) after 
reperfusion28,29. The group of Starzl showed 20 years ago that hyaluronic acid (HA) levels in effluent 
higher than 400 ?g/L are a strong predictor of PNF. HA is a glycosaminoglycan catabolized by the liver 
hepatocyte microvasculature. In a cohort of 70 patients, 6 PNF patients were correctly classified as 
PNF, but another 6 patients, presumed to develop PNF based on the 400 ?g/L cut-off showed a 
normal clinical outcome30. Similar findings were retained in a validation study31, again positioning the 
test as a marker for identifying safe livers. 
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The proposed glycomarker for PNF prediction managed to identify the 3 patients with PNF, without 
false positives. It is based on the increased abundance of one single undergalactosylated biantennary 
glycan (NGA2F). Undergalactosylated biantennary glycans were previously shown to be exclusively 
present on IgG19, relating it to inflammatory states. Although the pathophysiology of PNF is complex, 
extensive ischemic- and preservation injury has been recognized as a main pathophysiological 
driver32,33. IgG undergalactosylation is a marker of necroinflammation also found in patients with 
rheumatoid arthritis34 and increasing levels of liver fibrosis19. In this cohort, in PNF and non PNF 
patients comparable levels of IgG concentration in perfusate were measured, highlighting that the 
increased abundance of NGA2F in PNF patients is not related to a potential increase of total 
perfusate IgG but to specific glycomic alterations. The single measurement of peak 1 is a powerful 
representation of the rise of the other undergalactosylated glycan and is believed to represent the 
inflammatory disturbances in the donor liver that will fail after transplantation.  
The accuracy for the prediction of PNF was extremely high (100%). On the other hand we found no 
clear relationship between the perfusate glycomic profile and the occurrence of EAD. We speculate 
that this might be related to the fact that EAD is a complex and multifactorial syndrome that is not 
only related to the quality of the donor liver graft but also to recipient characteristics and intra- and 
postoperative events. This information will of course not be captured in the pretransplant glycomic 
profile. On the other hand, PNF is mainly related to very low quality grafts which can be captured 
quite convincingly by the glycomic profile. 
Concerns could be raised that the glycomarker measurement in perfusate is a mere contamination of 
donor serum. However, in one patient with PNF we were able to analyse the serum sample of the 
liver donor. Interestingly, the donor sample did not show an increased abundance of our 
glycomarker, in contrast to the perfusate of the same patient that showed a significant increase.  
Machine perfusion (MP) is a new approach in liver transplantation to improve graft preservation of 
ECD grafts. There is a huge need for biomarkers that can evaluate the quality of the liver graft during 
machine perfusion25, and the role of this glycomarker needs to be explored in machine perfusion. 
A drawback in the application of this technique is the turnover time that requires 48 hours. However, 
sample preparation for serum samples has been simplified and can be used on cheap and widely 
available high-throughput microfluidics CE platforms including the MCE-202 MultiNA, 2100 
Bioanalyzer and eGene system35. Validation of the technique for perfusate is ongoing in order to 
reduce the turnover time to a clinically acceptable time frame. 
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In conclusion, the study provides a strong proof-of-concept that the glycomic analysis of perfusate 
predicts with 100% accuracy the occurrence of PNF. A validation of these data in a multicenter 
clinical trial is ongoing.  
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V. The potential of glycomics-based
biomarkers to assess the outcome after
liver transplantation in the early transplant
period using serum glycomic analysis
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5.1 ABSTRACT 
Background :  Graft failure after liver transplantation (LT) remains a challenge for transplant 
professionals and sometimes requires retransplantation. Pretransplant estimation of graft function 
using scores like donor risk index has limited use in individual patients. Diagnosis of early allograft 
dysfunction after liver transplantation by clinical criteria can predict graft survival. However, 
biomarkers that reliably identify patients at risk for graft failure after LT are lacking. Analysis of N-
glycans in serum (glycomics) has shown to reflect the underlying liver function in liver disease but has 
never been assessed after liver transplantation.  
Aims : The aim of this study was to assess the potential of serum glycomics as predictive markers for 
graft loss after liver transplantation.  
Methods: Serum glycomic profiles were analysed before and after liver transplantation in 127 liver 
transplant recipients using an optimized glycomic technology on a DNA sequencer.  The major 
outcome parameters (graft and patient survival) were related to the observed glycomic alterations.  
Results : The assessment of 2 serum glycans, NG1A2F (an agalacto, core-alpha-1,6-fucosylated 
biantennary glycan structure) and NA3 (a triantennary glycan), combined as log(NG1A2F/NA3) on 
day 7 after liver transplantation was strongly associated with graft loss (hazard ratio = 7.222; 
p<0.001; 95% CI 2.352-22.182) and patient death (hazard ratio = 3.885; p=0.30; 95% CI 1.127-13.276) 
during the first year after liver transplantation (cox regression analysis). In multivariate cox 
regression model including early allograft dysfunction (according to Olthoff) and Donor Risk Index, 
this biomarker, called GlycoTransplantTest, was the only independent predictor of graft survival 
(p=0.003). 
Conclusion :  Assessment of GlycoTransplantTest, a glycomic serum marker, on day 7 post liver 
transplantation is a strong predictor of graft and patient survival during the first year after liver 
transplantation.  
 
5.2 INTRODUCTION   
Since the first successful orthotopic liver transplantation (LT) by Starzl in 19631, LT has become the 
treatment of choice for end stage liver disease and selected patients with hepatocellular carcinoma 
(HCC)2.  Outcome after LT has steadily improved due to refinement of surgical techniques and 
introduction and improvement of immunosuppressive drugs. Survival rates now reach 96% and 71% 
at 1 and 10 years after LT respectively3.  Graft loss occurs in 7 to 10% of adults4 and requires 
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retransplantation in these patients5. Retransplantation can be early (caused by primary graft non-
function or hepatic artery thrombosis) or late (ischemic cholangiopathy, chronic rejection or 
recurrence of the primary liver disease). The donor graft quality is increasingly recognized as a major 
driver of post-transplant outcome. Moreover, the shortage of donor organs has lead to the increased 
use of extended criteria donors (ECD). These ECD grafts show unfavorable characteristics including 
advanced age, steatosis, DCD and others increasing the risk for ischaemia-reperfusion injury6.  
The choice for retransplantation is based on a clinical appreciation by the transplant team and the 
use of liver enzymes and radiological imaging. However, it can be hard to define the need and the 
right timing for retransplantation, balancing between the wish to avoid a futile retransplantation and 
the need to perform an inevitable and life-saving  retransplantation.  Both pretransplant- and post-
transplant clinical scores and biomarkers have been related to graft- and patient survival.  A 
pretransplant evaluation using the Donor Risk Index (DRI)7 identifies liver grafts at increased risk for 
graft failure based on donor criteria (age, donation after cardiac death, split/partial grafts, race, 
height and cause of death, cold ischemia time and allocation zone). Although DRI has not been 
challenged since its development more than 10 years ago, it lacks the individual prognostic value that 
would allow to discard inferior donor grafts from the donor pool8. A European donor risk index was 
developed using the Eurotransplant (ET) database resulting in the ET-DRI9. The major differences 
between both are the addition of latest serum GGT and rescue allocation. Donor height and race 
were not included in this score. The predictive value of pre-operative MELD score remains 
unclear101112.  
Posttransplant markers can be divided in clinical scores and functional tests. The general concept is 
that these measure early allograft dysfunction (EAD) which has shown to be related to decreased 
organ and patient survival1314. The most widely accepted definition for EAD has been validated by 
Olthoff13 and is based on the presence of one or more of the following postoperative laboratory 
analyses: bilirubin >or=10mg/dL on day 7, international normalized ratio >or=1.6 on day 7, and 
alanine or aspartate aminotransferases >2000 IU/L within the first 7 days after LT. Other scores are 
based on single measurement of (peak) AST or ALT values15, bilirubin12, lactate16, factor V17 and 
platelet counts18 but do not increase the diagnostic power of this definition.  Functional tests include 
the indocyanine green (ICG)19,20 – plasma disappearance rate and  the liver maximal function capacity 
(LiMax)21. These show encouraging results but lack a robust external validation. This overview points 
out that novel omics-based biomarkers have not been widely explored in this field.  
We formerly showed that the analysis of the whole serum glycomic profile, which consists of 
measuring the N-glycans on the total protein content in serum (also called glycomics), does reflect 
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hepatic (dys)function22. Glycomic analysis of whole serum can be easily performed using a glycan 
analytical method that uses standard DNA-sequencing equipment2324. Based on this paradigm, we 
developed several biomarkers based on specific glycoalterations for the diagnosis of liver fibrosis25 
and cirrhosis24, HCC26,27 and NASH28,29.  
In this manuscript we studied glycomic alterations in the early post-transplant period and defined a 
glycomic signature on day 7 after LT , called GlycoTransplantTest,  that predicts organ and patient 
survival during the first year after liver transplantation.  
 
5.3 MATERIALS AND METHODS 
5.3.1 PATIENTS 
The patients in this monocentric prospective cohort underwent liver transplantation in the Liver 
Transplant Unit of Ghent University Hospital (Belgium) between 1 December 2012 and 31 December 
2014.  
 
5.3.2 DESIGN 
From every patient one serum sample was collected in the 24 hour timeframe before liver 
transplantation. After liver transplantation daily serum samples were collected during 14 days, and 
after 1,3,6 and 12 months after liver transplantation. After centrifugation, serum samples were 
frozen to minus 21° Celsius. Clinical data were retrieved from the medical files. 
After collection of all serum samples, the serum samples were defrosted and glycomic analysis was 
performed. The resulting glycomic profiles were related to donor graft and patient outcome.  
 
5.3.3 GLYCOMIC ANALYSIS 
Five microliter of serum were processed according to the in-solution deglycosylation method 
described by Vanderschaeghe et al.25. Briefly, denaturing buffer containing SDS was added to the 
serum and incubated for 5 min at 95°C. Then, the samples were treated with Peptide N-glycosidase F 
to release the N-glycans from their denatured carrier proteins. After enzymatic removal of the 
terminal sialic acid residues, the glycans were labeled with 8-aminopyrene-1,3,6-trisulphonic acid 
and analysed using an ABI3130 DNA sequencer as described23. The result of this analysis is a total 
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desialylated serum protein electropherogram (Fig. 1), which consists of 13 peaks. Each peak 
represents a well-identified glycan30. The numerical height of every peak is quantified and normalised 
to the sum of all peak heights, thus represented as a percentage of total peak height.   
 
5.3.4 STATISTICS  
Statistical analysis was performed using IBM©SPSS©Statistics Version 22.0. Based on Mann Whitney U 
test, clinical characterstics were compared between patients that developed graft loss and those 
who did not. ROC analysis was performed and the Youden index was used to select an optimal cut-
off. Logistic regression was performed to calculate the relation to the different outcome variables at 
every defined time-point (2 weeks, 1 month, 3 months and 12 months after LT). The patients were 
classified according to these cut-offs, and cumulative survival was calculated with the Kaplan-Meier 
method. Cox regression analysis was used to estimate the hazard ratio for graft loss and death for 
potential prognostic biomarkers. Finally a multivariable cox regression analysis was performed. 
Statistical significance was set at the alpha level = 0.05. 
 
5.3.5 ETHICS 
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved 
by the Ghent University Hospital ethics committee.    
 
5.4 RESULTS 
5.4.1 PATIENT CHARACTERISTICS 
In this study, 127 liver transplant patients were eligible. However, finally 113 patients were included 
in the final analysis as the serum sample on postoperative day 7 that is crucial for the measurement 
of the newly developed GlycoTransplantTest was not available (n=10) or because the patient 
underwent retransplantation before day 7 due to primary non function (n=4). Seven liver transplants 
were retransplantations, 1 one was a second retransplantation.  
Baseline characteristics are summarized in table 1. In this cohort, 3 patients died within 1 month 
after LT and 11 patients died within the first post transplant year. Eight deaths were directly liver-
related (ischemic cholangiopathy (n=5), small for size syndrome (n=1), HCV recurrence (n=2), 2 were 
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transplant-related (sepsis from abdominal source, n=1; sepsis from respiratory source, n=1), one 
patient death was not transplant related (rapidly progressive pharyngeal carcinoma).  
 
Table 1. Baseline characteristics of the liver transplant patients (n=113). 
  Number Percentage 
Mean Age 50.65 (SD 13.52)   
Mean MELD    
Sex Male 
Female 
61 
52 
54 
46 
Indication Alcoholic cirrhosis 
PSC 
HCV 
ALF 
Polycystic Disease 
ITBL 
HBV 
NASH 
AIH 
Hyperoxaluria 
HCC 
Other* 
35 
13 
12 
11 
8 
7 
5 
4 
4 
3 
3 
8 
31.0 
11.5 
10.6 
9.7 
7.1 
6.2 
4.4 
3.5 
3.5 
2.7 
2.7 
7.1 
Retransplantation 
(1) 
 7 6.2 
Retransplantation 
(2) 
 1 0.9 
*other : adenomatosis (2), primary non function (2), Budd Chiari syndrome (1), Familial amyloid 
polyneuropathy (1), chronic allograft rejection (1), hemangioendothelioma (1) 
 
Graft loss was observed in 4 patients within 2 weeks after LT, in 9 more within the first 
month, in 4 more within the first 3 months, and in 5 more patients within the first year after 
LT. Graft loss was related to ischemic cholangiopathy (n=9), sepsis (n=7), hepatic artery 
thrombosis (n=2), HCV recurrence (n=2) and severe EAD (n=2). 
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Figure 1 : The glycomic analysis and GlycoTransplantTest 
Panel A: The structures of the N-glycan peaks in the total serum of a cirrhotic patient as obtained 
using capillary electrophoresis yields 13 peaks. From left to right : Peak 1 is an agalacto, core-alpha-
1,6-fucosylated biantennary (NGA2F), peak 2 is an agalacto, core-alpha-1,6-fucosylated bisecting 
biantennary (NGA2FB), peak 3 and peak 4 are single monogalacto, core-alpha-1,6-fucosylated 
biantennary structures (NG1A2F), peak 5 is the bigalacto biantennary glycan NA2, peak 6 is the 
bigalacto, core-alpha-1,6-fucosylated biantennary glycan NA2F, peak 7 is the bigalacto, core-alpha-
1,6-fucosylated bisecting biantennary glycan NA2FB, peak 8 is the triantennary glycan NA3, peak 9 is 
the branching alpha-1,3-fucosylated triantennary glycan NA3Fb, peak 9 is the core-alpha-1,6-
fucosylated triantennary glycan NA3Fc, peak 10 is the branching alpha-1,3-fucosylated and core 
alpha-1,6-fucosylated triantennary glycan NA3Fbc, peak 11 is a tetra-antennary (NA4) and peak 12 is 
a branching alpha-1,3-fucosylated tetra-antennary (NA4Fb) glycan. The symbols used in the 
structural formulas are: square indicates beta-linked N-acetylglucosamine (GlcNAc); yellow circle 
indicates beta-linked galactose, triangle indicates alpha/beta-1,3/6-linked fucose; green circle 
indicates alpha/beta-linked mannose.  
Panel B: Glycomic profile before and 24 hours after liver transplantation in the same patient with 
liver end-stage cirrhosis. Note the rapid changes and disappearance of the cirrhotic glycomic 
signature, formerly published as GlycoCirrhoTest24. The GlycoCirrhoTest driving rise of NA2FB 
disappears 24 hours after liver transplantation.   
Panel C: The newly developed GlycoTransplantTest is based on the increased abundance of peak 3, 
an agalacto, core-alpha-1,6-fucosylated biantennary glycan (NG1A2F) and the decreased abundance 
of peak 8, a triantennary glycan (NA3). Upper panel shows a patient with a high score on the 
GlycoTransplantTest with a bad post-transplant outcome; the lower panel shows a low score in a 
patient with a good post-transplant outcome.  
 
 
Mean DRI in patients who experienced graft loss or death was 1.804 (SD 0.382) compared to 
1.679 (SD 0.386) in patients without graft loss or death (p=0.189).  
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5.4.2 DEVELOPMENT OF THE GLYCOTRANSPLANTTEST 
Analysis of the whole serum glycome after liver transplantation using DSA-FACE yields a desialylated 
glycomic profile consisting of 13 peaks (Figure 1). Every peak represents an N-glycan and the value of 
the peak height is normalized on the total value of the peak heights (sum of all 13 peaks), thus 
enabling comparison of relative peak heights between different serum samples. The specific 
structure of these 13 N-glycans has been identified before (Figure 1)23,24.  
We searched for a specific glycomic signature in patients with increased risk of graft loss or death 
during the first year after liver transplantation, based on a serum glycomic assessment during the 
first week after liver transplantation.  
A logistic regression was performed (univariate analysis) for every glycan in relation to graft survival 
at 2 weeks, 1 month, 3 months, and 1 year and in relation to patient survival at 1 month and 1 year 
(supplementary data). Looking for the glycans showing the most complete coverage of deleterious 
outcome for graft of patient, the highest prognostic value was observed on day 7 after LT. In patients 
with adverse post-transplant outcome we observed an increase of the undergalactosylated glycans 
NGA2F, NGA2FB and the NG1A2F isomers, an increase of NA2F and NA2FB and a mild increase of 
NA2 and the tetraantennary glycan NA4FB. On the other had in these patients, a decrease was 
observed of the triantennary glycans NA3, NA3FB, NA3FC, NA3FBC, a mild decrease of the 
tetraantennary glycan NA4.  Only 7 glycans showed significant changes according to patient outcome 
(supplementary file 1).  
After further analysis, the appearance of a graft loss or patient death could be captured by only 2 
glycans, an increase of peak 3, an agalacto, core-alpha-1,6-fucosylated biantennary glycan (NG1A2F) 
and a decrease of peak 8, a triantennary glycan (NA3). This signature is summarized in only one 
variable (log(NG1A2F/NA3)), called the GlycoTransplantTest.  
5.4.3 PROGNOSTIC PERFORMANCE OF THE GLYCOTRANSPLANTTEST 
Graft survival  
There is a strong correlation between the GlycoTransplantTest, based on the measurement of 2 
single glycans on day 7 after liver transplantation, and graft loss (Figure 2). Based on ROC curve 
analysis the area under the curve (AUC) for graft loss 2 weeks after LT was 0.824 (p=0.028; 95%CI 
0.597-1.000), for graft loss 1 month after LT it was 0.810 (p<0.0001;  95%CI 0.686-0.934), after 3 
month 0.816 (p<0.0001;  95%CI 0.712-0.920) and after 1 year 0.784 (p<0.0001;  95%CI 0.684-0.884). 
The odds ratio’s for graft loss for an increase of GlycoTransplantTest with 1 (univariate analysis) were 
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respectively 9.165 (p=0.012; 95%CI 01.636-51.343), 7.865 (p<0.0001; 95%CI 2.521-24.539), 8.118 
(p<0.0001; 95%CI 2.784-23.675) and 5.844 (p<0.0001; 95%CI 2.398-14.243).  
Considering the strongest prognostic performance for prediction of graft loss 3 months after liver 
transplantation, we defined a cut-off for the GlycoTransplantTest. From the ROC analysis the Youden 
–index pointed at an optimal cut-off of -0.81 showing a sensitivity of 82.4% and a specificity of 70.5%.  
The Kaplan-Meier curve shows a significant discrimination regarding graft survival (Log Rank 
p<0.0001) when using this cut-off for the GlycoTransplantTest (Figure 3), with patients above the cut-
off of –0.81 showing a worse graft survival.  
Using cox regression analysis (univariate), the hazard ratio for graft loss according to the 
GlycoTransplantTest cut off was 7.222 (p<0.001; 95% CI 2.352-22.182).  
 
Patient survival  
Based on ROC analysis, the GlycoTransplantTest was not related to patient death after 1 month (AUC 
0.817, p=0.062) but was related to  patient death after one year (AUC 0.702, p=0.028; 95%CI 0.566-
0.838). The odds ratio for patient survival after 1 month and 1 year for an increase of 
GlycoTransplantTest with 1 (univariate analysis) were not significant.  
Based on the Youden–index the optimal cut-off was -0.74 showing a sensitivity of 63.3% and a 
specificity of 70.1%. Using the same cut-off of –0.81 as for graft survival, sensitivity was 63.3% and 
specificity 65.3%.  
Using cox regression analysis (univariate), the hazard ratio for patient death according to the optimal 
GlycoTransplantTest cut off of –0.81 was 3.885 (p=0.030; 95% CI 1.127-13.276). The discriminative 
value is again illustrated by the Kaplan-Meier curve (Log Rank test: p= 0.020) (Figure 3).  
 
5.4.4 PROGNOSTIC PERFORMANCE OF AST AND ALT 
In order to challenge the prognostic potential of the GlycoTransplantTest, we studied the prognostic 
potential of the routinely analysed transaminases. AST and ALT were analysed on daily bases during 
the first week after transplantation. Only during the first 4 days after LT, AST and ALT were 
significantly related to these outcome variables. In literature peak transaminases during the first 
three days after LT have been attributed a prognostic power for graft and patient survival. Based on 
this knowledge, we focused on AST and ALT in the first 3 days after LT15,31.   
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Figure 2. The GlycoTransplantTest is significantly increased in patients with worse outcome. Mean 
values with 95% confidence intervals are presented. Comparison between groups was performed 
using Mann Withney U test.  
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Figure 3. Prognostic performance of the GlycoTransplantTest compared to AST on postoperative 
day 2. Kaplan Meier curves are shown according to the defined cut-off. GlycoTransplantTest shows a 
better discriminative value than AST on POD2 between patients with graft loss versus graft survival 
(left panel) and between patients who die during the first year after LT versus survivors (right panel). 
P values were calculated using Log rank test.  
 
 
Graft survival 
ROC analysis for AST and ALT on postoperative day (POD) 1 , POD2 and POD 3 for prediction of graft 
loss after 2 weeks, 1 month, 3 months and 1 year was performed. AUC showed disappointing values 
between 0.531 and 0.740, without statistical significance.  
However, after logistic regression (univariate analysis), AST on POD 2 showed a significant association 
with graft loss at 1 month (OR 1.194, p=0.006; 95% CI 1.051-1.356), 3 months (OR 1.138, p=0.034; 
95% CI 1.010-1.282) and 12 months (OR 1.129, p=0.041; 95% CI 1.005-1.269).  AST on POD 3 was 
significantly associated with loss of transplant organ at 1 month (OR 1.311, p=0.029; 95% CI 1.028-
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1.672). ALT on POD2 was also significantly related to graft loss at 1 month (OR 1.248, p=0.029; 95% CI 
1.022-1.524). ALT on POD 3 showed a strong relation with graft loss at 2 weeks (OR 1.306, p=0.041; 
95% CI 1.011-1.687) and 1 month (OR 1.474,p=0.020; 95% CI 1.062-2.046). OR are calculated for a 
rise of AST or ALT of 500 U/L). 
Using cox regression analysis (univariate analysis), the hazard ratio for graft loss according to AST and 
ALT during POD 1 to 3 failed to show a significant prognostic value. Eg, a cut-off of 2000 U/L for AST 
on POD2 lacks a significant discriminative value as illustrated by the Kaplan-Meier curve  (Log Rank 
test: p= 0.780) (Figure 3). 
Patient survival 
In contrast to graft survival, a significant relationship was observed using ROC analysis between AST 
on POD2 (AUC 0.890, p=0.022;  95%CI 0.737-1) and POD 3 (AUC 0.894, p=0.020; 95% CI 0.757-1) and 
ALT on POD 3 (AUC 0.869, p=0.030; 95% CI 0.668-1) with patient survival at 1 month. There was no 
significant predictive value for survival at 1 year.  
Based on the youden-index, an optimal cut-off was derived from the AUC for AST on POD 2 of 1000 
U/L, yielding a sensitivity of 100% and a specificity of 71%.   
Using logistic regression (univariate analysis) AST on POD1 (OR 1.202, p=0.016; 95% CI 1.035-1.396), 
AST POD2 (OR 1.289, p=0.005; 95% CI 1.078-1.541) and ALT on POD 2 (OR 1.462, p=0.011; 95% CI 
1.090-1.960) were significantly related with patient survival at 1 month but none was at 1 year. OR 
are calculated for a rise of AST or ALT of 500 U/L).  
Using cox regression analysis (univariate analysis), only AST on POD 2  was predictive for patient 
death (HR 1.098, p=0.016; 95% CI 1.017-1.186). The lack of discriminative power, however based on 
the cut-off of 1000 U/L for AST on POD2 is illustrated by the Kaplan-Meier curve.  
5.4.5 MULTIVARIATE COX REGRESSION ANALYSIS 
Graft survival  
Next, we built a multivariate Cox regression model taking into account the GlycoTransplantTest, AST 
POD 1, 2 and 3 and ALT on POD 1, 2 and 3. Only GlycoTransplantTest and AST on POD1 and 3 were 
predictive for graft loss during the first year after transplantation with a hazard ratio of respectively 
8.003 (p<0.0001; 95% CI 3.00-21.347), 1.413 (p=0.007; 95% CI 1.101-1.813) and 0.297 (p=0.031; 95% 
CI 0.099-0.896). 
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When a new multivariate Cox regression model was built including GlycoTransplantTest, EAD (as 
defined by Olthoff32 and thus including peak transaminases) and DRI, only the GlycoTransplantTest 
was independently related to graft loss (p=0.003).  
 
Patient survival 
A similar model was built regarding patient survival including GlycoTransplantTest (using the cut-off 
of -0.74), AST on POD 1, 2 and 3 and ALT on POD 1, 2 and 3. GlycoTransplantTest (HR 5.231, p=0.025; 
95% CI 1.374-19.920) and ALT on POD1 (HR 0.998, p=0.048; 95% CI 0.997-1.000) were predictive for 
patient death.  
In a model including GlycoTransplantTest, EAD and DRI, none of these parameters was significantly 
related to patient survival. 
 
5.4.6 CORRELATION OF GLYCOTRANSPLANTTEST AND EAD 
An intriguing question is whether the GlycoTransplantTest is not just a diagnostic marker of EAD, as 
EAD is also related with graft failure and patient death during the first year after liver 
transplantation. However, using Spearman’s correlation analysis we found no correlation between 
the GlycoTransplantTest and EAD as defined by Olthoff32 (R=.0.39; p=0.685).   
 
5.5 DISCUSSION   
Based on the simple measurement of 2 glycans in serum on day 7 after LT we can reliably predict the 
risk of graft loss and patient death during the first year after LT. This measurement was incorporated 
into a new biomarker, called the GlycoTransplantTest. The overall hazard ratio for graft loss during 
the first year after LT using this assessment was 7.222 (p<0.001;95% CI 2.352-22.182) using a cut-off 
above -0.81. As can be appreciated from the Kaplan Meier curve (Figure 4), the optimal performance 
was observed for the prediction of graft loss at 3 months with an odds ratio of 8.118 (p<0.0001; 
95%CI 2.784-23.675).   
This work adds to the increasing evidence that glycomic-based biomarkers reflect in a reliable way 
specific dysfunctions occurring in the liver22,24,28,30,33–35. Although 7 out of 13 peaks in the glycomic 
analysis were significantly altered in patients with a poor outcome, this information could be 
captured in a glycomic signature with only 2 single N-glycans, the increase of peak 3, an agalacto, 
core-alpha-1,6-fucosylated biantennary glycan (NG1A2F) and the decrease of peak 8, a triantennary 
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glycan (NA3). We and others formerly showed that the undergalactosylation in the whole serum N-
glycome is caused by undergalactosylation of immunoglobulins and not by liver derived proteins25,36. 
The increased undergalactosylation is believed to be a reflection of the important inflammatory 
response in the failing liver due to factors related to ischemia/reperfusion damage37, infections or 
sepsis. Oweira et al. showed an independent association between postoperative inflammation after 
LT and graft loss and patient death38. This inflammatory response has been related  to an increase of 
IL-639, IL-2R, IL-7, IP-10, MIG37. Also IL-8, CCL2 and CCL5 are upregulated in the early postoperative 
phase resulting from the Nf-kB pathway37. Interestingly, this study demonstrates that the increase of 
peak 3 (NG1A2F) is an elegant and robust marker of this inflammatory response.  
In contrast to the undergalactosylated glycans, the decrease of NA3, a triantennary glycan, is 
hepatocyte-driven25 and could be caused by a disturbed glycosylation process in the failing liver. It is 
well known that glycosylation, one of the most important posttranslational modifications in human 
physiology, is strictly controlled by the upregulation of specific glycosyltransferases22. The action of 
N-acetylglucosaminyltransferase V (GnT-V), involved in the formation of precursor glycans of NA3,
might be diminished in favour of an elevation of N-acetylglucosaminyltransferase III (GnT-III),
responsible for the formation of bisecting GlcNAc structures, like NA2FB. Indeed, GnT-V competes for
the same substrate as  GnT-III26. As a matter of fact, NA2FB was shown to be significantly increased in
patients with worse outcome. Noteworthy, an increase of triantennary glycans (like NA3) can be
considered a marker of liver regeneration. In human HCC samples an increased enzymatic activity of
GnT-V has been observed40. Second, in a two-thirds partial hepatectomy model in rats, GnT-V activity
was increased in hepatocytes and non-parenchymal cells during regeneration41. Possibly, the
decreased levels of NA3 in patient with graft loss illustrate a lack of the required regeneration
capacity after liver transplantation resulting in graft failure. 
In this cohort, we confirmed the predictive role of peak transaminases during day 1 to 3 regarding 
graft loss and patient death, as reported earlier by other groups12,15,31,4213. However, in the same 
cohort, the prognostic value of the GlycoTransplantTest was superior to AST and ALT measurement. 
Furthermore, in a multivariate Cox regression model including the GlycoTransplanttest, EAD (as 
defined by Olthoff32) and DRI, only the GlycoTransplantTest was independently predictive of graft 
survival.  
According to this analysis the GlycoTransplantTest might be an attractive tool in the management of 
patients with suboptimal graft function in the first week after liver transplantation. In these patients 
it can be difficult to estimate whether the patient’s liver function will recover or whether a 
retransplantation will be unavoidable. In this monocentric cohort we showed the best prognostic 
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performance for graft survival with a single measurement of GlycoTransplantTest at day 7 after LT. 
Hence, this marker could be an additional tool to assess the patients need for retransplantation. It 
could also be an interesting tool in trials studying therapeutic strategies in early graft failure where 
liver grafts at increased risk of failure could be identified.  
The main limitation is the monocentric character of this study and the current absence of external 
validation. To our knowledge however, this is the first biomarker that offers this high predictive value 
with an OR for graft loss at 3 months of 8.118 (p<0.0001; 95%CI 2.784-23.675).  
The GlycoTransplantTest is measured using a routine DNA-sequencer and will shortly be 
implemented on less expensive and widely available high-throughput microfluidics CE platforms, 
which will make the technology accessible for routine clinical laboratories.  
We conclude in line with previous reports of our group that have highlighted the value of glycomics-
based biomarkers in liver disease24,29,30,35, that a glycomic assessment of serum at day 7 after liver 
transplantation offers a reliable marker of graft function that is an independent predictor of graft 
survival within the first year after LT and is related to patient survival. Hence, it could be an attractive 
tool for guidance in decision making when a retransplantation is considered. The application of this 
technology on high-throughput microfluidics CE platforms could facilitate an easy implementation in 
clinical practice.  
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Supplementary Table 
Overview of glycomic alterations related to outcome. Only glycans with a significant association 
with outcome are shown. Significant associations are markerd in gre?. Results are presented as p-
values after logistic regression (univariate analysis). For the marker “Max value day 1 to 7” the 
highest value between day 1 and 7 was used.   
Peak 1 
NGA2F 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.663 0.059 0.492 0.650 
Patient survived 1 year 0.795 0.463 0.732 0.915 
Organ survived 2 weeks 0.791 0.912 0.506 0.882 
Organ survived 1 month 0.519 0.779 0.063 0.051 
Organ survived 3 months 0.474 0.734 0.018 0.023 
Organ survived 1 year 0.269 0.763 0.025 0.035 
Peak 3 
NG1A2F 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.348 0.294 0.949 0.589 
Patient survived 1 year 0.051 0.234 0.090 0.557 
Organ survived 2 weeks 0.208 0.050 0.103 0.041 
Organ survived 1 month 0.017 0.551 0.012 0.002 
Organ survived 3 months 0.010 0.243 0.001 0.003 
Organ survived 1 year 0.007 0.106 0.001 0.009 
Peak 5 
NA2 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.065 0.379 0.248 0.093 
Patient survived 1 year 0.968 0.395 0.752 0.492 
Organ survived 2 weeks 0.840 0.720 0.248 0.316 
Organ survived 1 month 0.061 0.014 0.020 0.791 
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Organ survived 3 months 0.028 0.014 0.019 0.836 
Organ survived 1 year 0.028 0.030 0.058 0.920 
Peak 6 
NA2F 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.539 0.215 0.982 0.387 
Patient survived 1 year 0.007 0.119 0.013 0.310 
Organ survived 2 weeks 0.043 0.098 0.759 0.423 
Organ survived 1 month 0.280 0.370 0.231 0.086 
Organ survived 3 months 0.352 0.825 0.054 0.139 
Organ survived 1 year 0.026 0.356 0.009 0.037 
Peak 7 
NA2FB 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.563 0.115 0.304 0.295 
Patient survived 1 year 0.396 0.849 0.043 0.250 
Organ survived 2 weeks 0.856 0.674 0.453 0.268 
Organ survived 1 month 0.878 0.311 0.533 0.471 
Organ survived 3 months 0.796 0.617 0.274 0.121 
Organ survived 1 year 0.377 0.825 0.024 0.015 
Peak 8 
NA3 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.307 0.206 0.994 0.278 
Patient survived 1 year 0.118 0.720 0.346 0.084 
Organ survived 2 weeks 0.510 0.843 0.420 0.078 
Organ survived 1 month 0.010 0.017 0.058 0.008 
Organ survived 3 months 0.010 0.118 0.042 0.006 
Organ survived 1 year 0.004 0.123 0.045 0.004 
Peak 9 
NA3FB 
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Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.600 0.608 0.810 0.742 
Patient survived 1 year 0.613 0.199 0.412 0.728 
Organ survived 2 weeks 0.603 0.578 0.395 0.817 
Organ survived 1 month 0.090 0.050 0.032 0.143 
Organ survived 3 months 0.128 0.117 0.014 0.411 
Organ survived 1 year 0.181 0.046 0.014 0.935 
Peak  9bis 
NA3Fc 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.128 0.207 0.527 0.043 
Patient survived 1 year 0.521 0.730 0.786 0.383 
Organ survived 2 weeks 0.084 0.475 0.304 0.030 
Organ survived 1 month 0.014 0.027 0.497 0.037 
Organ survived 3 months 0.045 0.312 0.956 0.018 
Organ survived 1 year 0.038 0.439 0.944 0.052 
Peak  10 
NA3FBc 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.633 0.098 0.739 0.793 
Patient survived 1 year 0.554 0.254 0.491 0.936 
Organ survived 2 weeks 0.406 0.629 0.264 0.164 
Organ survived 1 month 0.036 0.020 0.043 0.046 
Organ survived 3 months 0.057 0.094 0.043 0.099 
Organ survived 1 year 0.041 0.037 0.030 0.054 
Peak 11 
NA4 
Max value day 1 to 
7 Value Day 1 
Value Day 
3 Value Day 7 
Patient survived 1 month 0.669 0.121 0.681 0.904 
Patient survived 1 year 0.840 0.038 0.364 0.174 
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Organ survived 2 weeks 0.903 0.647 0.325 0.731 
Organ survived 1 month 0.161 0.053 0.030 0.516 
Organ survived 3 months 0.148 0.080 0.014 0.739 
Organ survived 1 year 0.127 0.011 0.010 0.739 
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Relevant results of ROC curve analysis for the prognostic value of GlycoTransplantTest 
Graft loss at 2 weeks: AUC = 0.824 (p=0.028; 95%CI 0.597-1.000) 
Graft loss at 1 month: AUC =0.810 (p<0.0001;  95%CI 0.686-0.934) 
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Graft loss after 3 month : AUC = 0.816 (p<0.0001;  95%CI 0.712-0.920) 
Graft loss after 1 year :  AUC = 0.784 (p<0.0001;  95%CI 0.684-0.884) 
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Patient death at one month : AUC =  0.817 (NS)  
Patient death at one year: AUC = 0.702 (p=0.028; 95%CI 0.566-0.838). 
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VI. The potential of glycomics-based biomarkers
to assess the development of acute cellular 
rejection after liver transplantation
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6.1 ABSTRACT 
Non-invasive biomarkers for acute cellular rejection (ACR) are an unmet medical need. In this 
exploratory study we assessed whether specific glycomic changes could be observed in the serum of 
liver transplant patients during the development of ACR (confirmed by  liver biopsy). Serum glycomic 
analysis was performed as described before using DSA-FACE. In a cohort of 108 liver transplant 
patients, 38 ACR episodes were identified. The glycomic profiles were compared between these 
episodes and non-ACR serum samples.  
A significant increase of NA2F (a bigalacto, core-alpha-1,6-fucosylated biantennary glycan) and a 
reciprocal significant decrease of NA2 (a bigalacto biantennary glycan) was observed in ACR serum 
samples compared to non-ACR serum samples. However, the clinical relevance of this finding is 
unclear, as there was an important overlap between both groups. However, these data provide a first 
proof-of-concept that (subtle) glycomic alterations are present in serum during ACR development 
after liver transplantation.  
 
6.2 INTRODUCTION 
A non-invasive diagnostic marker for ACR after LT is an unmet medical need and liver biopsy remains 
mandatory for the confirmation of ACR1. We explored whether specific glycoalterations are related 
to the development of ACR after liver transplantation.  
 
6.2 METHODS AND MATERIALS 
 
6.2.1 DESIGN 
This was a monocentric prospective cohort study at Ghent University Hospital. All patients who 
underwent liver transplantation in the Liver Transplant Unit of Ghent University Hospital (Belgium) 
between 1 December 2012 and 31 December 2014 were eligible.  
From every patient one serum sample was collected in the 24 hour timeframe before liver 
transplantation. After liver transplantation daily serum samples were collected during 14 days, and 
after 1,3,6 and 12 months after liver transplantation.  Supplementary serum samples were taken at 
the moment of suspicion of ACR, as characterized by an increase of liver enzymes. ACR was 
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confirmed and graded by liver biopsy examination according to the Banff staging system2. CMV 
infection was assessed by CMV PCR measurement in serum. 
After centrifugation, serum samples were frozen to minus 21° Celcius. Clinical data were retrieved 
from the medical files.  
After collection of all serum samples, the serum samples were defrosted and glycomic analysis was 
performed. The resulting glycomic profiles were related to donor graft and patient outcome.  
6.2.2 GLYCOMIC ANALYSIS 
Five microliter of serum were processed according to the in-solution deglycosylation method 
described by Vanderschaeghe et al.3. Briefly, denaturing buffer containing SDS was added to the 
serum and incubated for 5 min at 95°C. Then, the samples were treated with Peptide N-glycosidase F 
to release the N-glycans from their denatured carrier proteins. After enzymatic removal of the 
terminal sialic acid residues, the glycans were labeled with 8-aminopyrene-1,3,6-trisulphonic acid 
and analysed using an ABI3130 DNA sequencer as described4. The result of this analysis is a total 
desialylated serum protein electropherogram, which consists of 13 peaks. Each peak represents a 
well-identified glycan. The numerical height of every peak is quantified and normalised to the sum of 
all peak heights, thus represented as a percentage of total peak height.   
6.2.3 STATISTICS 
Statistical analysis was performed using IBM©SPSS©Statistics Version 22.0. The relative abundance 
of every peak was compared between ACR episodes and non-ACR episodes using Mann Whitney U 
test. A general linear mixed model was built that compared the relative abundance of every peak 
during ACR compared to non-ACR samples.  
6.2.4 ETHICS 
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved 
by the Ghent University Hospital ethics committee.    
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6.3. RESULTS  
6.3.1 PATIENT CHARACTERISTICS  
In this analysis, the results of 108 consecutive patients were collected. The baseline characteristics 
are summarized in table 1. 
 
Table 1. Baseline characteristics of the liver transplant patients (n=113). 
  Whole Cohort Patients without 
ACR 
Patients with 
ACR 
 
  Number (SD) Number ( SD) Number (SD)  
Mean Age  50.65 (13.21) 53.2 (15.74) 50.39 (13.46) p=0.677 
Sex Male 
Female 
61  
52  
41 
34 
20 
18 
p=0.506 
 
Acute cellular rejection was diagnosed in 38 patients and confirmed on liver biopsy examination. ACR 
grade 1 was found in 22 patients, grade 2 in 14 patients and grade 3 in 2 patients.  
 
Table 2.  ACR episodes and CMV reactivation episodes 
 Incidence Percentage 
ACR grade 1 22 20.37% 
ACR grade 2 14 12.96% 
ACR grade 2 2 1.86% 
CMV reactivation 38 35.19% 
 
6.3.2 GLYCOMICS IN ACR 
We compared the mean levels of every single glycan during ACR episodes and non-ACR episodes 
amongst all patients.  All ACR episodes were pooled for this analysis. The results are summarized in 
table 3.  CMV reactivation episodes were excluded for this analysis. Two glycans showed significant 
alterations during ACR episodes compared to non-ACR episodes. The relative abundance of NA2F, a 
bigalacto, core-alpha-1,6-fucosylated biantennary glycan, was significantly increased during ACR 
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episodes, whereas the relative abundance of NA2, a bigalacto biantennary glycan, was decreased 
during ACR episodes (Figure 1).  
Table 3. Comparison of mean values of glycan-abundance between rejection and non-rejection 
episodes (Mann Whitney U test). 
ACR (SD) No ACR (SD) p-value
NGA2F  5,31 (3.42) 6,07 (3.82) 0.311 
NGA2FB  1.05 (1.08) 1.09 (0.80) 0.482 
NG1A2F (peak 3) 2.67 (1.44) 2.89 (1.60) 0.642 
NG1A2F (peak 4) 3.73 (1.77) 4.20 (2.00) 0.255 
NA2  41.86 (15.50) 45.13 (13.30) 0.042 
NA2F  12.30 (5.06) 11.76 (4.28) 0.033 
NA2FB  4.31 (2.23) 4.17 (2.42) 0.193 
NA3  7.34 (3.59) 8.06 (3.52) 0.320 
NA3FB 5.18 (3.24) 5.28 (3.00) 0.770 
NA3FC 0.928 (0.54) 0.83 (0.49) 0.142 
NA3FBC 2.49 (1.38) 2.63 (1.36) 0.789 
NA4 1.43 (0.93) 1.40 (0.80) 0.669 
NA4FB 0.59 (0.47) 0.55 (0.42) 0.686 
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Figure 1. Relative abundance of NA2F was significantly increased during ACR episodes, whereas the 
relative abundance of NA2 was significantly decreased. *p=<0.05 
 
 
 
*
*
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6.3.3 GLYCOMICS IN CMV REACTIVATION 
We compared the mean levels of every single glycan during CMV reactivation episodes and non-CMV 
reactivation episodes amongst all patients.  All ACR episodes were excluded for this analysis. The 
results are summarized in table 4.  One glycan, NA3FB (a branch fucosylated tri-antennary glycan) 
showed a significant increase during CMV reactivation (Figure 2).  
Table 4. Comparison of mean values of glycan-abundance between CMV reactivation and non 
reactivation episodes (Mann Whitney U test). 
CMV reactivation (SD) No CMV reactivation (SD) p-value
NGA2F  5.35 (2.85) 6.08 (3.83) 0.420 
NGA2FB  1.00 (0.83) 1.09 (0.80) 0.289 
NG1A2F (peak 3) 2.63 (1.34) 2.89 (1.60) 0.516 
NG1A2F (peak 4) 3.72 (1.95) 4.21 (2.00) 0.071 
NA2  43.46 (14.07) 45.15 (13.29) 0.206 
NA2F  11.32 (4.18) 11.77 (4.28) 0.790 
NA2FB  4.19 (2.59) 4.17 (2.42) 0.856 
NA3  8.03 (2.60) 8.036 (3.52) 0.938 
NA3FB 6.61 (3.72) 5.26 (2.91) 0.013 
NA3FC 0.80 (0.49) 0.834 (0.49) 0.730 
NA3FBC 2.72 (1.45) 2.63 (1.36) 0.747 
NA4 1.59 (0.95) 1.36 (0.80) 0.130 
NA4FB 0.65 (0.48) 0.55 (0.42) 0.163 
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Figure 2. Relative abundance of NA3FB was significantly increased during CMV reactivation 
episodes. *p=<0.05 
 
  
*
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6.3.4 GENERAL LINEAR MIXED MODEL FOR ACR AND CMV REACTIVATION   
A general linear mixed model  could not confirm the relevance of these glycoalterations during ACR 
and CMV in this integrated approach (table 5).  
Table 5: Comparison of the relative abundance of the difference glycans during the ACR episodes. A 
general linear mixed model  was used.  P-values are shown. 
ACR Grade 1 ACR Grade 2 ACR Grade 3 CMV 
reactivation 
NGA2F  0.749 0.990 0.704 0.686 
NGA2FB  0.948 0.907 0.921 0.812 
NG1A2F 
(peak 3) 
0.694 0.873 0.794 0.734 
NG1A2F 
(peak 4) 
0.602 0.970 0.619 0.605 
NA2  0.538 0.925 0.610 0.782 
NA2F  0.881 0.772 0.772 0.816 
NA2FB  0.893 0.825 0.887 0.988 
NA3  0.721 0.952 0.644 0.990 
NA3FB 0.615 0.701 0.935 0.318 
NA3FC 0.829 0.918 0.691 0.901 
NA3FBC 0.798 0.983 0.782 0.870 
NA4 0.755 0.730 0.884 0.525 
NA4FB 0.677 0.652 0.862 0.833 
6.4. DISCUSSION 
In the introduction of this booklet, we included a review that highlights the medical need for non-
invasive diagnostic markers for ACR after liver transplantation. Hoping to answer this question, we 
studied the behavior of glycans during the development of acute cellular rejection in this exploratory 
analysis. When comparing the mean values of several glycans during ACR and non-ACR episodes, a 
significant increase was observed of the relative abundance of NA2F (a bigalacto, core-alpha-1,6-
fucosylated biantennary glycan) and a reciprocal significant decrease of NA2 (a bigalacto biantennary 
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glycan). These changes were not apparent during CMV reactivation, another frequent cause of 
increased transaminases after liver transplantation. However, in general linear mixed model  this 
observation could not be confirmed. Furthermore, as can be appreciated from figure 1, there is an 
important overlap between both ACR and non-ACR episodes.  
Increased alpha-1,6-fucosylation has been observed in cholestatic liver diseases5. This fucosylation of 
N-linked glycans within polarized hepatocytes directs glycoproteins to the basolateral surface and 
into the bile canaliculli. As a consequence, alpha-1,6- fucosylated glycoforms are normally rare in the 
blood and are enriched in the bile. Thus, if liver cells become depolarized, the alpha1–6 fucosylated 
glycoforms rise in abundance in the blood. The inflammatory changes observed during ACR might 
lead to depolarization of the hepatocyte and result in the increase of NA2F.  
Acute cellular rejection is often diagnosed in an early stage and the majority of the ACR episodes in 
this cohort were mild to moderate. This means that the inflammatory changes are modest, what 
might explain the subtle changes in the whole serum protein glycomic signature.  
Although this finding is not useful for clinical practice at this moment, we need to explore this more 
in detail. First of all, we are including more patients in order to have more patients and more ACR 
and CMV reactivation events. This will allow us to confirm this observation and to study sequential 
measurements of the glyco-alterations before and during the treatment of ACR in individual patients. 
An approach using the delta of these glycoalterations in single patients during ACR has not yet been 
performed.  
In conclusion, only subtle changes in the glycomic signature were observed during the development 
of ACR. However, we believe that the inclusion of more patients with ACR will clarify the potential 
role of glycomics in the diagnosis of ACR. From a pathophysiological point of view, it could make 
sense that a specific glycomic signature for ACR can be found.  
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7.1. ABSTRACT 
Acetaminophen-induced acute liver failure (APAP-induced ALF) is a rare but life-threatening illness. A 
small proportion of these patients will require urgent liver transplantation. The decision to list for 
transplantation is guided by clinical criteria, e.g. the Kings’ college or Clichy criteria. Serum N-glycans 
(glycomics) are altered in several liver diseases but have not been assessed as prognostic markers in 
ALF. The first goal of this work was the serial assessment of the whole serum glycomic profile during 
the evolution of APAP-induced acute liver injury. The second goal was an evaluation of the potential 
of serum glycomics as prognostic markers in APAP-induced acute liver injury. 
During APAP-induced acute liver injury and the recovery of acute liver injury consistent glycomic 
changes are observed, reflecting the regeneration process. Recovery of acute liver injury was 
characterized by an increased fucosylation and increased branching of sugar structures. In this cohort 
of 11 patients, a distinct glycomic profile was present at admission in patients with transplant-free 
survival (p=0.036).  In contrast, patients requiring liver transplantation  showed an increased 
undergalactosylation, a sign of major inflammation, at admission.  
In conclusion, the recovery of APAP-induced acute liver injury is characterized by increased 
fucosylation and increased branching. Furthermore, glycomic assessment of serum at baseline can 
predict transplant-free survival in  APAP-induced ALF. 
 
7.2. INTRODUCTION 
Acute liver failure (ALF) is a rare but life-threatening illness that occurs in fewer than 10 cases per 
million persons per year. It is most often observed in previously healthy young adults1. ALF was 
originally named “fulminant hepatic failure” and defined as “a severe liver injury, potentially 
reversible in nature and with onset of hepatic encephalopathy within 8 weeks of the first symptoms 
in the absence of pre-existing liver disease”2. In the Western world acetaminophen (N-acetyl-p-
aminophenol; APAP; paracetamol) overdose, is the leading cause of ALF34. If the antidote N-
acetylcysteine is administered within 10 hours of ingestion, outcome is excellent in the majority of 
patients5,6.   
The main challenge in the care for patients with APAP-induced ALF is the identification of patients 
that will not survive with medical therapy alone. Early identification of patients that will require liver 
transplantation is of utmost importance7.  
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Various prognostic models have been developed, mainly based on historical patient cohorts treated 
without liver transplantation. The most well-known models are the King’s college criteria which 
include specific criteria for APAP-induced ALF8 and the Clichy9 criteria, although the latter was initially 
developed for ALF caused by viral hepatitis. Both have been externally validated10,11,12. Key factors in 
these models are age, development of encephalopathy and coagulopathy. King’s college criteria also 
include acidosis and renal failure. These models are daily used for clinical decision making. However 
these criteria have clinically acceptable specificity but a more limited sensitivity11,12. The need for 
improved identification of candidates for transplantation is clear1. 
We have previously shown that “glycomics”-based biomarkers based on profiling the N-glycans from 
the total serum protein using capillary electrophoresis (CE), are useful for fibrosis monitoring13 and 
diagnosis of cirrhosis14 in patients with chronic liver diasease, and for the identification of patients 
with non alcoholic steatohepatitis among patients with non alcoholic fatty liver disease15,16. Indeed, 
glycomics-based biomarkers are particularly attractive for use in liver diseases, as hepatocyte-
secreted glycoproteins and immunoglobulin G are the dominant glycosylated serum proteins17–19.  
In this study, an assessment was performed of the alterations of the serum protein N-glycomic 
profile during the development and recovery of paracetamol-induced acute liver injury and ALF. 
Furthermore we investigated whether the serum protein N-glycomic profile is predictive for outcome 
in paracetamol-induced ALF. 
7.3. MATERIALS AND METHODS 
This single center study was performed in the department of Gastroenterology and Hepatology of 
Ghent University Hospital (Belgium), which is a referral unit for liver transplantation.  
7.3.1 STUDY COHORT AND STUDY DESIGN 
This exploratory cohort consisted of 11 patients. Patients were eligible upon admission for APAP 
intoxication with elevated liver enzymes (>2x ULN) and decrease of prothrombin time below 60%.  
From admission on, a daily serum sample was taken until normalization of coagulation or liver 
transplantation. Serum samples were prospectively collected between 1 June 2012 and 31 December 
2015 and stored at minus 20°C.  
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7.3.2 GLYCOMIC ANALYSIS 
N-glycan analysis was performed using DSA-FACE as described before19.  In summary, five microliter 
of serum was processed according to the in-solution deglycosylation method described by 
Vanderschaeghe et al.19. Briefly, denaturing buffer containing SDS was added to the serum and 
incubated for 5 min at 95°C. Then, the samples were treated with Peptide N-glycosidase F to release 
the N-glycans from their denatured carrier proteins. After removing the terminal sialic acid residues, 
the glycans were labeled with 8-aminopyrene-1,3,6-trisulphonic acid and analyzed using an ABI3130 
DNA sequencer as described20. The result of this analysis is a total serum protein electropherogram, 
which consists of 13 peaks (Figure 1). Each peak represents a well-identified glycan21. The numerical 
height of every peak is quantified and normalized to the sum of all peak heights, thus represented as 
a percentage of total peak height.   
 
For every serum sample, the relative abundance of 13 individual N-glycans was analysed (Figure 1). 
The molecular structure of every glycan has been elucidated and extensively described in former 
publications 14,21.    
The relative abundance of every glycan was calculated and the day-by day evolution of glycans was 
studied in order to observe the evolution of these glycans during ALF up to 7 days after admission.  
 
7.3.3 STATISTICAL ANALYSIS 
Statistical analysis was performed using IBM©SPSS©Statistics Version 22.0. Mann Whitney U test was 
used when mean levels of biomarkers were compared between patients that recovered 
spontaneously and those who needed liver transplantation. Statistical significance was set at the 
alpha level = 0.05. 
 
7.3.4 ETHICS 
The study adheres to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by 
the Ghent University Hospital ethics committee.  Informed consent was obtained.  
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Fig 1. The structures of the N-glycan peaks in a human total serum sample. The structures of the N-
glycan peaks in a human total serum sample as obtained using capillary electrophoresis yields 13 
peaks. From left to right : Peak 1 is an agalacto, core-alpha-1,6-fucosylated biantennary (NGA2F), 
peak 2 is an agalacto, core-alpha-1,6-fucosylated bisecting biantennary (NGA2FB), peak 3 and peak 4 
are monogalacto, core-alpha-1,6-fucosylated biantennary structures (NG1A2F), peak 5 is the 
bigalacto biantennary glycan NA2, peak 6 is the bigalacto, core-alpha-1,6-fucosylated biantennary 
glycan NA2F, peak 7 is the bigalacto, core-alpha-1,6-fucosylated bisecting biantennary glycan NA2FB, 
peak 8 is the triantennary glycan NA3, peak 9 is the branching alpha-1,3-fucosylated triantennary 
glycan NA3Fb, peak 9bis is the core-alpha-1,6-fucosylated triantennary glycan NA3Fc, peak 10 is the 
branching alpha-1,3-fucosylated and core alpha-1,6-fucosylated triantennary glycan NA3Fbc, peak 11 
is a tetra-antennary (NA4) and peak 12 is a branching alpha-1,3-fucosylated tetra-antennary (NA4Fb) 
glycan. The symbols used in the structural formulas are: square indicates beta-linked N-
acetylglucosamine (GlcNAc); yellow circle indicates beta-linked galactose, triangle indicates 
alpha/beta-1,3/6-linked fucose; green circle indicates alpha/beta-linked mannose. 
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7.4. RESULTS 
7.4.1 PATIENT CHARACTERISTICS 
Eleven patients were included in this study with APAP-induced acute liver injury. All patients were 
treated with intravenous N-acetylcystein and maximal supportive care. Patients were admitted to an 
intensive care unit if appropriate. Demographic and clinical characteristics of the patients in this 
cohort are described in table 1. Two of those patients fulfilled the King’s college criteria for liver 
transplantation for APAP-induced ALF11 and underwent urgent liver transplantation.  
 
Table 1. Summary of patient characteristics. 
Patient 
Number  
Age Sex Regular 
alcohol 
intake 
Peak 
AST 
(U/l) 
Peak 
ALT 
(U/l) 
Lowest 
PT (%) 
Encefalopathy Outcome  King’s college 
criteria for liver 
transplantation 
 
1 29 M Yes 9311 4582 32 No Recovery  No  
2 44 W Yes 12359 8297 28 No Recovery  No  
3 48 W No 3260 4001 45 No Recovery  No  
6 24 M Yes 8481 5710 28 No Recovery  No  
7 56 W Yes 5116 6136 12 No Recovery  No  
8 56 M No 1247 727 45 No Recovery  No  
9 45 M Yes 33414 5742 12 No Recovery  No  
14 57 M No 401 2302 52 No Recovery  No  
15 30 W No 11942 11085 16 No Recovery  No  
12 41 W Yes 22848 8604 9 Yes LT  Yes  
18 21 W No 7091 3600 14 Yes LT  Yes  
Legend : M: male; W: woman; LT : liver transplantation 
 
7.4.2 SERIAL ASSESSMENT OF GLYCOMICS DURING ALF 
Serial serum samples were available for the 9 patients with a spontaneous recovery. The evolution of 
the relative abundance of every glycan for these 9 patients is summarized in Figure 2. Both patients 
that underwent urgent liver transplantation had only one serum sample available.  
All glycans of all patients on the same time point from admission were integrated in a scatter plot in 
order to reveal underlying trends during the recovery of acute liver injury (Figure 3). The first 4 peaks  
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Fig 2. Individual evolution of relative 
abundance of glycans presented for 
every single patient with spontaneous 
recovery of ALF. X axis: time from 
admission (days). Y axis : relative 
abundance of the glycan. Results are 
shown for the 13 glycans that were 
analysed. 
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Fig 3. Evolution of every glycan for 
patients with spontaneous recovery of 
ALF. The scatter plot integrates individual 
results of glycans of all patients on the same 
time point. The best fitting line shows the 
trend in the temporal dynamics of the glycan. 
X axis: time from admission (days). Y axis : 
relative abundance of glycan. 
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are NGA2F,NGA2FB and NG(1)A2F (peak 3 and 4 are isomers of the same sugar structure). Peak 1 is 
an agalacto, core-alpha-1,6-fucosylated biantennary (NGA2F), peak 2 is an agalacto, core-alpha-1,6-
fucosylated bisecting biantennary (NGA2FB), peak 3 and peak 4 are monogalacto, core-alpha-1,6- 
fucosylated biantennary structures (NG1A2F). Throughout recovery, these glycans first show a stable 
or even maybe a downward trend, especially in peak 3. The fifth peak, the bigalacto biantennary 
glycan NA2, showed a stable trend. Peak 6, known as NA2F, a bigalacto, core-alpha-1,6-fucosylated 
biantennary glycan, showed an upward trend. Peak 7, the bigalacto, core-alpha-1,6-fucosylated 
bisecting biantennary glycan NA2FB, showed a stable trend. Peak 8, the triantennary glycan NA3, 
showed a downward trend. Peak 9, the branching alpha-1,3-fucosylated triantennary glycan NA3Fb 
and peak 9bis, the core-alpha-1,6-fucosylated triantennary glycan NA3Fc , trended upwards. Peak 10, 
the branching alpha-1,3-fucosylated and core alpha-1,6-fucosylated triantennary glycan NA3Fbc, 
showed a downward trend. The two last peaks, NA4 (a tetra-antennary glycan) and NA4Fb 
(branching alpha-1,3-fucosylated tetra-antennary glycan) showed an upward trend. 
In conclusion, the most significant evolutions during the recovery of acute liver injury in patients not 
receiving liver transplantation are, compared to the baseline value : 
1/ A possible moderate decrease of undergalactosylated sugar structures (especially peak 3) 
2/ An increase of NA2F and NA2FB, both core-fucosylated biantennary glycans 
3/ A marked and consistent increase of the complex branch fucosylated triantennary sugar NA3Fb 
and the tetra-antennary sugars NA4 and NA4Fb 
7.4.3 PREDICTIVE VALUE OF GLYCANS FOR OUTCOME IN ACUTE LIVER INJURY 
We compared the relative abundance of serum N-glycans in the first available serum sample upon 
admission, considering that in patients with ALF a rapid decision must be made to list the patient for 
liver transplantation or not.  
The relative abundance of 4 glycans (both isomers of NG(1)A2F, NA2FB and NA3Fb) was significantly 
different at admission between patients that underwent liver transplantation and those who did not 
(p=0.036) as shown in Figure 4. The relative abundance of the NG(1)A2F isomers and NA2FB was 
increased at baseline in both patients undergoing liver transplantation compared to those who 
recovered. The relative abundance of NA3Fb was decreased at baseline in those patients in need of 
liver transplantation. 
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Fig 4. The relative abundance of NG(1)A2F (peak3), NG(1)A2F (peak4), NA2FB at baseline in 
patients with ALF with spontaneous recovery is significantly lower than in patients requiring liver 
transplantation (p=0.036). The relative abundance of NA3FB at baseline in patients with ALF with 
spontaneous recovery is significantly higher than in patients requiring liver transplantation 
(p=0.036). Groups were compared using Mann Withney U test.  
 
7.5 DISCUSSION  
This work describes the temporal dynamics of serum N-glycans in patients with APAP-induced acute 
liver injury and the potential role of serum N-glycans (glycomics) in the prediction of outcome in 
APAP-induced acute liver injury.  
It is well established now that the measurement of serum N-glycans in whole serum is altered in 
underlying liver disease. During the last years our group contributed largely in the development of 
glycomics-based biomarkers that support this concept14,17,20,22,23. This led to the development of 
glycomics-based biomarkers for liver fibrosis19, cirrhosis14, non alcoholic steatohepatitis15 and 
hepatocellular carcinoma (HCC)24.   
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In contrast to our former work that studied “stable” liver disease states, this work focused on  
dynamic alterations during a rapidly and dramatically evolving liver disease by excellence, acute liver 
failure. Glycomic analysis of daily serum samples in patients with APAP-induced ALF showed 
consistent glycomic alterations during the evolution and recovery of ALF.  The first finding is a trend 
towards a moderate decrease of the undergalactosylated sugar structures (peak 1-4). We and others 
formerly showed that undergalactosylation in the whole serum N-glycome is caused by 
undergalactosylation of immunoglobulins and not by liver derived proteins19,25. The development of 
APAP-induced ALF is characterized by the development of a complex inflammatory response, 
regulated by an interplay of different immune cells26. For example in mice, total leukocytes in the 
liver increases about threefold 18 hours after APAP injection27. The increased undergalactosylation 
reflects this important inflammatory response in ALF, especially in the patients who were in need of a 
LT, as these patients might show a more pronounced inflammatory reaction.  
The second finding is a decrease of the non-fucosylated triantennary glycan NA3 and an increase of 
the fucosylated biantennary glycans NA3FB and NA3FBc. This finding is consistent with a report from 
1990 from the group of King’s college London that found increased fucosylation of several serum 
proteins in fulminant liver failure and patients with hepatocellular carcinoma28 (measured by 
increased lectin binding). A few years later, the group of Clichy reported an increase in alpha-1,6-
fucosylation in patients with acute hepatitis29. In contrast to the undergalactosylated glycans, these 
glycans are hepatocyte derived19. Although the pathophysiological rationale for this increased 
fucosylation is not fully elucidated, it is well known that N-glycan fucosylation is strictly controlled by 
the upregulation of specific fucosyltransferases17. Some data suggest that this increased fucosylation 
might be a marker of regeneration. In sera of HCC patients an increased abundance of branch 
alpha(1,3)-fucosylated triantennary glycan NA3Fb, involved in branch fucosylation, has been 
described24. The increase of serum alpha-1,3-fucosyltransferase activity is not specific for HCC but is 
also increased in gastric30,31 and ovarian32 cancer.  
Furthermore, HCC patients express an increased enzymatic activity of alpha-1,6 fucosyltransferase 
activity33, responsible for core-fucosylation. Recently it was shown in a partial hepatectomy model in 
mice that alpha-1,6 fucosyltransferase activity (Fut8) was critical for the regeneration of the liver34. 
Fut8  (-/-) deficient mice suppressed hepatocyte proliferation, which is crucial for the recovery from 
ALF. Interestingly, suppletion of L-fucose, which can increase GDP-fucose synthesis through a salvage 
pathway, significantly rescued the delayed liver regeneration of Fut8(+/-) mice. Hence, these data 
strongly suggest that increased fucosylation, and in particular core fucosylation, is a marker of 
hepatocyte regeneration during the recovery of APAP-induced ALF. 
GLYCOMICS IN ACUTE LIVER FAILURE 
 
191 
 
The third finding is a significant and consistent increase of the complex branch fucosylated 
triantennary sugar NA3Fb and the tetraantennary sugars NA4 and NA4Fb. Several observations 
support the role of increased branching in hepatocellular carcinoma, a quintessential model of 
regeneration. First, in Hep G2 HCC cell lines and in human serum samples of patient with HCC 
increased fucosylated tri-35,36, tetra36-, and penta-antennary glycans were observed37. Second, 
beta1,6-GlcNac branching and thus f?rmation of triantennary glycans is catalyzed by N-
acetylglucosaminyltransferase 5 (GnT-V)38,39 and is increased in human HCC samples40. The last 
argument in favor of increased branching as a marker of liver regeneration was published by Miyoshi 
et al.41. In a two-thirds partial hepatectomy model in rats, enzymatic activity of GnT-V was increased 
in hepatocytes and nonparenchymal cells during regeneration. Hence, the temporal changes of 
serum N-glycan expression reflect the complex regeneration processes associated with recovery 
from ALF.  
In this cohort, 2 patients underwent urgent liver transplantation due to APAP-induced ALF, guided by 
the King’s college criteria for APAP-induced ALF8. An assessment of the glycomic profile at admission 
revealed distinct glycomic profiles in both transplanted patients, that allowed to predict at admission 
which patients would benefit from liver transplantation.  According to our data, 4 glycans, NG(1)A2F, 
NA2FB and NA3Fb could discriminate between both patient groups. The increased relative 
abundance of the NG(1)A2F isomers in patients requiring liver transplantation might be a marker of 
increased inflammation in the most sick patients. However, the important decrease of the relative 
abundance of NA3Fb in patients requiring liver transplantation might reflect the lack of sufficient 
regeneration capacity to recover from the ALF episode and thus the need for liver transplantation. To 
our knowledge, these data provide a proof-of-concept for the first biomarker that would allow to 
predict outcome in acute liver injury. 
This study is hampered by two major shortcomings. First of all the number of patients is limited and 
can only provide a proof-of-concept. It needs to be confirmed in a prospective multicenter study. 
Second, as both transplanted patients were rapidly listed for transplantation and transplanted, we 
could not follow the day-by-day evolution of the glycomic profile in these patients that did not 
recover. It would be interesting to follow the glycomic profile in these patients beyond the day of 
admission. 
Serum glycomic analysis was performed using capillary electrophoresis on a modified DNA 
sequencer, as described before19. The turnaround time of this analysis is less than 4 hours. During the 
last years, sample preparation has been simplified and it can be used on cheap high-throughput 
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microfluidics CE platforms e.g.  the MCE-202 MultiNA, 2100 Bioanalyzer and eGene system21, 
allowing an easy clinical implementation.       
In conclusion, in this study we provide a sequential analysis of the whole serum glycomic profile in 
patients with APAP-induced ALF. Furthermore, we provide a proof-of-concept that the glycomic 
profile at admission is predictive for transplant-free survival in APAP-induced acute liver injury. 
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VIII. General discussion and future perspectives
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VIII. GENERAL DISCUSSION AND FUTURE PERSPECTIVES
This PhD research found its roots in the observation that serum proteins display typical 
glycoalterations in humans with chronic liver disease as opposed to healthy adults1. This observation 
is supported by the fact that the majority of circulatory proteins are secreted by the liver and thus 
these glycoalterations can reflect pathological processes in the liver.  
Standardized protocols for sugar labeling and its application on a DNA sequencer using DSA-FACE has 
provided researchers with a technical environment that allows glycome analysis of the liver patient2. 
This pioneering work resulted ten years ago in the development of the first glycomics-based 
biomarker for the diagnosis of cirrhosis, called the GlycoCirrhoTest3. Although non-invasive markers 
for the quantification of liver fibrosis have become mainstream in clinical practice during the last 3 
years4, invasive liver biopsy was until then the standard of care for fibrosis and cirrhosis assessment.  
In the introduction of this work we provided a literature review of glycomics-based biomarkers for 
liver disease. This overview confirmed the solid diagnostic performance of glycome changes in 
relation to liver disease. My research work was primarily dedicated to exploring the potential of 
glycomics-based biomarkers as prognostic markers. The major glycomic alterations we discovered 
are summarized in figure 1.  
8.1. Glycomics-based biomarkers for prognosis in liver disease 
8.1.1. Risk of HCC development in compensated cirrhosis 
Liver cancer is the sixth most common cancer worldwide, the third cause of cancer-related death, 
and accounts for 7% of all cancers17. Cirrhosis is the main risk factor for the development of HCC. 
Although European16,18and American guidelines advocate ultrasonography-based screening for early 
HCC with or without measurement of AFP, adherence to these screening programs is disappointingly 
low and the incidence of HCC is rising. 
In our study we were able to show that the GlycoCirrhoTest, a glycomics-based serum marker, could 
radically change this approach. While the current screening strategy is a one-size-fits-all approach, 
we showed that the use of the GlycoCirrhoTest was able to assess the risk of HCC development in 
patients with compensated cirrhosis and this could allow for a personalized screening protocol. 
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Figure 1. Overview of glycomic alterations in relation to the disease state. Historical glycomic 
biomarkers GlycoFibroTest (for diagnosis of liver fibrosis) and GlycoNASHTest (for diagnosis of NASH) 
have also been included in this overview. 
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In a French cohort of 125 patients, a single measurement of the GlycoCirrhoTest, which is based on 
the measurement of 2 single glycans (a bisecting N-acetylglucosamine (GlcNAc)- containing N-glycan 
and a triantennary N-glycan) on serum glycoproteins was able to distinguish between patients with a 
high and a low risk of HCC development during the following 7 years. Indeed the median follow-up 
time in this study was 6.4 years. In a multivariate Cox Regression model including GlycoCirrhoTest, 
AFP and FIB-4 only GlycoCirrhoTest showed a significant and independent association with HCC 
development during follow up. 
This finding is supported by a strong pathophysiological rationale. The enzyme GnT-III responsible for 
the formation of bisecting GlcNAc residues, which are the driving glycans of the GlycoCirrhoTest, is 
increasingly expressed in cirrhotic nodules10,19. It is conceivable that with more hepatocytes actively 
dividing in such nodules, the risk for propagation of oncogenic mutations increases and hence the 
risk for HCC rises. Therefore a true marker for such nodular regeneration in liver cirrhosis should also 
be a good risk marker for HCC, as validated here for the GlycoCirrhoTest3. 
The findings of this study could be the basis for a radical change in the approach of the cirrhotic 
patient. In this era of personalized medicine such tools are highly valuable. Based on the result of the 
GlycoCirrhoTest, patients could be stratified in a low-risk or high-risk group for HCC development. 
These patients could be offered personalized screening regimens. For example, this study teaches us 
that patients with a low GlycoCirrhoTest value have an extremely low chance of HCC development 
(less than 5%) in the first 3 years of follow-up, whereas this risk is higher than 40% in the patients 
with a GlycoCirrhoTest value. It could make sense to offer the GlycoCirrhoTest low patients a yearly 
screening examination, whereas the GlycoCirrhoTest High group should be followed every six months 
as it is performed now.  
Yet, these results need to be interpreted with caution, as this is a monocentric study with a 
considerable but not extremely high number of patients included. However, from a statistical point 
of view the use of cross-validation and bootstrap validation confirmed the strong association of 
GlycoCirrhoTest with HCC development. This is a unique cohort with clinical data and serum that has 
been collected prospectively with a median follow-up time of almost 7 years. The search for similar 
cohorts that would allow validation has been difficult and disappointing. However, we have obtained 
an agreement with the French CIRRAL cohort to perform a validation of these findings in a cohort of 
patients with alcoholic cirrhosis and are in the phase of discussing the practicalities of this study.  
A proper validation of this study does not only require an independent validation of the correlation 
between GlycoCirrhoTest and HCC occurrence in cirrhotic patients. We need to demonstrate that it 
remains valid for hard endpoints, most ideally HCC related mortality. To prove this, we would need to 
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follow a prospective cohort of patients and randomize them to a classic screening program with 
ultrasonography (with or without AFP measurement) twice yearly and to a new screening program 
that is adapted to the value of the GlycoCirrhoTest, where patients with a low GlycoCirrhoTest value 
could be offered only a yearly follow-up visit. The results of this kind of study could only be expected 
within 10 years.  
The next step will be a pharmaco-economic evaluation of this strategy. If this strategy proves to be 
non-inferior to the current screening strategy, the financial repercussions could be very attractive. 
The reduction of visits by 50% in the GlycoCirrhoTest Low patients represents a real cost benefit, 
especially in countries where health insurance is not universal and where the distance to medical 
care can be larger than in Belgium.  
In conclusion, the observation that GlycoCirrhoTest is a predictor of HCC risk in patients with 
compensated cirrhosis could be a highly-expected game-changer that answers the desire for 
personalized medicine and cost reduction in modern medicine.  
  
8.1.2. OUTCOME AFTER LIVER TRANSPLANTATION 
  
A major part of this PhD dissertation covers the study of the role of glycomics-based biomarkers in 
liver transplantation, a thusfar unexplored area. We explored the potential of glycomics in three 
major fields, as elaborated in chapter 4, 5 and 6. Glycome profiles were both evaluated in the 
perfusate of the donor liver (before transplantation) and in serum.  
 
8.2.2.1 . Glycomic analysis of perfusate 
 
The glycomic analysis of perfusate was the most innovative and challenging field of this thesis as we 
did not only explore new indications for glycomic analysis but also explored the analytical and 
technical boundaries of our technique for glycome analysis.  
The team of Callewaert et al. developed the on-membrane deglycosylation and labeling method20 for 
glycan analysis in serum on a multicapillary electrophoresis-based ABI3130 sequencer. We applied 
this technology on perfusate samples and acquired perfusate electropherograms of excellent quality. 
The peak profile was comparable to the peak profile of serum showing the same peak structures.  
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From a theoretical point of view, perfusate analysis is an attractive alternative for liver biopsy or 
serum markers for the assessment of viability of the liver in liver transplantation. Perfusate is 
believed to represent the condition of the entire liver parenchyma and it is easy to collect in large 
volumes. However, only few perfusate markers have previously shown any value in the prediction of 
graft and patient outcome after LT21,22.  
Our study confirms the potential of perfusate analysis to guide donor allocation. In a cohort of 66 
liver transplant patients, three patients developed PNF and based on the glycomic signature of 
perfusate before liver transplantation we were able to predict the occurrence of PNF after liver 
transplantation with 100% accuracy.  
A few reflections should be made in the appraisal of these results.   
First, this is a monocentric study with a limited number of PNF patients. Although a validation of this 
cohort is needed (and is on the way) to confirm these findings, we have to face that it is a clinical 
reality that PNF occurs in a small amount of patients, varying between 1 and 10%. Multicenter 
studies will be needed in order to collect enough PNF patients and we have started a multicenter trial 
involving all Belgian liver transplant centers to collect perfusate using a standardized protocol in 
order to validate these findings.  
Second, the glycome signature is based on an increase of undergalactosylated glycans. The increased 
abundance of undergalactosylated glycans is a phenomenon that we also encountered in NASH 
patients and in the serum of liver transplant patients that are at greater risk of early graft loss. We 
know from previous reports that the undergalactosylated glycans in serum are present on IgG and 
not on liver-derived proteins. We measured IgG levels in perfusate and found their presence in the 
perfusate fluid (unpublished data). The levels of IgG were not increased in PNF patients compared to 
the non-PNF group. This implies that the undergalactosylation in this perfusate is a real glycomic 
alteration. The pathophysiological rationale is far from clear. However, it makes sense that the failing 
liver is a “stressed” organ, eg. by increased ischemia-reperfusion injury, with an important 
upregulation of inflammatory pathways, which is reflected by the increased abundance of 
undergalactosylated glycans. These livers are suffering and fail to develop the regeneration capacity 
to start functioning after liver transplantation.     
Third, the accuracy for the prediction of PNF was extremely high (100%). On the other hand we 
found no clear relationship between the perfusate glycome profile and the occurrence of EAD. We 
speculate that this might be related to the fact that EAD is a complex and multifactorial syndrome 
that is not only related to the quality of the donor liver graft but also to recipient characteristics and 
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intra- and postoperative events. This information will of course not be captured in the pretransplant 
glycome profile. On the other hand, PNF is mainly related to very low quality grafts, which can be 
captured quite convincingly by the glycome profile.  
If we can confirm the predictive power of perfusate glycomics for the occurrence of PNF this could 
have an important impact on allocation practices. Organ allocation these days is more “art” than 
“science”. Our tools for graft assessment are limited to a clinical appreciation and the use of scores 
like the (ET-)DRI, which lack the prognostic power in individual patients. On the other hand, we are 
faced with a decreasing quality of organs due to the shift of organ donors from the “young car driver” 
to the older “multimorbidic stroke patient”. All strategies that aim at expanding the donor pool like 
the use of DCD donors or the use of elderly donors have an additional negative impact on donor 
quality.     
A reliable biomarker that can predict organ failure with 100% certainty could help us to discard these 
unsafe organs from the donor pool and safely use donor organs where the clinician is in doubt 
regarding the quality. We remind the reader that our data were obtained in real clinical practice 
where all organs, including the PNF patients, were considered safe by the transplant team.  
Although we are convinced of the real clinical value of this glycomic marker for PNF, the current 
approach as published in the study reveals a major obstacle towards implementation in clinical 
practice. The technique that we used in the paper has a turn-around time of 48 hours because it was 
based on the on-membrane deglycosylation protocol20. In a concept where donor graft quality would 
be assessed before liver transplantation, this does not make any sense and makes this technique 
obsolete. However, we have been searching for a solution to this problem. The first logical step was 
the application of the newer and faster in-solution deglycosylation protocol that has been developed 
by the team of Prof. Callewaert20,23 with a turn-around time of 2 to 3 hours and the potential of 
application on clinical CE analyzers. However, applying this protocol to perfusate was disappointing 
as we did not obtain reliable signals (unpublished data). The main concern is that protein 
concentration in perfusate is much lower than in serum. In serum the normal total protein content is 
between 6 and 8 g/dl, where we measured mean levels of total protein between 0.2 and 0.3 g/dl in 
perfusate (unpublished data). This is a dilution factor of 25 to 30.  We have evaluated different 
techniques to concentrate the protein content of the perfusate without affecting the glycomic 
profile. The use of Amicon filters enabled the concentration of proteins in perfusate to a level where 
the in-solution deglycosylation protocol can be applied reliably. We are now in the phase of 
optimizing and validating this technique in order to allow rapid glycomic analysis of perfusate 
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(unpublished data) but have a proof-of-concept that glycomic analysis with the rapid in-solution 
deglycosylation protocol is feasible and reliable.  
Another intriguing question is how much cold ischemia time is necessary to obtain a representative 
glycomic profile and how the glycomic signature changes during cold ischemia. These data are non-
existing at this moment, as we have only performed measurements at the end of the cold ischemia 
time. An excellent experimental model to test the dynamics and value of glycomics perfusate analysis 
would be machine perfusion. We have approached partners to perform sequential perfusate 
sampling during the entire process of machine perfusion. This would allow for a systematic and 
comprehensive analysis of the glycomic profile and would reveal the dynamic behavior of glycomics 
during this process. It would also be useful to assess the potential of glycomics as biomarkers in 
machine perfusion.   
8.2.2.2. Glycomic analysis of serum 
In this project we collected and sequentially analyzed serum glycomic profiles in 127 liver transplant 
patients during the first year after liver transplantation. Two clinical questions were addressed. The 
first was whether a glycome signature during the first week after transplantation was associated with 
graft and patient survival during the first year after LT and the second whether a specific glycomic 
signature could be observed during the occurrence of ACR.  
8.2.2.2.1 The GlycoTransplantTest and graft and patient survival 
We defined a glycome signature that was predictive of graft and patient survival during the first year 
after liver transplantation. We showed that the best results were obtained by measuring the ratio of 
2 glycans, an agalacto core-alpha-1,6-fucosylated biantennary glycan and a triantennary glycan as  
log(NG1A2F/NA3) on day 7 after liver transplantation. In patients with a high level of this 
GlycoTransplantTest, hazard ratio for graft loss was 7.222 (p<0.001; 95% CI 2.352-22.182) and hazard 
ratio for patient death was 3.885 (p=0.30; 95% CI 1.127-13.276) during the first year after liver 
transplantation.  
This new biomarker opens new perspectives in transplant medicine. After liver transplantation, 7-
10% of patients will require retransplantation24. The reasons for this retransplantation can be due to 
surgical/technical complications, infections, rejection, disease recurrence or other complications. The 
first 3 reasons prevail in the first year after liver transplantation.  
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Interestingly, the measurement of the GlycoTransplantTest can disclose this increased risk for graft 
loss only based on one measurement one week after liver transplantation. The driving glycan of the 
GlycoTransplantTest is an agalacto core-alpha-1,6-fucosylated biantennary glycan NG1A2F. We can 
presume that this undergalactosylated glycan is a reflection of the ischemia/reperfusion damage25 
and the earlier described complications that lead to graft loss, as it is well-known that these are 
characterized by a complex inflammatory response26.  We speculate that the decrease of the 
triantennary glycan NA3  is the result of a disturbed glycosylation machinery in the failing liver and 
reflects the lack of regeneration capacity that is so hard needed after liver transplantation, due to a 
downregulation of N-acetylglucosaminyltransferase V (GnT-V). 
As clinicians we are convinced that the GlycoTransplantTest is an interesting tool. Already one week 
after transplantation we can estimate whether the newly transplanted graft and the patient have a 
good chance to survive the first year after transplantation. Patients with a GlycoTransplantTest 
below the cut-off of as described in chapter 5  can be reassured that they have a well-functioning 
liver with a high chance for a good outcome. Patiënts with a high value on the GlycoTransplantTest 
should be monitored more carefully. In these patients for whom retransplantation is being 
considered, the results of the GlycoTransplantTest can support the transplant team in the decision to 
list the patient more rapidly for retransplantation, rather than losing unnecessary time, which will 
affect the patient’s quality of life and might affect his general condition at the moment of 
retransplantation leading to a more complex surgery and recovery. To our knowledge clinical scores 
or biomarkers that can offer this solid prognostic value are not available.  
A critical reader might suggest that our marker is a mere biomarker of EAD. We have shown 
however, although there is a real overlap between EAD patients and patients with a high value on 
the GlycoTransplantTest, that there was no significant correlation between the GlycoTransplantTest 
and EAD as defined by Olthoff27. GlycoTransplantTest showed a better prognostic value than this 
clinical definition with regard to graft loss and patient survival. Furthermore, in a multivariate 
analysis, the GlycoTransplantTest and not EAD was the only independent predictor of graft survival 
(p=0.003).  
We are aware that this is a monocentric cohort study that requires validation in a second cohort. We 
have started collecting samples in a second cohort of patients at Ghent University Hospital from 1 
January 2015 that are reaching the required follow-up time of one year soon and we plan to validate 
the  GlycoTransplantTest in this independent cohort. Second, we have contacted other centers that 
are willing to provide serum samples for other historic cohorts in order to permit an external 
validation.  
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In conclusion, we believe that the GlycoTransplantTest is a powerful tool for the assessment of 
outcome during the first year after liver transplantation that could be used in decision-making 
regarding the need for liver re-transplantation. Furthermore, it could also be an interesting tool in 
trials studying therapeutic strategies in early graft failure where liver grafts at increased risk of graft 
loss could be identified.  
8.2.2.2.2. Acute Cellular Rejection 
The most common complication in the first year after liver transplantation is acute cellular 
rejection28. In the majority of patients ACR is easy to control and it should not affect long-term 
outcome if properly treated. ACR after liver transplantation is therefore not considered a major issue 
anymore in the transplant community. However, for a proper treatment, a proper diagnosis is 
needed and that is the very heart of the matter. For the diagnosis of ACR, a liver biopsy is needed. 
Although the risk for major complications is perfectly acceptable, a liver biopsy induces a lot of stress 
and anxiety to patients. Thus, a non-invasive marker for ACR would be highly appreciated.  
First of all we reviewed the literature for non-invasive markers for ACR, and concluded that the 
results were disappointing29. There is no reliable and validated diagnostic biomarker for ACR.  
In a cohort of 108 patients at Ghent University Hospital, ACR was observed in 38 patients. When 
comparing the relative abundance of every single glycan between non-ACR and ACR episodes, we 
discovered that 1 glycan, a core-fucosylated bi-antennary glycan NA2F was increased during ACR 
episodes whereas the biantennary glycan NA2 was significantly decreased during ACR episodes. 
However, in a general linear mixed model, the relative abundance of serum protein glycans was 
compared between ACR and non-ACR episodes and did not lead to a specific glycome signature that 
could relate to ACR. 
ACR is characterized by an inflammatory infiltration of the portal tract and hepatic necrosis in severe 
stages of ACR30.  Based on our insights it is not surprising that this inflammatory and damaging 
process in the liver affects glycosylation of liver-secreted serum proteins. The subtlety of these 
changes might be the reflection of the minor inflammatory process of the ACR in our cohort (more 
than half of ACR episodes were grade 1).  
Although these results are disappointing, as we could not define a solid glycome diagnostic signature 
for ACR, we will continue this work. More patients are being included in this prospective cohort in 
order to collect more ACR patients. Furthermore we will look deeper into this matter and study intra-
patient variations of glycan abundance in order to calculate deltas of the relative changes of glycans 
during follow up which might be more revealing of these subtle changes. In the end, if this could lead 
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to a reliable diagnostic marker of ACR, again it would have a major impact on clinical practice and 
could rival the major indication for liver biopsy after liver transplantation.  
 
8.1.3. SERUM GLYCOMICS IN ACUTE LIVER FAILURE  
ALF is a dramatic event that affects healthy and often young patients without any underlying liver 
disease and can require urgent liver transplantation in a minority of these patients. The need for 
urgent liver transplantation is based on clinical criteria, most often Kings College31 or Clichy criteria32 
are used. In a small cohort of patients with paracetamol-induced ALF, we explored the kinetics of 
several glycans and searched for distinct glycomic profiles in patients who showed a spontaneous 
recovery of ALF and those who needed urgent liver transplantation.  
The findings of this small study were exciting and intriguing. First of all we observed rapid and large 
changes during the occurrence and the recovery of ALF, illustrating that the serum glycans show 
rapid changes according to pathological processes in the liver. Second, we found a distinct glycome 
profile in patients that needed urgent liver transplantation compared to those who did not. We 
speculate that the increased abundance of the NG(1)A2F isomers might be a marker of increased 
inflammation in the most sick patients and that the important decrease of the relative abundance of 
NA3Fb in these patients might reflect the lack of sufficient regeneration capacity to recover from the 
ALF episode and thus the need for liver transplantation. 
Again, these data need validation in larger cohorts. We have decided not to publish these data until 
we can refine and confirm them in more patients. Collection of patient data and serum samples is 
ongoing. Furthermore, we were restricted by the fact that in the two patients that needed liver 
transplantation, we could only collect one sample (at admission) due to the rapid liver 
transplantation within 24 to 48 hours. It would be interesting to study the kinetics of these culprit 
glycans more comprehensively in these patients.  
The most widely applied prognostic system is the King’s College Hospital criteria (KCH Criteria), 
developed from a retrospective cohort of nearly 600 patients31. Several studies have shown positive 
predictive values ranging from 70% to nearly 100% and negative predictive values ranging from 25% 
to 94%3334,35. In a meta-analysis of studies using the KCH Criteria, the pooled sensitivity and specificity 
was 68% to 69% and 82% to 92%, respectively36,37. 
Although KCH Criteria have acquired an almost divine status in clinical practice, this is surprisingly not 
supported by the AASLD clinical practice guidelines38 that state that available prognostic scoring 
CHAPTER 8 
208 
systems do not adequately predict outcome and determine candidacy for liver transplantation. 
Reliance entirely upon these guidelines is thus not recommended. 
So the field is open for improvement. There is a need for robust biomarkers that can guide the 
clinician in the decision whether or not to transplant a patient with ALF. Although the KCH criteria 
have saved innumerable lives during the last decades, some patients undergo unnecessary 
transplantation and others are denied transplantation for no reason. I doubt that a single biomarker 
once will be able to appreciate the complexity of a condition like ALF. However, our preliminary data 
provide a proof-of-concept that the assessment of serum glycomics in ALF can identify patients in 
need of liver transplantation and we need to clarify the question whether glycomics can improve the 
prognostic accuracy of the currently used prognostic models.  
8.2. FUTURE  PERSPECTIVES 
Our work in the field of glycomics as biomarkers in liver disease has given some answers to real 
medical questions. As it should be in research, our work has generated more uncertainty than clarity 
and is the source of new questions. 
The first step in turning uncertainty into clarity is the validation of our new biomarkers. The most 
promising biomarker is the perfusate glycomarker for PNF prediction. A patent application has been 
filed for this marker (PCT/EP2016/065383) and we have started a multicentric validation study in the 
6 Belgian liver transplant centers. Inclusion is ongoing and we plan to have a preliminary analysis by 
mid 2017. For these samples, the short protocol for perfusate analysis will be used. If the results of 
this trial confirm the proof-of-concept, industrial partners will be contacted for commercialization of 
this test.  
Validation studies for the other markers are also in the pipeline. We have an agreement with the 
French CIRRAL cohort, a prospective cohort of patients with alcoholic liver cirrhosis for a validation of 
the GlycoCirrhoTest as predictive markers for cirrhosis. The GlycoTranplantTest will be validated in 
Ghent University with a new prospective cohort whose inclusion is ongoing (from 1 January 2015 
onwards). Inclusion of ALF patients is also ongoing in order to increase the number of patients in this 
study.  
Besides the validation of these glycome signatures, we plan to study the role of glycomics in new 
indications. First of all we will study the role of glycomics in kidney transplantation. We have 
hypothesized that glycomic changes, excluding the undergalactosylated glycans,  are liver-specific for 
the reasons described before. Inclusion of kidney transplant patients is ongoing in collaboration with 
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Prof. Dr. Van Laecke from the department of Nephrology (Ghent University Hospital) in order to 
study the behavior of glycomics after kidney transplantation in comparison to liver transplantation. 
We expect that this exercise will increase our insights in the specific role of the liver in the serum 
protein glycosylation.  
Another study is the role of glycomics in the prognosis of patients with HCC. Some reports have 
proposed that the baseline glycomic profile is predictive of the time to relapse and of the overall 
survival3940.  We plan to validate these findings in our HCC-cohort.  
The final project is a pan-european project supported by the European Foundation for the study of 
chronic liver failure (EF-CLIF)-consortium. This scientific consortium has performed cutting-edge 
clinical research regarding chronic liver failure and defined the concept of acute-on-chronic liver 
failure (ACLF) based on the CANONIC study41. A new prospective multicenter study, the PREDICT 
study, in patients with ACLF will start in 2017 and we will participate. Furthermore, an ancillary study 
from our center has been approved by the steering committee of the PREDICT study that will study 
the behavior of glycomics in ACLF. In comparison to the studies proposed in this thesis, we will try to 
define a glycomic signature that predicts outcome in ACLF.  
8.3. CONCLUSION 
In this thesis we have explored the prognostic potential of glycomics-based biomarkers in liver 
disease. We have identified several specific glycomic signatures in serum that are associated with a 
high risk of HCC development in cirrhotic patients, with graft loss and patient death after liver 
transplantation and with transplant-free survival in paracetamol-induced acute liver failure. 
Furthermore we showed that glycomic analysis of perfusate in liver transplantation is technically 
feasible and that pretransplant assessment of the glycome of perfusate is predictive of primary non-
function after liver transplantation. All these biomarkers have a tremendous potential for 
translantion into clinical practice with a real impact on current clinical practice. Furthermore, all this 
research was based on a robust protocol for N-glycan analysis using DNA-sequencers that can easily 
be transferred to clinical CE-analyzers. This guarantees an easy implementation of these biomarkers 
in routine clinical laboratories.   
Besides the potential clinical applications, this work confirms the strength of glycomic analysis for 
biomarker discovery. This work adds to the increasing literature that liver disease is associated with 
specific glycoalterations, which is supported by a strong pathophysiological rationale.   
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These newly discovered glycome signatures here-presented, the knowledge that serum glycoproteins 
are mainly liver-derived and the elegant technique for glycomic analysis are more than ever 
promising a sweet future for glycomics as a barometer for acute and chronic liver disease.   
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IX. SUMMARY
In this work we explored the potential of glycomics to detect prognostic biomarkers in liver disease 
and liver transplantation. Glycans are sugar structures present on proteins and lipids, and 
glycosylation is the most common posttranslational modification in the human body. Interestingly, 
most of the proteins present in serum are produced by the hepatocytes and thus, disease states that 
affect the liver might be reflected in an altered serum glycome profile. Our research team formerly 
showed the validity of this hypothesis, and based on this concept, diagnostic biomarkers were 
developed for the diagnosis of liver fibrosis, cirrhosis, non alcoholic steatohepatitis and 
hepatocellular carcinoma (HCC). The identification of these markers was possible by the 
development of an efficient technique applied on adapted DNA sequencers.  
In this work first a literature review is provided that covers several topics : first a general introduction 
on chronic liver disease and liver transplantation is provided, with a focus on biomarkers for acute 
cellular rejection. The second part is a review of the current knowledge of glycomics-based 
biomarkers in liver disease.  
The next sections cover original research work. First I demonstrate that the GlycoCirrhoTest, a 
biomarker that was formerly developed for the diagnosis of cirrhosis, is not only a diagnostic marker 
of cirrhosis, but also a prognostic marker that can predict whether a patient with compensated 
cirrhosis has a low or a high risk to develop HCC. This is a new tool that could be used in the follow-
up of patients with cirrhosis, as these patients need six-monthly screening for HCC by 
ultrasonography. This GlycoCirrhoTest could help in the development of personalized screening 
protocols for cirrhotic patients according to the value of this test. 
In a next section we assessed the potential value of glycomics to develop prognostic biomarkers in 
the field of liver transplantation. We first showed that it was technically feasible to measure glycome 
profiles on perfusate, the fluid in which the liver is transported from the organ donor to the liver 
recipient. We successfully identified a specific glycome signature that is 100% predictive of a 
patient’s risk for developing primary non-function, a dramatic complication in the first hours upon 
liver transplantation that requires urgent retransplantation. This biomarker could prevent the 
transplantation of unsafe donor livers.  We also studied serum glycome profiles after liver 
transplantation and discovered that a specific glycome signature 1 week after liver transplantation 
serves as an independent predictor of graft loss during the first year after liver transplantation. This 
glycome marker could be an additional tool to guide transplant physicians in the decision to select 
patients for retransplantation when a liver graft shows suboptimal liver function.  
In chapter 6 we searched for a specific glycome signature that could guide clinicians in the diagnosis 
of acute cellular rejection (ACR), which is the most important indication for liver biopsy after liver 
transplantation. Although, we found significant glycome alterations during the development of ACR, 
these findings cannot currently be used as a diagnostic marker for ACR.  
Finally we studied glycome alterations during the development and recovery of paracetamol-induced 
acute liver failure. We were able to define a specific glycome signature that was congruent with the 
Kings College criteria for the selection of patients who were in need of urgent liver transplantation.  
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In conclusion, the work described in this PhD-dissertation adds to the increasing evidence that the 
whole serum protein glycome is a robust surrogate marker of processes that affect the liver. 
Furthermore, we were able to identify several potential prognostic biomarkers with real clinical 
utility in cirrhosis and liver transplantation. Validation studies of the most promising glycomics-based 
biomarkers are ongoing.  
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In dit werk hebben we het potentieel verkend van “glycomics” als prognostische biomerkers in 
leverziekten en levertransplantatie. Glycanen zijn suikerstructuren die aanwezig zijn op eiwitten en 
vetten, en glycosylatie is de meest voorkomende post-translationele modificatie in het menselijk 
lichaam. De meeste eiwitten die in het serum van mensen aanwezig zijn worden geproduceerd door 
de levercellen. Ziektetoestanden die de lever aantasten zouden dus kunnen vertaald worden in een 
gewijzigd glycosilatieprofiel in het serum.  
Ons onderzoeksteam heeft vroeger al aangetoond dat deze hypothese correct is. Gebaseerd op dit 
concept werden de laatste jaren diagnostische biomerkers ontwikkeld die de diagnose kunnen 
bevestigen van leverfibrose, levercirrose, niet alcoholische steatohepatitis en primaire leverkanker of 
hepatocellulair carcinoma (HCC). Dit was mogelijk dankzij de ontwikkeling van een performante 
techniek die toegepast wordt op DNA sequencers.  
Deze doctoraatsthesis bestaat vooreerst uit een literatuuroverzicht dat diverse onderwerpen 
overschouwt. Eerst wordt een algemene inleiding over chronische leverziekten en levertransplantatie 
gegeven, met een focus op biomerkers voor acute cellulaire rejectie (of afstoting van de lever). Het 
tweede deel van de inleiding geeft een overzicht van de huidige stand van zaken aangaande 
diagnostische merkers voor leverziekten gebaseerd op glycomics-technologie.  
De volgende hoofdstukken bevatten origineel werk. Ten eerste hebben we aangetoond dat de 
GlycoCirrhoTest, een biomerker die voorheen ontwikkeld werd voor de diagnose van levercirrose, 
niet alleen een diagnostische merker is, maar ook een prognostische merker die kan voorspellen of 
patiënten met levercirrose een groot of een laag risico hebben om de daaropvolgende jaren een 
hepatocellulair carcinoma te ontwikkelen.  Op dit ogenblik worden patiënten met levercirrose om de 
6 maanden opgevolgd met een echografie gezien het hogere risico op HCC. Met deze biomerker 
zouden we patiënten een gepersonaliseerd opvolgingsprotocol kunnen aanbieden naargelang hun 
risicoprofiel op HCC.  
In een volgend hoofdstuk werd het potentieel van glycomics in het domein van levertransplantatie 
onderzocht. Eerst hebben we aangetoond dat het technisch mogelijk is om glycomics te bepalen op 
perfusievloeistof, de vloeistof waarin de donorlever vervoerd wordt van de donor naar de patiënt die 
de levertransplantatie ondergaat. We konden met succes een specifiek glycosylatieprofiel bepalen 
dat met 100% nauwkeurigheid kon aantonen welke patiënten na de transplantatie een primary non 
function ontwikkelden, een ernstige complicatie waarbij de nieuwe lever niet goed functioneert en 
waarbij een dringende hertransplantatie noodzakelijk is. Het gebruik van deze biomerker zou kunnen 
toelaten om onveilige donororganen niet te gebruiken voor levertransplantatie. 
Daarnaast hebben we ook aangetoond dat de analyse van het glycosylatieprofiel in serum op dag 7 
na levertransplantatie een onafhankelijke voorspeller van de kans op verlies van het de donorlever 
binnen 1 jaar na levertransplantatie. Deze biomerker zou een nuttig hulpmiddel kunnen zijn voor 
transplantatieartsen in de beslissing om een patiënt met een lever die slecht functioneert na 
levertransplantatie opnieuw te transplanteren.  
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In hoofdstuk 6 onderzochten we of we een specifiek glycosylatieprofiel in serum konden vinden voor 
de diagnose van acute cellulair rejectie of afstoting. We vonden significante veranderingen in het 
glycosylatieprofiel tijdens afstoting van de transplantlever, maar de wijzigingen waren onvoldoende 
om nu als biomerker gebruikt te worden.  
Tenslotte hebben we glycosylatieveranderingen bestudeerd bij patiënten die een acuut leverfalen 
ontwikkelen ten gevolge van paracetamol. We konden hierbij een specifiek glycosylatieprofiel 
identificeren dat voorspellend is voor de noodzaak aan een dringende levertransplantatie, congruent 
met de zogenaamde Kings College criteria.  
We kunnen dus concluderen dat het werk dat in deze doctoraatsthesis is voorgesteld  extra bewijs 
brengt dat de glycoomanalyse van bloed op robuuste wijze reflecteert wat zich in de lever afspeelt. 
Bovendien konden we verschillende potentiële biomerkers ontwikkelen met een reële klinisch nut bij 
patiënten met levercirrose en levertransplantatie. Validatiestudies zijn lopende voor de meest 
veelbelovende onder deze glycosylatiemerkers.  
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Wetenschappelijk onderzoek is bij uitstek teamwerk. Alle bevindingen die in deze doctoraatsthesis 
beschreven zijn, zijn dus niet alleen mijn verdienste, maar het resultaat van de samenwerking met 
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patiënten toe anderzijds zijn zeer inspirerend.  
Dank ook aan mijn copromotor Prof. Dr. Roberto Troisi. Dit werk was een echte chirurgisch-medische 
samenwerking, die enkel dankzij de interesse en de inzet van u en uw team chirurgen mogelijk was. 
Ik denk hier in het bijzonder aan de peroperatieve staalnames. Dank ook voor het altijd grondig 
nalezen van mijn werk en de steeds zeer kritische maar terechte en nuttige commentaren die ons 
werk steeds naar een hoger niveau brachten.  Dank ook aan het team transplantchirurgen met Prof. 
Dr. Xavier Rogiers, Prof. Dr. Frederik Berrevoet en Dr. Aude Vanlander en de transplantcoordinatoren 
Luc Colenbie, Ivo Haentjens, Marc Vandervennet, Nelly Mauws en Christel Walraevens om mee de 
staalnames bij levertransplantpatiënten in goede banen te leiden.  
Dank ook aan Prof. Dr. Nico Callewaert van het VIB. Het is de intense samenwerking tussen 
basiswetenschappers en clinici die de geneeskunde echt vooruithelpt en translationele research 
mogelijk maakt. Ik heb enorm veel geleerd van u en kijk uit naar de verdere samenwerking die 
ongetwijfeld zeer vruchtbaar zal zijn.  
Ook een bijzonder woord van dank voor alle medewerkers van het VIB. Ik heb zeer intensief mogen 
samenwerken met Dieter Vanderschaeghe en Annelies Van Hecke. Jullie hebben mij de 
basisbeginselen en zoveel meer van de glycobiologie en glycoomanalyse bijgebracht. 
Ik wil ook alle medewerkers van het labo hepatologie van de Universiteit Gent bedanken voor de 
hulp bij het verzamelen van serumstalen, het uitvoeren van analyses etc. In het bijzonder  dank ik 
hier ook Agnes Paradissis die in de laatste fase van het doctoraat veel praktisch werk uit mijn handen 
genomen heeft, en Lindsey Devisscher, postdoctorale medewerker hepatologie, voor al haar nuttige 
labo-inzichten. Dank ook aan onze datamanager Elien Glorieus om onze biobank al die jaren te 
blijven beheren, en de nodige stalen snel beschikbaar te maken.  
Dank ook aan mij collega’s artsen Prof. Dr. Anja Geerts, Prof. Dr. Danny De Looze, Prof. Dr. Karen 
Geboes, Prof. Dr. Stéphanie Laurent, Dr. Marc De Man en Dr. Pieter Hindryckx om mij de vrijheid en 
tijd te geven om aan dit doctoraat te werken. Ook een zeer speciaal woord van dank aan Prof. Dr. 
Martine De Vos die diensthoofd was als ik aan dit doctoraat begon om mij van in het begin hierin te 
steunen.  
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